---
document_datetime: 2023-09-21 20:02:54
document_pages: 108
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/carmustine-obvius-h-c-4326-ii-0002-epar-assessment-report-variation_en.pdf
document_name: carmustine-obvius-h-c-4326-ii-0002-epar-assessment-report-variation_en.pdf
version: success
processing_time: 136.9348849
conversion_datetime: 2025-12-20 09:14:39.86116
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

30 April 2020 EMA/CHMP/332634/2020 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Carmustine Obvius

International non-proprietary name: carmustine

Procedure No. EMEA/H/C/004326/II/0002

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

Official address

Domenico Scarlattilaan 6

Address for visits and deliveries

●

●

Refer to www.ema.europa.eu/how-to-find-us

Send us a question

Go to www.ema.europa.eu/contact

Telephone

+31 (0)88 781 6000

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................6                                                          |
|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ................................................................................................ | 6                                                                                                        |
| 1.2. Steps taken for the assessment of the product                                                                      | ....................................................... 6                                                |
| 2. Scientific discussion                                                                                                | ................................................................................7                        |
| 2.1. Introduction                                                                                                       | ...................................................................................................... 7 |
| 2.1.1. Problem statement                                                                                                | .......................................................................................... 7             |
| 2.1.2. About the product                                                                                                | ........................................................................................... 9            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                        | ..... 10                                                                                                 |
| 2.2. Non-clinical aspects..........................................................................................     | 10                                                                                                       |
| 2.2.1. Ecotoxicity/environmental risk assessment........................................................                | 10                                                                                                       |
| 2.2.2. Discussion on non-clinical aspects....................................................................           | 15                                                                                                       |
| 2.2.3. Conclusion on the non-clinical aspects..............................................................             | 15                                                                                                       |
| 2.3. Clinical aspects                                                                                                   | ................................................................................................ 16      |
| 2.3.1. Introduction                                                                                                     | ................................................................................................. 16     |
| 2.3.2. Pharmacokinetics                                                                                                 | .......................................................................................... 19            |
| 2.3.3. Pharmacodynamics........................................................................................         | 20                                                                                                       |
| 2.3.4. PK/PD modelling............................................................................................      | 22                                                                                                       |
| 2.3.5. Discussion on clinical pharmacology                                                                              | ................................................................. 22                                     |
| 2.3.6. Conclusions on clinical pharmacology                                                                             | ............................................................... 22                                       |
| 2.4. Clinical efficacy                                                                                                  | ................................................................................................ 22      |
| 2.4.1. Dose response studies....................................................................................        | 22                                                                                                       |
| 2.4.2. Main studies                                                                                                     | ................................................................................................. 23     |
| 2.4.3. Discussion on clinical efficacy ..........................................................................       | 82                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy...................................................................          | 84                                                                                                       |
| 2.5. Clinical safety .................................................................................................. | 84                                                                                                       |
| 2.5.1. Discussion on clinical safety                                                                                    | ............................................................................ 99                          |
| 2.5.2. Conclusions on clinical safety .........................................................................100      |                                                                                                          |
| 2.5.3. PSUR cycle                                                                                                       | ..................................................................................................101    |
| 2.6. Risk management plan.....................................................................................101       |                                                                                                          |
| 2.7. Update of the Product information                                                                                  | .....................................................................104                                 |
| 2.7.1. User consultation..........................................................................................104   |                                                                                                          |
| 3. Benefit-Risk Balance............................................................................105                  |                                                                                                          |
| 3.1. Therapeutic Context ........................................................................................105    |                                                                                                          |
| 3.1.1. Disease or condition......................................................................................105    |                                                                                                          |
| 3.1.2. Available therapies and unmet medical need                                                                       | ....................................................105                                                  |
| 3.1.3. Main clinical studies                                                                                            | ......................................................................................105                |
| 3.2. Favourable effects...........................................................................................105   |                                                                                                          |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ..........................................105                                                            |
| 3.4. Unfavourable effects........................................................................................106    |                                                                                                          |
| 3.5. Uncertainties and limitations about unfavourable effects                                                           | .......................................106                                                               |
| 3.6. Benefit-risk assessment and discussion                                                                             | ..............................................................106                                        |
| 3.6.1. Importance of favourable and unfavourable effects                                                                | ...........................................106                                                           |
| 3.6.2. Balance of benefits and risks..........................................................................107       |                                                                                                          |

<div style=\"page-break-after: always\"></div>

3.6.3. Additional considerations on the benefit-risk balance .........................................  107

3.7. Conclusions  ....................................................................................................  107

4. Recommendations ...............................................................................  107

5. EPAR changes  ......................................................................................  108

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Ie1      | Iodine-131 (radiolabeled)                                   |
|----------|-------------------------------------------------------------|
| ABMT     | Autologousbonemarrowtransplantation                         |
| AHCT     | Autologous haematopoietic cell transplantation              |
| AHSCT    | Autologous haematopoietic stem cell transplantation         |
| ALL      | Acute 1ymphocyticleukaemia                                  |
| allo-SCT | Allogeneic stem cell transplantation                        |
| AML      | Acute myeloid leukaemia                                     |
| aNHL     | Aggressive NHL                                              |
| APBPCT   | Autologous peripheral blood progenitor cell transplantation |
| APBSCT   | Autologoup peripheral blood stem cell transplantation       |
| ASCT     | Autologousstem cell transplantation                         |
| BCNU     | Carmustine                                                  |
| BCOP     | BCNU, cytoxan, vincristine andprednisone                    |
| BEAM     | Carmustine, etoposide, cytarabine, and melphalan            |
| BEM      | BCNU, etoposide and melphalan                               |
| BEP      | BCNU, etoposide and cisplatin                               |
| BMT      | Bonemarrowtransplantation                                   |
| BNLI     | British National Lymphoma Investigation                     |
| BuCy     | Busulfan and cyclophosphamide                               |
| BUCYVP16 | Busulfan, etoposide and cyclophosphamide                    |
| CBV      | Cyclophosphamide, BCNU and etoposide                        |
| CBVP     | Etoposide, BCNU and cisplatin                               |
| CE±P     | Cyclophosphamide, etoposide ± cisplatin                     |
| CEB      | Cyclophosphamide, etoposide, and BCNU                       |
| CHOP     | Cytoxan, adriamycin, vincristine and prednisone             |
| CI       | Confidence interval                                         |
| CML      | Myelogenousleukaemia                                        |
| CMV      | Cytomegalovirus                                             |
| CNS      | Central nervous system                                      |
| CO2      | Carbon dioxide                                              |
| CR       | Complete remission/response                                 |
| CSF      | Cerebrospinal fluid                                         |
| CTC      | Carboplatin, cyclophosphamide, and thiotepa                 |
| DFS      | Disease-free survival                                       |
| DLBCL    | Diffuse large B cell 1ymphoma                               |
| DNA      | Deoxyribonucleic acid                                       |
| EFS      | Event-free survival                                         |
| ERA      | Environmental RiskAssessment                                |
| FDA      | Food and Drug Administration                                |
| G-CSF    | Granulocyte colony-stimulating factor                       |
| GVHD     | Graft-versus-host disease                                   |
| hICE     | Ifosfamide, carboplatin, and etoposide                      |
| HL       | Hodgkin's 1ymphoma                                          |

<div style=\"page-break-after: always\"></div>

| HSCT   | Haematopoieticstemcelltransplantation                |
|--------|------------------------------------------------------|
| IARC   | International Agency for Research on Cancer          |
| INFa   | Interferon-a                                         |
| iNHL   | Indolent 1ymphoma                                    |
| LAK    | Lymphokine-activated killer                          |
| MDS    | Myelodysplastic syndrome/ myelodysplasia             |
| MGMT   | Methylguanine methyltransferase                      |
| MOPP   | Mustine, vincristine, procarbazine, and prednisolone |
| MTD    | Maximumtolerated dose                                |
| NHL    | Non-Hodgkin's lymphoma                               |
| NIPCs  | Non-infective pulmonary complications                |
| NK     | Natural killer                                       |
| NRM    | Non-relapse mortality                                |
| 06BG   | O°-Benzylguanine                                     |
| OS     | Overall survival                                     |
| PBPC   | Peripheral bloodprogenitorcells                      |
| PBSC   | Peripheral blood stem cells                          |
| PBSCT  | Peripheral blood stem cell transplantation           |
| PCNSL  | Primary CNS 1ymphoma                                 |
| PCR    | Polymerase chain reaction                            |
| PCV    | Procarbaxzine, lomustine and vincristine             |
| PFS    | Progression-free survival                            |
| PR     | Partial remission/response                           |
| RFS    | Relapse-free survival                                |
| RIC    | Reduced-intensity conditioning                       |
| RNA    | Ribonucleic acid                                     |
| RR     | Relative risk                                        |
| RRT    | Regimen-related toxicity                             |
| SmPC   | Summaryof Product Characteristics                    |
| SOS    | Sinusoidal obstruction syndrome                      |
| t-AML  | Therapy-related AML                                  |
| TBI    | Total body irradiation                               |
| t-MDS  | Therapy-related MDS                                  |
| TMZ    | Temozolomide                                         |
| TRM    | Transplant-related mortality                         |
| UK     | United Kingdom                                       |
| US     | United State                                         |
| Vs.    | Versus                                               |
| WHO    | Word Health organization                             |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Obvius Investment B.V submitted to the European Medicines Agency on 13 May 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include: 'carmustine with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases' for Carmustine Obvius; as a consequence, sections 4.2 and 4.8 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Natalja Karpova

Co-Rapporteur:

Andrea Laslop

| Timetable        | Actual dates   |
|------------------|----------------|
| Submission date: | 13 May 2019    |

<div style=\"page-break-after: always\"></div>

| Timetable                                                                                      | Actual dates      |
|------------------------------------------------------------------------------------------------|-------------------|
| Start of procedure:                                                                            | 20 July 2019      |
| CHMP Rapporteur's preliminary assessment report circulated on:                                 | 16 September 2019 |
| CHMP Co- Rapporteur's preliminary assessment report circulated on:                             | 13 September 2019 |
| PRAC Rapporteur's preliminary assessment report circulated on:                                 | 20 September 2019 |
| PRAC RMP advice and assessment overview adopted by PRAC on:                                    | 3 October 2019    |
| Updated CHMP Rapporteur(s) (Joint) assessment report circulated on:                            | 10 October 2019   |
| Request for supplementary information and extension of timetable adopted by the CHMP on:       | 17 October 2019   |
| MAH's responses submitted to the CHMP on:                                                      | 20 December 2019  |
| CHMP Rapporteur's (Joint) preliminary assessment report on the MAH's responses circulated on:  | 29 January 2020   |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on:          | 30 January 2020   |
| PRAC RMP advice and assessment overview adopted by PRAC on:                                    | 13 February 2020  |
| Updated Rapporteur(s) (Joint) assessment report on the MAH's responses circulated on:          | 21 February 2020  |
| 2 nd Request for supplementary information and extension of timetable adopted by the CHMP on:  | 27 February 2020  |
| MAH's responses submitted to the CHMP on:                                                      | 26 March 2020     |
| CHMP Rapporteur(s) (Joint) preliminary assessment report on the MAH's responses circulated on: | 23 April 2020     |
| CHMP opinion:                                                                                  | 30 April 2020     |
| The CHMP adopted a report on similarity of Carmustine Obvius with Tepadina and Mozobil on:     | 30 April 2020     |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The MAH initially applied for the following indication 'carmustine with or without total body irradiation (TBI),  as  conditioning  treatment  prior  to  allogeneic  or  autologous  haematopoietic  progenitor  cell transplantation (HPCT) in haematological diseases.'

The final claimed indication is: 'as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin's disease / Nonhodgkin's lymphoma'

<div style=\"page-break-after: always\"></div>

## Epidemiology

Indications for HSCT in Europe (Passweg JR et al 2016) are leukaemias (including primarily AML, ALL and myelodysplastic syndrome (MDS)/myelodysplastic (MD)/myeloproliferative neoplasm (MPN) : 33% of total; 96% of which were allogeneic); lymphoid neoplasias including non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma and plasma cell disorders: 57% 11% allogeneic); solid tumors 4% (3% allogeneic); and non-malignant disorders; 2203 (6% 88% allogeneic) in 2014 (J R Passweg et al 2016).

## Biologic features, Aetiology and pathogenesis

Haematopoietic stem cell transplantation (HSCT) has been in use for treatment of malignancies since the  1950s  (Burman  et  al.,  2018).  HSCT  can  be  performed  with  stem  cells  collected  from  another individual  (allogeneic  transplantation)  or  from  the  same  patient  who  will  receive  them  (autologous transplantation)  (Burman  et  al.,  2018).  Over  the  past  10  to  20  years,  there  have  been  significant improvements in the field of HSCT with increased applicability to lymphoma. The upper age limit for HSCT has continued to climb for both autologous stem cell transplantation and allogeneic SCT (Kuruvilla, 2016).

## Clinical presentation, diagnosis and stage/prognosis

Intensive chemotherapy as a conditioning regimen prior to autologous hematopoietic stem cell transplantation (HSCT) is used for a subset of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), especially those with aggressive or refractory disease.

## Management

Allogeneic haematopoietic cell transplantation (HCT) is a potentially curative procedure for a variety of malignant and non-malignant conditions. When developed initially, allogeneic HCT was considered an approach  to  rescue  patients  from  the  toxic  side  effects  of  supra-lethal  doses  of  radiation  and chemotherapy used to treat various underlying diseases by transplanting haematopoietic stem cells, which had the ability to reconstitute haematopoiesis. However, it soon became evident that much of the effectiveness  of  HCT  in  malignant  diseases  stemmed  from  the  immunologic  reactions  of  donor  cells against  malignant  host  cells  (Gyurkocza  et  al.,  2010).  Autologous  HCT  is  the  i.v.  infusion  of haematopoietic  stem  and  progenitor  cells  designed  to  re-establish  marrow  and  immune  function  in patients  with  a  variety  of  acquired  malignant  disorders,  who  are  being  treated  with  high  dose chemotherapy or chemo-radiotherapy to treat the disease. These include haematologic malignancies (for example, Hodgkin's lymphoma (HL), B and T cell lymphoma and multiple myeloma) (Forman, 2017). Carmustine has been used for more than 40 years and has a well-defined place in different oncological treatment protocols, such as in BEAM (carmustine [BCNU], etoposide, cytarabine, and melphalan) and transplantation of haemopoietic stem cells in patients with chemo-sensitive first relapse of Hodgkin's disease irrespective of length of initial remission (Schmitz et al., 2002). Various clinical studies reported that CBV (cyclophosphamide, BCNU and etoposide) and BEAM regimens are effective therapy in patients with lymphomas (Bierman et al., 1996; Burns et al., 1995; Buser et al., 2007; Caballero et al., 1997; Geisler et al., 1998; Law et al., 2006; Neben et al., 2000; Nademanee et al., 1995; Przepiorka et al., 1999;  Rossi  et  al.,  2003;  Wadhwa  et  al.,  2005).  CBV  as  a  preparative  regimen  for  allogeneic transplantation  in  combination  with  cyclosporine  and  methylprednisolone  as  graft-vs.-host  disease prophylaxis has acceptable toxicity and is an effective therapy in patients with relapsed or high-risk nonHodgkin's lymphoma (NHL) (Rossi et al., 2003).

<div style=\"page-break-after: always\"></div>

BCNU can  cause  gastrointestinal  disorders  (mild  to  moderate  nausea  and  vomiting  and  diarrhoea), haemorrhagic complications, interstitial pneumonitis, pulmonary complications, veno-occlusive disease, myelodysplastic syndrome (MDS) (Fernández-Jiménez et al., 1999; Ingram et al., 2008; Law et al., 2006; Moormeier et al., 1990; Przepiorka et al., 1999; Rossi et al., 2003).

In various clinical studies, BCNU 300 mg/m 2  is used in combination with other chemotherapeutic agents in patients with refractory or recurrent lymphoma before allogenic or autologous HSCT with or without TBI (Bierman et al., 1996; Burns et al., 1995; Buser et al., 2007; Geisler et al., 1998; Ingram et al., 2008; Liu et al., 2010; Przepiorka et al., 1999; Wadhwa et al., 2005). In a phase I dose escalation study, BCNU 150 - 750 mg/m2 is used in combination with other chemotherapeutic drugs in patients with refractory NHL (Moormeier et al., 1990). In another studies, BCNU (600 mg/m2, 450 mg/m2 or 300 mg/m2) is used in combination with other chemotherapeutic agents in patients with haematological malignancies (Ager et al., 1996; Bolwell et al., 2002; Fleming et al., 1999). Based on clinical studies, Carmustine Obvius (300 -600 mg/m2  intravenously) is given in combination with other chemotherapeutic agents in adult patients with haematological malignancies before HPCT.

## 2.1.2. About the product

Carmustine Obvius 100 mg powder and solvent for concentrate for solution for infusion was registered via  centralised  procedure  according  to  the  Article  10(1)  of  Directive  2001/83/EC,  as  amended.  The reference product was Carmubris-Trockenstechampull mit lösungmittel, 100 mg (Emcure Pharma UK, Ltd., UK) authorized via national authorisation procedure in Austria in 1996 (1-21762).  Carmustine Obvius received the authorisation granted via centralized authorization procedure on 18   July 2018. The Company Obvius applied to the EMA claiming eligibility to the centralised procedure on the basis that it would address the shortage and impact an area of treatment need.

The  active  substance  carmustine  (100  mg  per  vial)  is  a  cell-cycle  phase  non-specific  antineoplastic belonging to the nitrosourea group of compounds (bischloroethylnitrosourea), which are considered to function as alkylating agents and thereby slowing the growth of cancer cells. It is believed to alkylate DNA and RNA and may also inhibit enzymatic processes by carbamoylation of amino acids in proteins

Carmustine Obvius is currently indicated as effective in the following malignant neoplasms as a single agent  or in combination  with other antineoplastic  agents  and/or  other  therapeutic  measures (radiotherapy, surgery):

- -Brain tumours (glioblastoma, Brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases
- -Secondary therapy in non-Hodgkin's lymphoma and Hodgkin's disease.

The Applicant submitted an application to include a new indication:

- with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases.

The final indication following assessment is 'as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin's disease / Non-hodgkin's lymphoma'.

Carmustine  is  given  in  combination  with  other  chemotherapeutic  agents  in  patients  with  malignant haematological diseases before HPCT at a dose of 300 - 600 mg/m 2  intravenously.

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

This application is based on bibliographic evidence.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

An updated environmental risk assessment was included in this application to evaluate whether the addition of the new indications may result in a significant increase in the environmental exposure.

## 2.2.1. Ecotoxicity/environmental risk assessment

In accordance with Article 8(3) of Directive 2001/83/EC, as amended, the evaluation of the potential environmental risks posed by Carmustine Obvius 100 mg powder and solvent for concentrate for solution for infusion should be submitted. Using the Guideline on the Environmental Risk Assessment (ERA) of Medicinal products for human use (EMEA/CHMP/SWP/4474/00 corr 2, 2006) and Questions and Answers (Q&amp;A) for the same document (EMA/CHMP/SWP/44609/2010 Rev 1, 2016) a Phase I (pre-screening) stage evaluation is performed.

The objective is an estimation of exposure using an action limit of &lt; 0.01μg of active substance per litre of surface water known as PECsurface water (Predicted Environmental Concentration in surface water).

This ERA is an update of a previous version submitted when Marketing Authorisation was first granted for Carmustine Obvius 100 mg powder and solvent for concentrate for solution for infusion.

It is filed in the context of a type II variation for addition of a new therapeutic indication. The new therapeutic indication is 'with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases'.

According to Question 2 in the Q&amp;A document, a new ERA should be provided in case a type II variation results in an increase of the patient population, e.g. when additional indications are claimed. As this is the case, an updated version of the previously submitted ERA containing information on the prevalence of the additional indication and an updated calculation of PECsurface water is presented.

Indications and posology

Previously authorised indications are described in the SmPC as follows:

Carmustine is effective in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):

- -Brain tumours (glioblastoma, Brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases
- -Secondary therapy in non-Hodgkin's lymphoma and Hodgkin's disease

According to the submitted SmPC, the following new indication is claimed in addition:

- -with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases.

Posology for the new indication is described as follows:

<div style=\"page-break-after: always\"></div>

Conditioning treatment prior to HPCT

Carmustine is given in combination with other chemotherapeutic agents in patients with haematological diseases before HPCT at a dose of 300 - 600 mg/m2 intravenously.

## Phase I of the environmental risk assessment of carmustine:

## 1- Screening for Persistence, Bioaccumulation and Toxicity:

A published value for the octanol-water partition coefficient (Kow) for Carmustine of 1.53 is available (Chabner et al., 2014). This value is supported by Xie (2012). Since this value falls well below the action limit of 4.5, no further assessment for persistence, bioaccumulation and toxicity is required.

This conclusion remains unaffected from the addition of a new indication in this updated document.

- Previously filed PEC calculation based on already authorised indications

## 2- Calculation of the Predicted Environmental Concentration (PEC):

The calculation of PECSURFWATER for carmustine was performed according the following formula and assumptions:

<!-- image -->

where

DOSEai = Maximum daily dose consumed per inhabitant (mg/inhabitant per day)

Fpen = Fraction of marked penetration (refined value, see below)

WASTEinh = Amount of wastewater per inhabitant per day (200 litre/inhabitant per day)

DILUTION = Dilution factor (10).

The following calculations were presented in the previous version of this ERA:

Disease prevalence data:

Glioblastoma: 1/100,000  [Orphanet]

Medulloblastoma: 1/909,000  [Orphanet]

Astrocytoma: 1/12,500  [Orphanet]

Metastatic brain tumours: 7-14/100,000  [Owonikoko et al, 2014]1

Multiple myeloma: 1-5/10,000  [Orphanet]1

Hodgkin's disease:1/40,000  [Orphanet]

Non-Hodgkin's lymphoma: 1-5/10,000  [Orphanet]1

1  In order to regard a worst-case scenario, the higher end of this range was used in the calculation below

Treatment regime:

Carmustine Obvius 100 mg powder and solvent for concentrate for solution for infusion has a maximum of infusion once every six weeks according to the proposed SmPC

(EMA/CHMP/SWP/44609/2010, 2011- page 3), resulting in ttreatment = 1 day and

<div style=\"page-break-after: always\"></div>

ntreatment = 9 per year.

Calculation of refined Fpen values:

Refined Fpen for indication glioblastoma:

Fpen = 1/100,000 patients/inhabitants x (1 d x 9)/365 d = 0.00000025

Refined Fpen for indication medulloblastoma:

Fpen = 1/909,000 patients/inhabitants x (1 d x 9)/365 d = 0.00000003

Refined Fpen for indication astrocytoma:

Fpen = 1/12,500 patients/inhabitants x (1 d x 9)/365 d = 0.00000197

Refined Fpen for indication metastatic brain tumour:

Fpen = 14/100,000 patients/inhabitants x (1 d x 9)/365 d = 0.00000345

Refined Fpen for indication multiple myeloma:

Fpen = 5/10,000 patients/inhabitants x (1 d x 9)/365 d = 0.00001233

Refined Fpen for indication Hodgkin's disease:

Fpen = 1/40,000 patients/inhabitants x (1 d x 9)/365 d = 0.00000062

Refined Fpen for indication Non-Hodgkin's lymphoma:

Fpen = 5/10,000 patients/inhabitants x (1 d x 9)/365 d = 0.00001233

Using the equation of Du Bois* (Du Bois &amp; Du Bois, 1916) the body surface area in a human weighing 70 kg with a height of 185 cm can be calculated to 1.85 m2. According to the proposed SmPC the maximum dose of Carmustine Obvius 100 mg powder and solvent for concentrate for solution for infusion is 200mg/m 2  which thereby equal a maximum dose per inhabitant of 370 mg.

PECsurface water can then be calculated as follows, for each indication:

* Body surface area = weight (kg) 0.425  x height (cm) 0.725  x 0.007184

Calculation of PEC values

Indication glioblastoma:

PECsurface water = 370 x 0.00000025

200 x 10 = 0.00000004625 mg/liter equals 0.00004625 μg/liter

Indication medulloblastoma:

PECsurface water = 370 x 0.00000003

200 x 10 = 0.00000000555 mg/liter equals 0.00000555 μ g/liter

Indication astrocytoma:

PECsurface water = 370 x 0.00000197

200 x 10 = 0.00000036445 mg/liter equals 0.00036445 μ g/liter

Indication metastatic brain tumour:

PECsurface water = 370 x 0.00000345

<div style=\"page-break-after: always\"></div>

200 x 10 = 0.00000063863 mg/liter equals 0.00063863 μ g/liter

Indication multiple myeloma:

PECsurface water = 370 x 0.00001233

200 x 10 = 0.00000228105 mg/liter equals 0.00228105 μg/liter

Indication Hodgkin's disease:

PECsurface water = 370 x 0.00000062

200 x 10 = 0.000000115 mg/liter equals 0.0001147 μ g/liter

Indication Non-Hodgkin's disease:

PECsurface water = 370 x 0.00001233

200 x 10 = 0.00000228105 mg/liter equals 0.00228105 μ g/liter

It was concluded that the emission of active substance for each indication is below the action limit of &lt; 0.01μg/liter.

## Sum PECsurface water water for all indications = 0.00573168 μg/liter

Thus, the emission of active substance for all indication is also below the action limit of &lt; 0.01 μg/liter.

Even though high-dose therapy (e.g. 450 mg/m2 or once a day infusion for consecutive days) may be used for individual cases in cancer therapy, it is unlikely that the action limit of &lt; 0.01μg/liter for PEC surface water will be exceeded.

Based upon the above shown calculation, and as no other environmental concerns are apparent, it was assumed that Carmustine Obvius 100 mg powder and solvent for concentrate for solution for infusion is unlikely to represent a risk for the environment following its prescribed usage in patients. The conduct of ERA studies was therefore not deemed necessary.

## Calculation of additional environmental entry based on the added indication

## Disease prevalence data and treatment regime

For an estimation of prevalence, the latest figures published by the European Society for Blood and Marrow Transplantation (EBMT) were regarded. EBMT published information on the prevalence of HSCT (i.e. the number of transplants performed) in 2017 in their annual report [EBMT annual report, 2018] based on a publication by one of the society's members [Passweg et al., 2019]. The total number of transplants reported in 2017 was 45,418 (in 41,100 patients; 23,945 autologous (58%) and 17,155 allogeneic (42%) patients). As described in the publication by Passweg et al., 3,101 transplants (in 2,948 patients) were performed in non-European countries but nevertheless included in the analysis. These non-European countries were Algeria, Iraq, Iran, Israel, Jordan, Lebanon, Saudi Arabia, South Africa and Tunisia.  EMBT  stated  that  across  indications,  data  from  these  countries  make  up  6.9%  of  all  data. Subtraction of 6.9% from the overall transplantation numbers in the respective indication therefore gives a good estimation of the respective numbers limited to Europe alone.

In addition, several non-EU but European countries (e.g. Russia, Turkey) were included in the analysis. As no information was provided on the relative extent of their contribution to overall transplantation numbers, it is not possible to calculate and subtract the number of transplantations performed in nonEU countries from the publication.

The number of transplants was further stratified with regard to indication. Figures on the number of transplantations relating to the indications listed in the updated SmPC are presented below in Table 1

<div style=\"page-break-after: always\"></div>

and used for calculation of the prevalence. According to Eurostat, the EU population on January 1st 2018 was estimated at 512,000,000 [Eurostat, 2018].

Table 1: Numbers of HCT in Europe 2017 by relevant indication [Passweg et al. 2019]

| Indication   | allo-HCT   | AHCT   | Tota|Eur+Non-Eur   | TotalEur*   |   prevalence[per10,000 inhabitants]** |
|--------------|------------|--------|--------------------|-------------|---------------------------------------|
| AML          | 6,676      | 360    | 7,036              | 6,543       |                                  0.14 |
| HL           | 444        | 2,152  | 2,596              | 2,540       |                                  0.05 |
| NHL          | 1,275      | 6,530  | 7,805              | 7,259       |                                  0.15 |

Allo-SCT: allogeneic (haematopoietic) stem cell transplantation; AML: acute myeloid leukaemia; ASCT: autologous (hematopoietic) stem cell transplantation; HL: Hodgkin's lymphoma; NHL: Non-Hodgkin's lymphoma;

*EBMT data include information of 9 non-European neighboring countries, which make up 6.9% of the total data set. Targeted over the thumb, 7% of the number of total data were subtracted to receive an approximated value for AML, HL and NHL patientstreated with HCTin Europe.Nevertheless, for a conservative estimationof PEC, the total number includingnon-Europeancountrieswasusedfor theprevalencecalculation.

** Prevalence was calculated with Eurostat data of 01.01.2018: 512,000,000

As  can  be  observed  in  Table  1,  the  reported  number  of  HSCTs  in  the  three  relevant  indications corresponds to an overall prevalence of 0.3 transplantations in 10,000 inhabitants. This estimation of prevalence  clearly  represents  an  overestimation:  The  number  of  HSCTs  include  several  countries belonging to Europe geographically while not being part of the EU, as it was not possible to subtract HSCTs from these countries based on the publication. The population of these countries was not added to the EU population for the calculation of prevalence.

Also, data from several non-European countries were included in the calculation. This was done as a precautionary  measure  in  case  that  their  contribution  to  HSCT  numbers  in  the  relevant  indications deviated from the 6.9% reported across all indications. As a conservative approach, the calculation of Fpen  and  PECsurface  water  resulting  from  the  added  indication  was  performed  based  on  the overestimated prevalence rate described above.

This figure relates to the number of interventions conducted per year. Treatment is received once prior to  each  intervention,  resulting  in  ttreatment  =  1  day  and  ntreatment  =  1  per  year  since  the  number  of interventions, not the number of patients were used for the prevalence estimation.

## Calculation of refined Fpen value

Refined Fpen value for the indication 'Conditioning treatment prior to HPCT':

Fpen = 0.3/10,000 patients/inhabitants x (1 d x 1)/365 d = 0.000000082

## Calculation of new PEC value

The single dose administered before each intervention is according to the SmPC 300 - 600 mg/m 2 .

In line with the calculations presented above for the existing indications, an individual weighing 70 kg with a height of 185 cm with a body surface area of 1.85 m 2  is assumed. The resulting maximum daily dose (based on a dose of 600 mg/m 2 ) for the new indication is 1,110 mg.

PECsurface water is correspondingly calculated:

PECsurface water = (1,110 x 0.000000082) / (200 x 10)= 0.000000046 mg/liter equals 0.000046 μg/litre

200 x 10 = 0.00000011 mg/liter equals 0.00010545 μ g/liter

<div style=\"page-break-after: always\"></div>

It can be concluded that the emission of active substance related to the additionally claimed indication is below the action limit of &lt; 0.01μg/liter.

## The new sum PECsurface water for all indications = 0.00577768 μg/liter

Thus, the emission of active substance for all indication is still below the action limit of &lt; 0.01 μg/liter.

The Applicant has concluded that the resulting PEC for the new indication, as well as for the sum of new and previous indications, fall well below the action limit. All other features of the compound, which was already found not to fall into the PBT category during previous evaluation, remain unchanged. Therefore, this assessment ends in Phase I as in the previous version. The conduct of environmental studies is not deemed necessary.

## 2.2.2. Discussion on non-clinical aspects

The initially proposed extension of indication to include the use of carmustine with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell  transplantation  (HPCT)  in  haematological  diseases  and  the  new  narrower  version  of  previously proposed indication is based on published scientific literature. No new non-clinical data was revealed from an updated Non-clinical Overview and published literature data submitted as part of this type II variation application.

As for environmental risk assessment the Applicant followed the recommendations laid down in the EMA 'Guideline on the environmental risk assessment of medicinal products for human use' EMEA/CHMP/SWP/4447/00 corr 2 and evaluated whether the addition of the new indications may result in a significant increase in the environmental exposure. Thus, the predicted environmental concentrations  were  calculated  based  on  refined  market  penetration  factors  (Fpen)  for  the  already registered as well as requested new indications.

## Assessment of paediatric data on non-clinical aspects

Carmustine Obvius is contraindicated in paediatric patients (see SmPC section 4.3).

## 2.2.3. Conclusion on the non-clinical aspects

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of carmustine.

- Considering the above data, carmustine should be used according to the precautions stated in the SmPC in order to minimize any potential risks to the environment.

Guidelines for the safe handling and disposal of antineoplastic agents must be observed. Any unused medicinal product or waste material should be disposed of in accordance with local requirements

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The current application for a new indication is based on literature review. Compliance of the published studies with the GCP principles is not stated in the Clinical Overview.

- Tabular overview of clinical studies

## Conditioning treatment prior to HPCT

A total of 4715 adult patients were treated with carmustine intravenously, in combination with other chemotherapeutic drugs with or without TBI as preconditioning treatment prior to HPCT in clinical studies.

Table 1: allogenic HPCT patients

| Characteristic   | Conditioning treatment   |   No. of patinets | Reference                       |
|------------------|--------------------------|-------------------|---------------------------------|
| Lymphoma         | BEAM                     |                30 | Przepiorka et al., 1999         |
|                  | BEAM/fludarabine/TBI     |                11 | Buser et al.,2007               |
|                  | BEAM/alemtuzumab         |                44 | Ingramet al.,2008               |
| NHL              | CBV                      |                49 | Law etal.,2006:Rossiet al.,2003 |
| Total            | Total                    |               134 |                                 |

BEAM, carmustine, etoposide, cytarabine and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; NHL, non-Hodgkin lymphoma TBI, total body inradiation.

Table 2: Autologous HPCT in adult patients

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Characteristic                | Conditioning treatment          |   No. of patinets | Reference                      |
|-------------------------------|---------------------------------|-------------------|--------------------------------|
| Solid tumours or NHL          | Cyclophosphamide/ thiotepa/BCNU |                40 | Moormeier et al., 1990         |
| HL/NHL/AML/ mye- loma/CML/ALL | BEM                             |                72 | Ager et al., 1996              |
| Lymphoma                      | CBV                             |                35 | Sehn et al., 1998              |
| Lymphoma                      | CBV                             |                27 | Cucuianu et al. 1995           |
| Lymphoma                      | BEAM                            |                73 | Martin et al., 2015            |
| Lymphoma                      | BEAM/BEAC                       |                19 | Rodriguez et al., 2007         |
| Hodgkin's disease             | mimi-BEAM                       |                24 | Fernandez-Jimenez 12 al., 1999 |
| Hodgkin's disease             | mini-BEAM                       |                55 | Martin et al., 2001            |
| Hodgkin's disease             | BEAM                            |                32 | Raut et al.,2016               |
| Hodgkin's disease             | BEAM                            |                37 | Esbah et al.,2016              |
| Hodgkin's disease             | BEAM                            |                64 | Khattry et al., 2016           |
| Hodgkin's disease             | BEAM                            |               607 | Olivieri et al., 2018          |
| Hodgkin's disease             | BEAM                            |                72 | Patir et al., 2018             |
| Hodgkin's disease             | Dexa-BEAM/BEAM                  |               161 | Schmitz et al.2002             |
| Hodgkin's disease             | CVB/BEAM                        |                47 | Schmitz et al., 1993           |
| Hodgkin's disease             | CBV                             |                56 | Kessinger et al., 1991         |
| Hodgkin's disease             | CBV                             |               131 | Fleming et al., 1999           |
| Hodgkin's disease             | CBV                             |                62 | Burns et al., 1995             |
| Hodgkin's disease             | CBV                             |                78 | Neben et al.,2000              |
| Hodgkin's disease             | BEAM                            |                40 | Argiris et al., 2000           |
| Hodgkin's disease             | CBV                             |                85 | Bierman et al., 1996           |

<div style=\"page-break-after: always\"></div>

|                  | CBV                                           |   33 | Hurd et al., 1990      |
|------------------|-----------------------------------------------|------|------------------------|
|                  | CBV                                           |   04 | Lin et al., 2002       |
|                  | BEAC                                          |   70 | Lancet et al., 1998    |
| HL               | CBV                                           |   43 | Benekliet al.,2008     |
|                  | mini-BEAM                                     |   34 | Kuruvillaetal.2o06     |
|                  | BEAM                                          |  128 | Singer et al., 2019a   |
| NHL              | CBV                                           |   78 | Wheeler et al.,1993    |
|                  | CBV                                           |  110 | Bolwell et al., 2002   |
|                  | BEAM                                          |  269 | Singer et al., 2019b   |
|                  | BEAM                                          |   48 | Zaucha et al., 2008    |
|                  | BEAC                                          |   83 | Weaver et al., 1997    |
|                  | BEAC                                          |   27 | Weaver et al.,1998     |
|                  | BEAC/BEAM                                     |   97 | Jo et al.,2008         |
| NHL/HL           | BEAM                                          |  148 | Caballeroetal.1997     |
|                  | BEAM                                          |  100 | Geisler et al., 1998   |
|                  | BEAM                                          |   87 | Sakellari et al.,2015  |
|                  | CBV±cytarabine                                |   40 | Kessinger et al., 1989 |
| PCNSL            | Rituximab/BCNU/ thiotepa                      |   32 | Kasenda et al.,2017    |
| Multiple myeloma | BCNU/ melphalan                               |   49 | Comenz0 et al.,2006    |
|                  | BCNU/ cyclophospha mide/melphalan/doxorubicin |  200 | Child et al., 2003     |
| Total            | Total                                         | 3497 | 3497                   |

ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; BCNU, carmustine; BEAC, carmustine, etoposide, cytarabine and cyclophosphamide; BEM, carmustine, etoposide and melphalan; CBV, cyclophospha mide, carmustine, and etoposide; CML, chronic myeloid 1eukaemia; HL, Hodgkin lymphoma; BEAM, carmustine, etoposide, cytarabine and melphalan; NHL, non-Hodgkin lymphoma; PCNSL, primary central nervous system lymphoma.

## Carmustine with total body irradiation

A total of 334 patients with haematological diseases received BCNU intravenously, in combination with TBI/IFR and other chemotherapeutic drugs as conditioning treatment before allogenic or autologous HPCT.

Table 3: Allogenic/Autologous HPCT in adult patients

| Characteristic        | Conditioning treatment            |   No. of patinets | Reference           |
|-----------------------|-----------------------------------|-------------------|---------------------|
| Multiple myeloma      | BEM/TBI                           |                14 | Fermand et al.,1989 |
| NHL/Hodgkin's disease | CBV/BEAM/BEAC/TBI                 |                24 | Brice et al., 1992  |
| MCL                   | BCNU/cytoxan/etoposide /TBI       |                02 | Milpied et al.,1998 |
| NHL                   | BEP/IFR                           |                70 | Wadhwaet al.,2005   |
| Lymphoma              | Tositumoma-BEAM/ Rituxi- mab-BEAM |               224 | Vose et al.,2013    |
| Total                 | Total                             |               334 | 334                 |

BCNU, carmustine; BEAC, carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM, carmustine, etoposide, cytarabine and melphalan; BEM, carmustine, etoposide and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; MCL, mantle cell 1ymphoma; IFR, involved-field radiotherapy; NHL, non-Hodgkin lymphoma; TBI, total body irradiation.

## Carmustine without total body irradiation

A  total  of  750  patients  with  haematological  diseases  received  BCNU  intravenously  and  other chemotherapeutic drugs without TBI as conditioning treatment before autologous HPCT.

<div style=\"page-break-after: always\"></div>

Table 4: Autologous HPCT in adult patients

| Characteristic    | Conditioning treatment   |   No. of patinets | Reference                    |
|-------------------|--------------------------|-------------------|------------------------------|
| Hodgkin's disease | BCNU                     |                63 | Nademanee et al., 1995       |
| Hodgkin's disease | CBV                      |                74 | Horning et al., 1997         |
| Lymphomas         | BEAM/BEAC/CBV            |               373 | Caballeroetal.,2003          |
| NHL               | BEAM                     |                47 | Liu et al.,2010              |
| NHL               | CBV                      |                87 | Stockerl-Goldsteinetal. 1996 |
| NHL/HL            | BEM/BEAM                 |               106 | Mahendra et al., 1996        |
| Total             | Total                    |               750 | 750                          |

BCNU, carmustine; BEAC, carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM, carmustine, etoposide, cytarabine and melphalan; BEM, carmustine, etoposide and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.

## Paediatrics

A total of 152 patients with haematological diseases received BCNU intravenously, in combination with other chemotherapeutic drugs as conditioning treatment before autologous HPCT.

Table 5: Autologous HPCT in paediatric patients

| Characteristic    | Conditioning treatment   |   No. of patinets | Reference           |
|-------------------|--------------------------|-------------------|---------------------|
| Hodgkin's disease | CBV                      |                17 | Frankovichetal.2001 |
| HL/NHL            | CBV                      |                69 | Harrisetal.2011     |
| HL                | BEAM                     |                66 | Hazaretal.,2015     |
| Total             | Total                    |               152 | 152                 |

BEAM, carmustine, etoposide, cytarabine and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.

## 2.3.2. Pharmacokinetics

The  pharmacokinetics  of  carmustine  as  a  well-known  active  substance  was  described  in  the  initial marketing authorization. No new data were provided. Clinical overview contains information from the published literature.

## Administration/Distribution/Metabolism/Excretion

Intravenous  administered  BCNU  is  rapidly  degraded,  with  no  drug  intact  detectable  after  15  min (Martindale,  2014).  Though  Weiss  &amp;  Issell  (1982)  reports  that,  five  minutes  after  administration  no parent drug can be detected in plasma. Because of the good lipid solubility and the lack of ionization at the physiological pH, BCNU is very well transferred through the blood brain barrier. Within 30 min after intravenous  administration  drug  products  appear  in  the  spinal  fluid  at  concentrations  15  -  30  %  of concurrent plasma level (Weiss &amp; Issell, 1982). Though the SmPC BiCNU (2015) states that level of radioactivity in the cerebrospinal fluid (CSF) is at least 50 % higher than the level measured concurrently in  plasma.  The  distribution  of  BCNU  in  humans  is  characterised  by  a  two-chamber  model.  After intravenous infusion over one hour, the BCNU-level in plasma drops in a biphasic manner. The half-life α -and β -accounts to one to four and 18 - 69 min, respectively (SmPC BiCNU, 2015). It is presumed that the metabolites of BCNU cause its antineoplastic and toxic activity. Degradation product of BCNU can be detected in the urine up to 72 h after administration (Weiss &amp; Issell, 1982). Approximately 60 - 70 % of a total dose is excreted in the urine in 96 h and about 10% as respiratory CO2. The fate of the remainder is undetermined (DeVita et al., 1967).

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

The pharmacodynamics of carmustine are described in the initial marketing authorization.

## Mechanism of action

BCNU are lipid-soluble and have low molecular weight a characteristic that facilitate the entry into the brain.  BCNU  alkylates  DNA  and  RNA  and  has  also  been  shown  to  inhibit  several  enzymes  by carbamoylation of amino acids in proteins (Martindale, 2015). It is thought that the antineoplastic and toxic activities of BCNU may be due to metabolites. It is shown that DNAcross-linking does occur and that the reaction appears to proceed in two steps: Chlorethylation of a nucleophilic site on one strand and displacement of a chloride ion on the other strand. The result is an ethyl bridge between the strands that prevents unwinding of the DNA double helix, a lethal effect. The high alkylating activity very likely contributes to the toxic effect given interstitial pneumonitis. It is the alveolar lining cells that are injured (Weiss &amp; Issell, 1982; Woolley et al., 1976). In addition, BCNU is known to carbamylate lysine residues on proteins (Kann, 1978) causing protein carbamylation, a post translational protein modification that could irreversibly  inactivate  enzymes  including  glutathione  reductase  (Tew  et  al.,  1985;  Jochheim  &amp; Baillie, 1993; Vanhoefer &amp; Yin, 1997). Therefore, by inhibiting glutathione reductase an enzyme that plays critical roles in cellular oxidative balance, BCNU treatment may modulate the cellular oxidative status.

Chemotherapy induces high remission rates in high-grade lymphoma. However relapse remains a major problem. One approach to this is myeloablative chemotherapy with transplantation of autologous bone marrow or peripheral blood progenitor cells (PBPC). Immunological mechanisms have been suggested to play a role in the prevention of relapse after transplantation. Scheid et al. (1995) investigated the recovery of cellular immune functions after high-dose chemotherapy (BCNU, etoposide, cytarabine and melphalan or busulfan and cyclophosphamide) and PBPC transplantation in 5 patients (age: 18 - 49 years) with high grade NHL. All patients showed rapid reconstitution of natural killer (NK) and inducible lymphokine-activated killer (LAK)-activity 10 - 14 days after transplantation. Four of 5 patients showed higher levels of LAK-generation in the post-transplant period compared with levels prior to myeloablative treatment. Absolute lymphocyte counts in peripheral blood reached 1.0 × 109/L between days 10 and 13 with a predominance of CD8+ cells and an inversion of the CD4/CD8 ratio. Four of 5 patients had a transient increase in CD56+ and CD16+ cell counts post-transplant. No change in the proportion of CD25+ cells was noted. These results show that PBPC transplantation leads to a rapid recovery of cellular immune functions after myeloablative chemotherapy and provides evidence for an increased presence of LAK precursor cells early in the post-transplant period which can be activated by interleukin-2 to exert high levels of cytotoxicity.

Moos  et  al. (1998)  examined  the  clinical  significance  of  t(14;18)-positive  cells  in  samples  from  47 patients (male/female: 26/21; age: 26 - 56 [median: 45] years) with follicular NHL who underwent highdose therapy with autologous peripheral blood stem cell transplantation (APBSC). At the time of PBSC mobilisation, 25 patients were in first remission, while 22 patients had a history of previous treatment failure. At the same time, 43 patients had polymerase chain reaction (PCR)-positive cells in samples from bone marrow and/or peripheral blood. Independent of the remission status, high-dose cytarabine and mitoxantrone with granulocyte colony-stimulating factor  (G-CSF) support were administered for PBSC mobilisation. Following high-dose conditioning therapy which consisted of cyclophosphamide (200 mg/kg) and hyperfractionated TBI (14.4 Gy) or BEAM (BCNU, etoposide, cytarabine, melphalan), 34 patients received PCR-positive and 13 patients received PCR-negative autografts. After a median followup time of 20 months (range: 6 - 50) post-transplantation, 33 patients were in remission, while 14 patients had relapsed after a median time of 14.5 months (range: 10 - 42). Using the Andersen-Gill

<div style=\"page-break-after: always\"></div>

proportional hazards regression model for the analysis of RFS, PCR-positive findings in samples from bone marrow and/or peripheral blood at any given time-point after transplantation were associated with an increased estimated hazard ratio of 4.5 in comparison with a PCR-negative finding (p = 0.013). On the other hand, patients included while they were in first remission had a smaller estimated hazard ratio of 0.3 when compared with patients with a history of previous treatment failure (p = 0.048). For the latter group of patients, this translates into a significantly smaller probability of RFS in comparison to patients who were in first remission at the time of PBSC-mobilisation (p = 0.012). In conclusion, the remission status of the patients before autografting and the PCR status as assessed on the occasion of follow-up examinations are significant prognostic parameters for RFS in patients with follicular lymphoma undergoing high-dose therapy with PBSC autografting.

Rossi et al. (1997) reported on long-term haematological recovery and clinical outcome after high-dose chemotherapy supported by circulating progenitor cells transplantation in NHL patients, and analysed the  role  of  variables  which  might  influence  engraftment.  Sixty  three  consecutive  NHL  patients  were enrolled in this study. Two groups of patients were considered for analysis: the first 34 patients had untreated diffuse large cell lymphoma with unfavorable prognostic factors. A second group of 29 patients underwent  transplantation  for  resistant  or  relapsing  NHL  with  low,  intermediate  and  high-grade histology. All patients received the BEAM (BCNU 300 mg/m2 × 1 day; cytarabine 200 mg/m2 × 4 days, twice daily; etoposide 100 mg/m2 × 4 days, twice daily and melphalan 140 mg/m2 × 1 day) conditioning regimen. All patients showed a rapid haematological reconstitution. Forty-three patients (68%) achieved long-term complete trilineage engraftment within a median of 107 days from circulating progenitor cells transplantation.  The  neutrophil  count  was  the  first  parameter  reaching  complete  normalisation,  and haemoglobin was the last. Failure to meet the trilineage levels was due to lack of platelet recovery and was more frequent in patients transplanted in the setting of salvage protocols. By Kaplan-Meier analysis, the probability of a full reconstitution was 80% in patients to whom transplant was offered as part of a front-line therapy and 50% when transplant was given in the salvage programmes. Multivariate analysis showed that sustained long-term haematological reconstitution was significantly related to younger age, the time taken to achieve short-term reconstitution, and bone marrow involvement.

A comprehensive strategy of chemotherapy mobilisation of PBPC followed by high-dose chemotherapy for the treatment of refractory or relapsed Hodgkin's disease was evaluated. Patients with relapsed or refractory Hodgkin's disease were enrolled to receive cyclophosphamide, etoposide ± cisplatin (CE ± P) and recombinant human GCSF mobilisation of PBPCs. Patients achieving ≤ 2.5 × 106 CD34+ cells/kg following initial mobilisation were eligible to receive a second course of CE ± P. Unmanipulated PBPCs alone were infused following administration of high-dose BCNU, etoposide, cytarabine, and cyclophosphamide  (BEAC).  Thirty-eight  consecutive  patients  with  relapsed  or  refractory  Hodgkin's disease were initially enrolled to receive CE ± P. Analysis was performed on an intent-to-treat basis. A median of 6.4 × 106 CD34+ cells/kg (range: 0.66 - 62.3) were collected with a median of 3 (range: 2 9) leukaphereses. Twentyeight of 38 (74%) patients achieved ≥ 2.5 × 106 CD34+ cells/kg. Analysis of variables  potentially  effecting  mobilisation  of  CD34+  cells  revealed  that  only  the  amount  of  prior chemotherapy statistically influenced collecting CD34+ cells (p = 0.005). Two of six patients undergoing a second mobilisation procedure achieved ≥ 2.5 × 106 CD34+ cells/kg for a total of 30 patients eligible to proceed with high-dose BEAC. The 3-year Kaplan-Meier estimate of OS and PFS for all 38 patients is 65 and 53%, respectively. The 3-year OS and PFS for the 28 patients receiving BEAC is 77 and 64% respectively vs. 33 and 30% for the 10 patients not receiving BEAC. The strategy of CE ± P and BEAC was well tolerated with a 100-day treatment-related mortality of 3.6%. All patients experienced rapid and sustained haematologic recovery with PBPCs alone. The median time to an absolute neutrophil count ≥ 5 × 109/L and platelet transfusion independence was 10 days. Treatment of refractory or relapsed Hodgkin's utilizing a strategy of CE ± P PBPC mobilisation for haematopoietic reconstitution following

<div style=\"page-break-after: always\"></div>

high-dose BEAC is associated with acceptable toxicity and rapid engraftment. A 3-year PFS greater than 60% can be achieved in the community hospital setting (Weaver et al., 1996).

## 2.3.4. PK/PD modelling

Not applicable

## 2.3.5. Discussion on clinical pharmacology

As this concerns a bibliographic application, relevant publications on clinical pharmacology have been submitted with focus on the issues related to proposed indication.

The pharmacokinetic and pharmacodynamic profile of carmustine is well known, and published literature provides detailed information. The Applicant did not perform any new studies and provided summary of the published literature. The available information on the clinical pharmacology of the carmustine is considered adequate.

## 2.3.6. Conclusions on clinical pharmacology

Carmustine is well known active substance. Pharmacokinetics and pharmacodynamics of carmustine is well  known  and  well  described  in  the  literature.  Clinical  overview  on  the  clinical  pharmacology  of carmustine is adequate and acceptable. Information in Section 5.2 of the SmPC is adequate.

## 2.4. Clinical efficacy

## 2.4.1. Dose response studies

No dose response studies were performed. The Applicant refers to published data.

A reasonably tolerated dose of BCNU was determined in the initial clinical trial to be 250 mg/m2 of body surface in a single dose repeated at six-week intervals (DeVita et al., 1965).

As the major determinant of dose is the myelotoxicity some dose individualisation is necessary depending on the degree of marrow compromise by prior treatment or concurrent use of other drugs. Most clinicians have elected to administer the total dose over two or three days to diminish the emesis effect (Weiss &amp; Issell, 1982).

In various clinical studies, BCNU 300 mg/m2 is used in combination with other chemotherapeutic agents in patients with refractory or recurrent lymphoma before allogenic or autologous HSCT with or without TBI (Bierman et al., 1996; Burns et al., 1995; Buser et al., 2007; Geisler et al., 1998; Ingram et al., 2008; Kessinger et al., 1991; Lancet et al., 1998; Liu et al., 2010; Milpied et al., 1998; Przepiorka et al., 1999; Wadhwa et al., 2005; Weaver et al., 1997). In a phase I dose escalation study, BCNU 150 750 mg/m2 is used in combination with other chemotherapeutic drugs in patients with refractory NHL (Moormeier et al., 1990). In another studies, BCNU (600 mg/m2, 450 mg/m2 or 300 mg/m2) is used in combination with other chemotherapeutic agents in patients with haematological malignancies (Ager et al., 1996; Bolwell et al., 2002; Fleming et al., 1999).

A  review  summarised  in  2017,  that  the  different  dose  of  BCNU  is  dependent  on  the  BCNU  based conditioning regime. In a BEAM regime prior to HPCT, BCNU 300 mg/m2 is used, whereas in CBV, higher dosis of BCNU are applied (Damaj et al., 2017).

<div style=\"page-break-after: always\"></div>

The dose of carmustine used in conditioning regimen depends on the chosen regimen. The dose of 300 - 600 mg/m2 carmustine given intravenously before HPCT is considered acceptable and in line with available data from literature.

## 2.4.2. Main studies

## Clinical trials in the conditioning treatment prior to autologous HPCT

| Study Diagnosis          | Objective                                 | Design Comparisongroups (Regimes)    | Nt NBCNU (Median age)       | Results                                                                                                    |
|--------------------------|-------------------------------------------|--------------------------------------|-----------------------------|------------------------------------------------------------------------------------------------------------|
| Chen et al., 2015 HL+NHL | Analyse impact of HDT regimes on clinical | RS, COM BEAM vs.CBV vs. BuCy vs. TBI | 4917 BEAM: 1730 (55, 18-79) | 1-year incidence of IPS:3-6%; highest in recipients of CBVhigh (HR 1.9) and TBI (HR 2.0) compared to BEAM. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                    | outeome: IPS, TRM, PFS, OS                                                                               |                                              | CBVl: 1249 (49, 18-80) CBVleh: 604 (46, 18-74)                                                              | ly-TRM: 4-8%; similar between regimens. Among patients with NHL, there was 1signifieant interaction between histology. HDT regimen, and outcome. Compared to BEAM, CBVlow (HR 0.63)was associated with lower mortality inFL(P=0.001),and CBVhlgh (HRl.44)with higher mortality in DLBCL (P=0.001). For patients with HL, CBvhgh (HR1.54), CBVbw (HR1.53), BuCy (HR1.77) and TBI (HR 3.39) were associated with higher mortality compared to BEAM (P<0.001).                    |
|----------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------|-------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sellner et al., 2016 HL + NHL (PCNSL + DLBCL +FL)  | Analyse risks and benefits of TT-based regimes compared to BEAM: PFS. OS                                 | RS, COM BEAM 15. TT (including BEAM v. TEAM) | 1566 BEAM: 1031 (50 18-79) TT:535 (49, 19-74) matched analysis: BEAM: 199 (44, 19-72) TEAM: 110 (44, 19-66) | No signifieant differences between thiotepa and BEAM groups for any swvival end point were identified in the whole sample or disease entity subsets. Matched 1analysis:no sigmificant differences between the two groups for any survival end point; frequency ofcommon infectious and non- infectious complications including secondary malignancies SEM comparable between TEAM and BEAM                                                                                     |
| Olivieri et al., 2018 HL +NHL                      | Analyse safety and effieaey of BEAM and FEAM: frequency of severe infections (primary), OS, PFS, RI, NRM | RS, COM BEAM.FEAM                            | 1038 BEAM: 607 (53.1, 16.5-79.5) FEAM: 431 (52.7, 17.2-77.8)                                                | FEAM resulted in higher rates of gastrointestinal and infectious toxicihies, including severe oral mucosifis grade >3 (BEAM=31% vs. FEAM=44%, P=0.001), and sepsis from Gram-negative bacteria (mean isolates/patient: BEAM=0.1 Vs. FEAM=0.19, P<0.001 ). 2y-0S (83.9%; 95% CI, 81.5% to 86.1%) and PFS (70.3%; 95% CI, 67.4% to 73.1%) were not different in the two groups. Mortality from infection was higherin the FEAM group (sub-HR, 1.99; 95% C, 1.02 to 3.88; P=0.04) |
| Marchesi et al.,2018 HL + NHL (MCL. DLBCL, T- NHL) | Compare efficacy and safety ofFEAM and BEAM: PFS, OS, TRM                                                | RS, COM, IBEAMvs.FEAM                        | 362 BEAM: 200 (47, 15-69) FEAM: 162 (49, 15 69)                                                             | 2y-PFS BEAM: 76% Vs. FEAM: 74%; P=0.211 2y-0S BEAM: 87% vs.FEAM: 84%; P=0.578 2y-cumulative incidence of relapse BEAM:12% V5.FEAM:14%; P=0.235)                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                           |                                                           |                       |                                                           | significantly higher probability of being in a CR status at post-transplant day-100 assessment in the BEAM group compared with FEAM (87% vs 74.7%; P=0.01                                                                                                                                             |
|-------------------------------------------|-----------------------------------------------------------|-----------------------|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Khattry et al., 2016 HL + NHL             | Compare toxieity and efficacy of LACE vs. BEAM            | RS, COM, BEAMv.LACE   | 139 (26.5, 6-60) BEAM: 64 (25, 8 57) LACE: 75 (23 4-58)   | LACE and BEAM were comparable in swvival outcome: 5y-0S:46% Vs.47%(P=0.389) 5y-PFS:37% Vs.47% (P=0.938) TRM: 9% vs.13% (P=0.7448) The incidence of grade 3-4 oral mucositis (9 vs.38%; P<0.001) and parenteral nuhition requirement (32 Vs 69%; P=0.001) were significantly lower in the LACE cohort. |
| Sakellariet al., 2015 HL + NHL            | Evaluate efficacy and toxicity of BEAM vs. BuEM           | RS, COM BEAMvs.BuEM   | 137 BEAM:84 BuEM: 50                                      | BEAM and BuEM were comparable in: 2y-PFS: 63.2% V5. 65.6% (P=0.7) 2y-0S: 76.7% vs. 79.8% (P=0.89)                                                                                                                                                                                                     |
| Joffe et al. 2018 HL + NHL                | Compare outeome of BEAM and TECAM: PFS, OS, TRM           | RS, COM, BEAMvs.TECAM | 125 BEAM: 60 (43.5, 16-68) TECAM: 65 (55 (16-75)          | TECAM and BEAM had comparable results: 3y-PFS 49 Vs. 62%,P=0.16; 3y-OS 64 'S.A 71%6, P=0.44; TRM 1.6 vs.5%,P=0.35                                                                                                                                                                                     |
| Patir et al., 2018 NHL + HL               | Evaluate efficacy and toxicity of TECAM and BEAM: PFS, OS | RS, COM, BEAMvs.TECAM | 108 BEAM: 72 (49, 20 68) TECAM: 36 (54.5, 28-69)          | TECAM pue BEAM were comparable in swvival outcome: 2y-PFS: 55.7% vs. 52.9%, (P=0.811) 2y-0S: 55.9% vs. 67%, (P=0.238).                                                                                                                                                                                |
| Kothari et al. 2016 HL + NHL (DLBCL + FL) | Compare outeome of LEAM and BEAM: OS, PFS, NRM            | RS, COM, LEAM.BEAM    | 100 BEAM: 50 (51.0, 45.0-52.0) LEAM: 50 (52.5, 45.9-52.6) | no signifieant difference between LEAM and BEAM: 3y-0S: 86% V5. 86% 3y-PFS 69% vs. 75% The NRM was similarin both cohorts: 4%for LEAMvs.2%for BEAM at 100 days, and 4% for both cohorts at 12 months;                                                                                                 |

## Chen et al, 2015

The study analysed 4,917 patients (NHL, n=3,905; HL, n=1012) who underwent AHCT from 1995  to  2008  using  the  most  common  HDT  platforms:  BEAM  (n=1730);  CBV  (n=1853); busulphan and cyclophosphamide (BuCy) (n=789); and TBI-containing treatment (n=545). CBV was divided into CBVhigh and CBVlow based on BCNU dose.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Title: Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation   | Title: Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation   | Title: Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation   | Title: Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation   | Title: Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation                                                                                                                                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                               | Chen et al., 2015                                                                                                                                              | Chen et al., 2015                                                                                                                                              | Chen et al., 2015                                                                                                                                              | Chen et al., 2015                                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                         | Retrospective registry study                                                                                                                                   | Retrospective registry study                                                                                                                                   | Retrospective registry study                                                                                                                                   | Retrospective registry study                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                | Duration of main phase: Duration of Rum-in phase:                                                                                                              | Duration of main phase: Duration of Rum-in phase:                                                                                                              | Duration of main phase: Duration of Rum-in phase:                                                                                                              | 14-17 months Not applicable                                                                                                                                                                                                                                                                                                                                                          |
| Hypothesis                                                                                                                                                     | To analyse the impact of several commonly used HDT regimens on clinical outcomes                                                                               | To analyse the impact of several commonly used HDT regimens on clinical outcomes                                                                               | To analyse the impact of several commonly used HDT regimens on clinical outcomes                                                                               | To analyse the impact of several commonly used HDT regimens on clinical outcomes                                                                                                                                                                                                                                                                                                     |
| Treatments groups'                                                                                                                                             | BEAM                                                                                                                                                           | BEAM                                                                                                                                                           | BEAM                                                                                                                                                           | BCNU, etoposide, cytarabine, and melphalan. 3-year, 1730                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                | CBVlw                                                                                                                                                          | CBVlw                                                                                                                                                          | CBVlw                                                                                                                                                          | Low dose of cyclophosphamide, BCNU, and etoposide. 3-year, 1249                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                | CBVigh                                                                                                                                                         | CBVigh                                                                                                                                                         | CBVigh                                                                                                                                                         | High dose of cyclophosphamide, BCNU, and etoposide. 3-year, 604                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                | BuCy                                                                                                                                                           | BuCy                                                                                                                                                           | BuCy                                                                                                                                                           | busulphan and cyclophosphamide. 3-year, 789                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                | TBI                                                                                                                                                            | TBI                                                                                                                                                            | TBI                                                                                                                                                            | Total body inradiation. 3-year, 545                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                      | Primary endpoint                                                                                                                                               | OS                                                                                                                                                             |                                                                                                                                                                | The primary endpoint of this analysis was OS among the different conditioning regimens.                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                | Secondary endpoint                                                                                                                                             | IPS, relapse/progression PFS                                                                                                                                   | TRM. and                                                                                                                                                       | Secondary endpoints include IPS, TRM, relapse or progression, and PFS. TRM was defined as any death without recurent lymphoma.Relapseor progressionwas defined as evidence of disease recurence censored at the date of last contact and using death in remission as the competing hazard. PFS was defined as swvival without death or relapse censored at the date of last contact. |
| Database lock                                                                                                                                                  | 1995-2008                                                                                                                                                      | 1995-2008                                                                                                                                                      | 1995-2008                                                                                                                                                      | 1995-2008                                                                                                                                                                                                                                                                                                                                                                            |
| Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                 |
| Analysis deseription                                                                                                                                           | Primary Analysis                                                                                                                                               | Primary Analysis                                                                                                                                               | Primary Analysis                                                                                                                                               | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                     |
| Analysis population and                                                                                                                                        | 4,917 patients (NHL, n=3,905; HL, n=l,012) who underwent AHCT from 1995-2008 using the most common HDT platforms.                                              | 4,917 patients (NHL, n=3,905; HL, n=l,012) who underwent AHCT from 1995-2008 using the most common HDT platforms.                                              | 4,917 patients (NHL, n=3,905; HL, n=l,012) who underwent AHCT from 1995-2008 using the most common HDT platforms.                                              | 4,917 patients (NHL, n=3,905; HL, n=l,012) who underwent AHCT from 1995-2008 using the most common HDT platforms.                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| P-value           | 0.002 CBVhigh    |
|-------------------|------------------|
| Comparison groups | and CBVlow       |
| HR (95% CI)       | 1.75 (1.14-2.70) |
| P-value           | 0.01             |
| Comparison groups | BuCy and CBVbw   |
| HR (95% CI)       | 1.17 (0.75-1.84) |
| P-value           | 0.489            |
| Comparison groups | TBI and CBVlow   |
| HR (95% CI)       | 1.90 (1.19-3.04) |
| P-value           | 0.008            |
| Comparison groups | BuCy and CBVlgh  |
| HR (95% CI)       | 0.67 (0.42-1.06) |
| P-value           | 0.085            |
| Comparison groups | TBI and CBVh     |
| HR (95% CI)       | 1.08 (0.67-1.76) |
| P-value           | 0.746            |
| Comparison groups | TBI and BuCy     |
| HR (95% CI)       | 1.62 (0.99-2.65) |
| P-value           | 0.055            |
| Comparison groups | BuCy and BEAM    |
| HR (95% CI)       | 1.51 (1.15-1.97) |
| P-value           | 0.003            |
| Comparison groups | TBI and BEAM     |
| HR (95% CI)       | 2.01 (1.21-3.34) |
| P-value           | 0.007            |
| Comparison groups | BEAM and CBVu    |
| HR                | 0.63             |
| P-value           | 0.001            |
| Comparison groups | BEAM and CBVtigh |
| HR.               | 1.44             |
| P-value           | 0.001            |
| Comparison groups | CBVl and BEAM    |
| HR.               | 1.54             |
| P-value           | 0.001            |
| Comparison groups | CBVlow and BEAM  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | HR.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.53 c0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | BuCy and BEAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | HR.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.77                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | TBI and BEAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | HR.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 3.39                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Notes!               | The dose dishibution of BCNU vanied widely among recipients of CBV, clustering approximately aroumd 300 mg/m² (median 296 mg/m² [225-374 mg/m²]) and at 450 mg/m² (median 453 mg/m² [376-807 mg/m²]), which were then separated into CBVb\" and CBVlgh aroumd 300 mg/m² (median 293 mg/m² [227-347 mg/m²]).                                                                                                                                                                                | The dose dishibution of BCNU vanied widely among recipients of CBV, clustering approximately aroumd 300 mg/m² (median 296 mg/m² [225-374 mg/m²]) and at 450 mg/m² (median 453 mg/m² [376-807 mg/m²]), which were then separated into CBVb\" and CBVlgh aroumd 300 mg/m² (median 293 mg/m² [227-347 mg/m²]).                                                                                                                                                                                | The dose dishibution of BCNU vanied widely among recipients of CBV, clustering approximately aroumd 300 mg/m² (median 296 mg/m² [225-374 mg/m²]) and at 450 mg/m² (median 453 mg/m² [376-807 mg/m²]), which were then separated into CBVb\" and CBVlgh aroumd 300 mg/m² (median 293 mg/m² [227-347 mg/m²]).                                                                                                                                                                                |
| Analysis description | Secondary: IPS, TRMI and mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Secondary: IPS, TRMI and mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Secondary: IPS, TRMI and mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                      | The 1-year incidence of IPS was 3-6%; highest in recipients of CBVhigh (HR, 1.9) and TBI (HR 2.0) compared to BEAM. The l-year-TRM was 4-8%; similar between regimens. Compared to BEAM, CBVlow (HR, 0.63) was associated with lower mortality in FL (P=0.001), and CBVhivh (HR1.44) with higher mortality in DLBCL (P=0.001). For patients with HL, CBVl (HR,1.54), CBVk (HR,1.53), BuCy (HR, 1.77) and TBI (HR, 3.39) were associated with higher mortality compared to BEAM (P=0.001). | The 1-year incidence of IPS was 3-6%; highest in recipients of CBVhigh (HR, 1.9) and TBI (HR 2.0) compared to BEAM. The l-year-TRM was 4-8%; similar between regimens. Compared to BEAM, CBVlow (HR, 0.63) was associated with lower mortality in FL (P=0.001), and CBVhivh (HR1.44) with higher mortality in DLBCL (P=0.001). For patients with HL, CBVl (HR,1.54), CBVk (HR,1.53), BuCy (HR, 1.77) and TBI (HR, 3.39) were associated with higher mortality compared to BEAM (P=0.001). | The 1-year incidence of IPS was 3-6%; highest in recipients of CBVhigh (HR, 1.9) and TBI (HR 2.0) compared to BEAM. The l-year-TRM was 4-8%; similar between regimens. Compared to BEAM, CBVlow (HR, 0.63) was associated with lower mortality in FL (P=0.001), and CBVhivh (HR1.44) with higher mortality in DLBCL (P=0.001). For patients with HL, CBVl (HR,1.54), CBVk (HR,1.53), BuCy (HR, 1.77) and TBI (HR, 3.39) were associated with higher mortality compared to BEAM (P=0.001). |

## Sellner et al. (2016)

This  study  of  is  a  retrospective  registry  study  of  the  EBMT  database  and  aimed  to  provide information  on  the  potential  risks  and  benefits  of  TT-based  high-dose  regimens  for  AHCT  in distinct subtypes of lymphoma outside the PCNSL setting. TT-based regimens were compared to BEAM in AHCT for diffuse large DLBCL (excluding PCNSL), FL or HL. A total of 14,544 patients (589 thiotepa and 13,955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1,031 BEAMtreated  patients  were  matched  in  a  1:2  ratio  for  final  comparison.  No  significant  differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets.

## Olivieri et al. (2018)

This is a retrospective cohort study in 18 Italian centres to compare the frequency of infection and efficacy of BEAM (BCNU, 300 mg/m2 × 1 day; etoposide, 200 mg/m2 × 4 days; cytarabine, 400 mg/m2 × 4 day; melphalan, 140 mg/m2 × 1 day) and FEAM (fotemustine, 150 mg/m2 × 2 days; etoposide, 200 mg/m2 × 4 days; cytarabine, 400 mg/m2 × 4 day; melphalan, 140 mg/m2 × 1 day) regimens for AHCT in lymphomas performed from 2008 to 2015. Even though the study primarily aimed to analyse the frequency of infection events, secondary study endpoints included OS and PFS. Therefore, the retrospective study was included into the main studies. In this study, 1,038 patients (BEAM=607 [female 40.2%; age: 16.5-79.5 years], FEAM=431 [female 39.2%; age: 17.2-77.8 years]), of which 27% had HL, 14% indolent NHL, and 59% aNHL were enrolled. Baseline  characteristics  including  age,  sex,  stage,  B-symptoms,  extranodal  involvement, previous  treatments,  response  before  AHCT,  and  overall  conditioning  intensity  were  well balanced between BEAM and FEAM; notable exceptions were median AHCT year (BEAM = 2011 vs. FEAM = 2013, p &lt; 0.001), Sorror score ≥3 (BEAM = 15% vs. FEAM = 10%, p = 0.017), and radiotherapy use (BEAM = 18% vs. FEAM = 10%, p &lt; 0.001). Response status at day 100 postAHCT (overall response: BEAM = 91% vs. FEAM = 88%, p = 0.42), 2-year OS (83.9%; 95% confidence interval [CI], 81.5% to 86.1%) and PFS (70.3%; 95% CI, 67.4% to 73.1%) were not different in the two groups. Mortality from infection was higher in the FEAM group (sub-HR, 1.99; 95% CI, 1.02 to 3.88; p = 0.04). It was concluded by the authors that BEAM and FEAM do not appear different in terms of survival and disease control.

<div style=\"page-break-after: always\"></div>

The study of Marchesi et al. (2018) also compared FEAM regimen to the BEAM regimen due to supply shortening of BCNU in Italy. From January 2007 to January 2017, 362 consecutive lymphoma patients undergoing AHCT after BEAM (n = 200) and FEAM (n = 162) were analysed by reviewing clinical records in two centres of Rome. FEAM was administered according to the original protocol. Primary endpoint was the treatment response rate assessed at day -100 after AHCT. Secondary end-points were (a.o.) conversion rate into CR assessed at day +100 after AHCT, PFS and OS.

There was a significant difference in the median follow-up (77 months for BEAM vs 25 for FEAM; P &lt; 0.0001), due to the fact that FEAM was more recently introduced. A significantly higher probability of being in a CR status at post-transplant day-100 assessment in the BEAM group compared with FEAM (87% vs. 74.7%; P=0.01) was observed. No significant difference between the two cohorts in PFS (2-year-PFS BEAM: 76% vs. FEAM: 74%; P=0.211), cumulative incidence of relapse (2-year cumulative incidence of relapse BEAM: 12% vs. FEAM: 14%; P=0.235), and OS (2-year OS BEAM: 87% vs. FEAM: 84%; P=0.578) could be detected.

Khattry et al. (2016) compared the LACE (Lomustine 200 mg/m2, etoposide 1000 mg/m2, cytarabine 2000 mg/m2, cyclophosphamide 1800 mg/m2 and mesna 1800 mg/m2) vs. BEAM (BCNU 300 mg/m2 i.v. on day -6, etoposide at 200 mg/m2 i.v. on days -5 to -2, cytarabine at 200 mg/m2 i.v. twice daily on days -5 to -2 and melphalan at 140 mg/m2). LACE group consisted of  75  patients  (male/female:  56/19;  age:  4-58  [median:  23]  years)  and  BCNU  group  of  64 patients  (male/female:  51/13;  age:  8-57  [median:  25]  years)  undergoing  AHCT  for  primary refractory or relapsed lymphoma. Ninety-two patients with Hodgkin lymphoma and 47 with NHL were enrolled. Probability of OS (LACE 46% vs. BEAM 47%; P=NS) and PFS (LACE 37% vs. BEAM 47%; P=NS) at 5 years was comparable between two groups. The median days to myeloid (10 vs.  11;  P=0.007) and platelet engraftment (13 vs. 15; P=0.026) were shorter for the LACE cohort. The incidence of grade 3-4 oral mucositis (9 vs. 38%; P&lt;0.001) and parenteral nutrition requirement (32 vs. 69%; P&lt;0.001) were significantly lower in the LACE cohort. TRM in the LACE group was 9% compared to 13% in patients treated with BEAM (P=NS). The authors concluded that LACE has better toxicity profile compared to BEAM and results in similar long-term survival in primary refractory or relapsed lymphoma transplant.

Sakellari  et  al.  (2015) retrospectively  analysed  the  outcome  of  patients  (HL  and  NHL) condiioned with BCNU, etoposide, cytarabine and melphalan (BEAM, n=87; BCNU 300 mg/m2 on day-6, etoposide [200 mg/m2/day] and cytarabine [200 mg/m2/day] on days -5 to -2 and melphalan 140 mg/m2 on day-1) or Busulfex, etoposide and melphalan (BuEM, n=50; Busulfex 9.6 mg/kg, etoposide 800 mg/m2 and melphalan 140 mg/m2) in matched-pair analysis on a planned 2:1 ratio. Eighty-seven patients treated with BEAM who fulfilled the matching criteria were randomly selected. Two-year PFS/OS were 63.2%/76.7% for BEAM vs. 65.6%/79.8% for BuEM  after  64.7  and  42.7  months,  respectively.  BEAM  correlated  with  faster  engraftment, reduced infections, less mucositis and liver toxicity, and BuEM with less need for blood cell and platelet  transfusions  and  G-CSF  administration.  In  conclusion,  BuEM  was  well  tolerated  and equally highly efficacious as BEAM for NHL and offered marginally significantly improved PFS and OS in HL with acceptable toxicity and zero mortality.

Joffe et al. (2018) retrospectively compared BEAM (BCNU [300 mg/m2 i.v. day -7], etoposide [200 mg/m2 days -6 to -3], cytarabine [200 mg/m2 days -6 to -3], and melphalan [140 mg/m2 day -2] to the TECAM (thiotepa [40 mg/m2 days -5 to -2], etoposide [200 mg/m2 days -6 to 3], cytarabine [200 mg/m2 days -4 to -1], cyclophosphamide [60 mg/kg day -3], and melphalan [60 mg/m2 days -2 to -1] regime in 125 NHL and HL patients. There have been not statistically significant differences in PFS, OS and TRM (3 years PFS 49% vs. 62%, P=0.16; 3 years OS 64%

<div style=\"page-break-after: always\"></div>

vs. 71%, P=0.44; TRM 1.6% vs. 5%, P=0.35). The results also show comparable data for toxicity and  time  to  engraftment.  The  authors  conclude  that,  replacing  BCNU  by  thiotepa  and cyclophosphamide for AHCT conditioning, has comparable efficacy and safety profiles.

Patir et al. (2018) retrospectively analysed 108 relapsed/refractory lymphoma patients who had high-dose treatments (TECAM and BEAM regimens) followed by AHCT between October 2012 and February 2017. TECAM regimen (n=36 [male/female: 24/12]; age: 28-69 [median: 54.5] years)  consists  of  thiotepa  40  mg/m2  ×  4  days,  etoposide  200  mg/m2  ×  4  days, cyclophosphamide 60 mg/kg × 1 day, cytarabine at 200 mg/m2 × 4 days, and melphalan 60 mg/m2 × 2 days whereas BEAM (n=72 [male/female: 47/25]; age: 20-68 [median: 49] years) consists of BCNU 300 mg/m2 × 1 day, etoposide at 200 mg/m2 × 4 days, cytarabine 200 mg/m2 × 4 days, and melphalan 140 mg/m2 × 1 day. At a median follow-up period of 16 months (9 months for TECAM group; 27 months for BEAM group), the estimated 2-year PFS rates for the TECAM and BEAM groups were 55.7% and 52.9%, respectively (P=0.811). The estimated 2-year OS rate in the TECAM group (55.9%) was relatively inferior to that shown in the BEAM group (67%), but the differences were not significant (P=0.238). No differences were observed for time to  haematopoietic  recovery  and  duration  of  hospitalisation.  Incidences  of  transplant  related infectious and non-infectious complications were similar for each conditioning regimen. It was concluded that both BEAM and TECAM regimens have similar efficacy for lymphoma patients before AHCT

In the study of the study of Kothari et al. (2016) two cohorts of patients undergoing AHCT for relapsed/refractory B-cell lymphoma were compared (50 patients per cohort), one conditioned with BEAM (BCNU 300 mg/m2, etoposide 800 mg/m2 (in divided doses), cytarabine 1600 mg/m2 (in divided doses) and melphalan140mg/m2, and the other with LEAM (lomustine 200 mg/m2 instead of BCNU). There was no significant difference in OS or PFS between the two cohorts (median 3-year OS and PFS were 86% and 69%, respectively for LEAM, and 86% and 75%, respectively for BEAM. The NRM was similar in both cohorts: 4% for LEAM vs. 2% for BEAM at 100 days, and 4% for both cohorts at 12 months. In summary, LEAM and BEAM appear to be generally comparable conditioning regimens for autologous transplantation.

With the limitations of retrospective analysis, all these studies demonstrate that BCNU containing regimes  (especially  BEAM)  is  a  well-established,  widely  used  and  effective  method  for conditioning  prior  to  AHCT  in  HL  and  NHL.  To  date,  there  are  no  data  which  would  proof superiority above the BEAM regime in this setting. The fact, that all the cited studies above, are retrospective studies clearly hampers validity of the data. On the other hand, these retrospective analyses  were  performed  with  a  high  number  of  patients  for  each  study  and  in  total  8,402 patients.

## Clinical studies in the conditioning treatment prior to allogenic HPCT

Originally,  the  Applicant  has  refered  to  5  publications.  A  total  of  134  patients  with  haematological diseases received BCNU intravenously in combination with other chemotherapeutic drugs as conditioning regimen before allogenic HPCT.

There were 3 studies in Lymphoma patients, and 2 studies in NHL.

The efficacy endpoints used to evaluate efficacy of conditioning treatment prior allogenic HPCT were disease control (relapse rate); disease free-survival (DFS)/ event-free survival (EFS)), the transplantation-related mortality (TRM)/ non-relapse mortality (NRM) and overall survival (OS).

<div style=\"page-break-after: always\"></div>

Table 1:  Summary of studies:

| Study                                                                                       | Diagnosis                                                            | Objectives                                                                                                             | Nb. of patients (M/F, age)              | Regimen/transplantation                                                                                                                                                                                                                                  | Comparison groups            | Results                                                                                                                                                                                                                        |
|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase II, prospective uncontrolled (Przepiorka et al., 1999)                                | Primary refractory or recurrent intermediate- or low-grade lymphoma. | Primary: to determine the feasibility and tolerance of the BEAM regimen Secondary: assessment of antilymphoma activity | 30 (15/15; median age 42.5 [25- 61])    | BEAM (carmustine 300 mg/m2 i.v. day - 6, etoposide 200 mg/m2 i.v. twice daily days -5 to -2, cytarabine 200 mg/m2 i.v. twice daily days -5 to -2, and melphalan 140 mg/m2 i.v. day -1.) Marrow or blood stem cells from an HLA- identical donor on day 0 | No control group             | Median time from transplantation was 20 months (range 6-32 months) CR- 23 patients 2-year relapse rate - 23% (95%CI 4%- 42%) 2 year survival 48% (95%CI 28%-67%), 2 year disease-free survival (DFS) was 42% (95%CI 23%- 60%). |
| Two phase, non- randomized, single centre, prospective feasibility study (Buser et al 2007) | Relapsed/refractory lymphoma                                         | To compare HDC with BEAM + fludarabine +TBI + RIC HSCT with HDC BEAM delayed RIC HSCT                                  | Group A=10 (7/3 median age 51 [52- 63]) | Group A - High-dose chemotherapy (HDC): BEAM (etoposide 200mg/m2 twice daily intravenously (i.v.) for 4 consecutive days (total eight doses), BICNU (carmustine) 300 mg/m2 one                                                                           | Beam Fludarabine TBI Vs Beam | 3-year overall survival: Group A = 70+14%                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                           |                                              |                                                                        | Group B =11 (5/6; median age 48 [3-59])                              | dose i.v. at day 1, Ara-C 200mg/nr twice daily i.v. for 4 consecutive days (total eight doses), melphalan 140 mg/m2 once i.v. at day 5). Allogeneic RIC HSCT was performed on day + 28 of BEAM after using fludarabine 30 mg/m2 on 3 consecutive days i.v. and 2 Gy TBI for conditioning. Group B - HDC (BEAM). Fludarabine and TBI were administered just after BEAM, starting on day 2 of BEAM. HSCT was performed on day 6 after start of HDC.   | Group B =76+14% 3-year event- free survival Group A = 60+15% Group B =60+16% Cumulative incidence of acute and chronic GvHD ≥grade II Group A = 90±9% Group B = 36+15% ≥grade III Group A = 65% Group B = 36%   |
|-------------------------------------------|----------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Retrospective study (Ingram et al., 2008) | Relapsed, advanced stage follicular lymphoma | To compare BEAM + alemtuzumab allogenic HSCT with BEAM authologus HSCT | BEAM-allo =44 (median age 48y, range 3-59) BEAM- auto=82 (median age | BEAM-allo = (BCNU 300 mg/m2 day-6, cytarabine 200 mg/m2 twice daily day-5 to day-2, etoposide 200 mg/m2 day-5 to day-2 and melphalan 140 mg/m2 day- 1.). In addition, alemtuzumab (Campath 1-H), either at 10 mg/d or 20 mg/d days-5 to -1,); allogeneic HSCT BEAM-auto=82 ((BCNU 300 mg/m2 day- 6, cytarabine 200 mg/m2 twice daily                                                                                                                | The median time to neutrophil engraftment for the BEAM- auto versus BEAM-allo groups was 12 d (range 9-21                                                                                                       |

<div style=\"page-break-after: always\"></div>

| 56y, range 30-74)   | day-5 to day-2, etoposide 200 mg/m2 day-5 to day-2 and melphalan 140 mg/m2 day-1.)   |
|---------------------|--------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Retrospective study (Law et al 2006)   | Non-Hodgkin Lymphoma   | Safety and efficacy of CBV in an allogeneic setting                                                                        | 31 (21/10; median age 46)   | preparative regimen -BCNU 15 mg/kg (maximum dose, 550 mg/m2 actual body weight) on day 6 infused over 2 hours, etoposide 60 mg/kg on day 4 infused over 4 hours, and cyclophosphamide 100 mg/kg infused over 2 hours on day 2 + allogeneic HCT   | No control   | OS - 1 year 51% (33%- 69%); 5-years -47% (29%- 65%) EFS - 1-year 44% (26%- 62%) Relapse rate 1-year 33% (15 - 51%); 5- year 31% (13%-49%) incidence of grade II-IV acute GVHD - 29% chronic GVHD - 39%   |
|----------------------------------------|------------------------|----------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Retrospective study (Rosi et al 2003)  | Non-Hodgkin's lymphoma | Efficacy and toxicity of cyclophosphamide, BCNU, and VP-16 (CBV) as a suitable chemotherapy- only regimen for NHL patients | 18 (mean age 42)            | CBV (cyclophosphamide 750 mg/m2 every 12 h for 4 days [total dose 6 gm/m2], BCNU 112.5 mg/m2/day for 4 days [total dose 450 mg/m2], and etoposide 200 mg/m2 every 12 h for 4 days [total dose 1600 mg/m2]) followed by allotransplant            |              | 2-year relapse free estimate 56% 2-year OS 76% Overall NRM 17%                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

The  Applicant additionally provided  three  studies,  that  have  been  identified  as  studies  mainly supporting the evaluation of efficacy of BCNU-containing conditioning regimes for allo-HCT. Two of these studies investigate AML and one HL+NHL treatment. The total number of patients in these studies was 571.

| Study Diagnosis          | Objective                                                                           | Design Comparison groups(Regimes)                 | Nt NBCNU (Median age)                     | Results                                                                                                                                                                                                         |
|--------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Robinson al.2002 HL, NHL | etReport outcome ofRS,COM RIC- allogeneic progenitor cell transplantation: PFS, TRM | os,low Vs. intermediate Vs. high (BEAM) intensity | 188 (40,2-65) high intensity: 19 for BEAM | 1y-OS, 1y-PFS, TRM is not different between the groups                                                                                                                                                          |
| Bertz 2016 AML           | et al.Report outcome of PS,UC FBM                                                   |                                                   | 250 (66, 60-77)                           | 1y-OS,2y-OS and 5y-OS: 60.5% (95% CI: 54.6-66.9%), 48.5%(95%CI: 42.4-55.2%), 36.8% (95% CI: 30.8-43.8%) DFS at 1, 2 and 5 years: 48.7% (95% CI: 42.8-55.4%) 40.5%(95%CI:34.7-47.2%) 33.7% (95% CI: 27.9-40.6%), |
| 2008 a.o.AML/MDS         | Marks et al.Report outcome FBM: OS, PFS, NRM                                        | ofPS,UC FBM                                       | 133 (55.6, 23.8-73.7)                     | median follow-upof 58.5 months 3- and 5-year OS was 53.0% and 46.1%, EFS was 46.4% and 41.9% NRM after 100 days and 1 year was 15.8% and 26.3%                                                                  |

## Conditioning treatment prior to autologous HPCT

The Applicant refers to 41 publication. A total of 3497 patients with haematological diseases received BCNU intravenously as conditioning regimen before autologous HPCT.

Majority of references are related to the use of carmustine in NH, HL. There were 4 studies in Lymphoma patients, and 2 studies in multiple myeloma, one study in primary CNS lymphoma, solid tumors in NHL, one study combining HL, NHL, AML, myeloma, CML and AML patients.

The efficacy endpoints used to evaluate efficacy of conditioning treatment prior autologous HPCT were disease control (relapse rate); progression-free survival (PFS)/ disease free-survival (DFS)/ non-relapse mortality (NRM) and overall survival (OS).

<div style=\"page-break-after: always\"></div>

Table 2: summary of studies of Autologous HPCT in adult patients

| Characteristic                | Conditioning treatment                        |   No. of patinets | Reference                      |
|-------------------------------|-----------------------------------------------|-------------------|--------------------------------|
| Solid tumours or NHL          | Cyclophosphamide/ thiotepa/BCNU               |                40 | Moormeier et al., 1990         |
| HL/NHL/AML/ mye- loma/CML/ALL | BEM                                           |                72 | Ager et al., 1996              |
| Lymphoma                      | CBV                                           |                35 | Sehn et al.,1998               |
| Lymphoma                      | CBV                                           |                27 | Cucuianu et al., 1995          |
| Lymphoma                      | BEAM                                          |                73 | Martin et al., 2015            |
| Lymphoma                      | BEAM/BEAC                                     |                19 | Rodriguez et al., 2007         |
| Hodgkin's disease             | mini-BEAM                                     |                24 | Fernandez-Jimenez et al., 1999 |
| Hodgkin's disease             | mini-BEAM                                     |                55 | Martin et al., 2001            |
| Hodgkin's disease             | BEAM                                          |                32 | Raut et al., 2016              |
| Hodgkin's disease             | BEAM                                          |                37 | Esbah et al.,2016              |
| Hodgkin's disease             | BEAM                                          |                64 | Khattry et al., 2016           |
| Hodgkin's disease             | BEAM                                          |               607 | Olivieri et al., 2018          |
| Hodgkin's disease             | BEAM                                          |                72 | Patir et al., 2018             |
| Hodgkin's disease             | Dexa-BEAM/BEAM                                |               161 | Schmitz et al., 2002           |
| Hodgkin's disease             | CVB/BEAM                                      |                47 | Schmitz et al., 1993           |
| Hodgkin's disease             | CBV                                           |                56 | Kessinger et al., 1991         |
| Hodgkin's disease             | CBV                                           |               131 | Fleming et al., 1999           |
| Hodgkin's disease             | CBV                                           |                62 | Burns et al., 1995             |
| Hodgkin's disease             | CBV                                           |                78 | Neben et al., 2000             |
| Hodgkin's disease             | BEAM                                          |                40 | Argiris et al., 2000           |
| Hodgkin's disease             | CBV                                           |                85 | Bierman et al.,1996            |
|                               | CBV                                           |                33 | Hurd et al., 1990              |
|                               | CBV                                           |                04 | Lin et al., 2002               |
|                               | BEAC                                          |                70 | Lancet et al., 1998            |
| HL                            | CBV                                           |                43 | Benekli et al.,2008            |
| HL                            | mini-BEAM                                     |                34 | Kuruvilla et al.,2006          |
| HL                            | BEAM                                          |               128 | Singer et al.,2019a            |
| NHL                           | CBV                                           |                78 | Wheeler et al.,1993            |
| NHL                           | CBV                                           |               110 | Bolwell et al., 2002           |
| NHL                           | BEAM                                          |               269 | Singer et al., 2019b           |
| NHL                           | BEAM                                          |                48 | Zaucha et al., 2008            |
| NHL                           | BEAC                                          |                83 | Weaver et al., 1997            |
| NHL                           | BEAC                                          |                27 | Weaver et al., 1998            |
| NHL                           | BEAC/BEAM                                     |                97 | Jo et al.,2008                 |
| NHL/HL                        | BEAM                                          |               148 | Caballero et al., 1997         |
| NHL/HL                        | BEAM                                          |               100 | Geisler et al., 1998           |
| NHL/HL                        | BEAM                                          |                87 | Sakellari et al., 2015         |
| NHL/HL                        | CBV±cytarabine                                |                40 | Kessinger et al.,1989          |
| PCNSL                         | Rituximab/ BCNU/ thiotepa                     |                32 | Kasenda et al., 2017           |
| Multiple myeloma              | BCNU/ melphalan                               |                49 | Comenzo et al., 2006           |
| Multiple myeloma              | BCNU/ cyclophospha mide/melphalan/doxorubicin |               200 | Child et al.,2003              |
| Total                         |                                               |              3497 |                                |

ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; BCNU, carmustine; BEAC, carmustine, etoposide, cytarabine and cyclophosphamide; BEM, carmustine, etoposide and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; CML, chronic myeloid leukaemia; HL, Hodgkin lymphoma; BEAM, carmustine, etoposide, cytarabine and melphalan; NHL, non-Hodgkin lymphoma; PCNSL, primary central nervous system 1mnhoma

<div style=\"page-break-after: always\"></div>

Moormeier et al.(1990) - phase I dose escalation study, 40 patients (male/female: 19/21; age: 22 62 [median: 43] years) with refractory solid tumours or relapsed/refractory NHL were treated with highdose cyclophosphamide (2.5 g/m2 given intravenously over 1 h on days -6, -4, and -2 [total dose, 7.5 g/m2], thiotepa (225 mg/m2 given intravenously over 1 h on days -6, -4, and -2 [total dose, 675 mg/m2)], and BCNU (50 - 250 mg/m2 given intravenously over 1 h on days -6, -4, and -2 [total dose, 150 - 750 mg/m2]), followed by autologous stem cell rescue. Of the 40 patients who were treated, nine were  not  able  to  be  evaluated  for  response  to  treatment  because  of  early  death  or  lack  of  clearly measurable disease at diagnosis or follow-up.

Of the remaining 31 patients, 25 responded, for an overall response rate of 63% (95% CI ± 15%). There were 11 CR and 14 PR. The median time to disease progression was 14 weeks.

Conclusion  -  Although  this  regimen  provided  effective  cytoreduction,  its  use  in  heavily  pre-treated patients with bulky disease is of limited value

Ager et al. (1996) have investigated the toxicity of dose-escalation of BCNU, etoposide and melphalan ('BEM')  chemotherapy  with  ASCT  in  patients  (n  =  72;  age:  18  -  66  years)  with  haematological malignancies. Seventy-two patients with haematological malignancies (Hodgkin's disease, n = 20; NHL, n = 21; myeloma, n = 15; acute myeloid leukaemia, n = 13; chronic myeloid leukaemia, n = 2; ALL, n = 1) were treated with BCNU (600 mg/m2, 450 mg/m2 or 300 mg/m2 intravenously), etoposide 2 g/m2 intravenously  and  melphalan  140  mg/m2  intravenously  followed  by  ABMT,  n  =  51,  or  autologous peripheral blood progenitor cell transplantation (APBPCT), n = 21. Liver and pulmonary function was monitored pre-transplant and at

Sehn et al. (1998) - retrospective analysis of 35 patients (male/female: 14/21; age: 17 - 50 [median: 29] years) with primary diffuse large B-cell lymphoma of the mediastinum treated with high-dose CBV plus  autologous  haematopoietic  cell  transplantation  (AHCT)  to  determine  outcome  and  prognostic features for PFS. Thirty-five patients with primary diffuse large B-cell lymphoma of the mediastinum in first response (CR or PR) with poor prognostic features, with primarily refractory disease, or with relapsed disease following conventional chemotherapy, were treated with CBV (cyclophosphamide 6,000 - 7,200 mg/m2, BCNU, 450 mg/m2 and etoposide, 1,200 - 2,000 mg/m2) and AHCT.

Estimated  5-year  PFS  varied  significantly  with  patient  disease  status  at  transplantation.  Patients transplanted in first response had an estimated 5-year PFS rate of 83%, compared with 58% and 27% for primarily refractory and relapsed patients, respectively (p = 0.02). The strongest predictor of PFS was  chemotherapy  responsiveness  immediately  before  transplantation.  Patients  with  chemotherapyresponsive disease had a significantly greater PFS rate than patients with chemotherapy-nonresponsive disease (risk ratio, 3.60; 95% CI, 1.14 - 11.4). No other factors were found to be significant on univariate or multivariate analysis. Patients with primary diffuse large B-cell lymphoma of the mediastinum can achieve prolonged PFS following high-dose chemotherapy and AHCT. Outcomes are strongly correlated with disease status (first response vs. refractory vs. relapsed) at transplantation and chemotherapy responsiveness immediately before transplantation.

Cucuianu et al. (1995) assessed the efficiency of high-dose cytotoxic therapy followed by autologous bone marrow or peripheral progenitor cell rescue with haematopoietic growth factor support given in a group of 27 patients (16 men, 11 women) at the Department of Haematology of the Mont Godinne University Clinics, mainly in the same interval 1990 - 1994. The reasons for introducing such a therapy in these patients (6 with Hodgkin's disease, 14 with intermediate or high grade, aggressive NHL and 7 with low grade follicular NHL) were relapse of disease after conventional therapy (11 cases), resistance to initial therapy (5 patients) or because of histologically proven transformation to a more aggressive form (one case); in 10 patients with extended, poor prognosis forms, the procedure was used as part of

<div style=\"page-break-after: always\"></div>

the first line therapy. The conditioning high dose chemotherapy was given according to various regimens, most of them containing cyclophosphamide, BCNU and etoposide, with or without TBI. In 14 patients, bone marrow graft was used, while PBPC were infused in the remaining 13 patients. The number of infused CFU-GM ranged between 7,650 and 3,900,000/kg, with a mean value of 461,000/kg.

The median time intervals req uired to reach an absolute neutrophil count &gt; 500/μL, a platelet count &gt; 50,000/μL and a haematocrit &gt; 30% were 13 days, 20 days and 23 days respectively. Growth factors (GM-CSF and G-CSF) and PBPC use shortened the time for neutrophil recovery as well as neutropeniarelated  complications.  No  procedure-related  death  was  observed,  and  CR  was  achieved  in  22  cases (81.4%); after a mean follow-up of 32.6 months, 14 patients (55.5%) are alive and free of disease, while in 7 patients (31% of the complete responders) relapse occurred at an average time interval of 8.2 months since the procedure.

Martin et al. (2015) - retrospective analysis of 73 consecutive patients (male/female: 54/19) aged over 65 years treated for aggressive or relapsed lymphoma by high-dose chemotherapy with BEAM (BCNU 300 mg/m2 on day -7, etoposide 100 mg/m2 every 12 h on days - 6 to -3, cytarabine 100 mg/m2 every 12 h on days -6 to -3 and melphalan 140 mg/m2 on day - 2)) at full dosage followed by ASCT. Patient data were obtained from medical charts from two institutions. Median age was 67 years (65 74). Significant comorbidities were present in 24.7% of patients.

The  median  number  of  days  for  grade  4  neutropenia  was  9  (5  -  18).  The  early  treatment-  related mortality rate (&lt; 100 days) was 2.7%. The estimated 2-year PFS and OS rates were 67.2% and 78.5%, respectively.

Conclusion  -  the  full-dose  high-dose  chemotherapy-  ASCT  regimen  is  feasible,  safe  and  efficient  in selected patients over 65 years old.

Fernández-Jiménez  et  al.(1999 ). From  February  1992 to June 1998  twenty-four patients (male/female: 17/7; age: 18 - 59 years) receiving mini-BEAM therapy for resistance or relapse of their Hodgkin's  disease  were  included  in  a  study.  Four  patients  had  obtained  no  response  with  initial chemotherapy (refractory), 8 had obtained an incomplete response, 7 were in first relapse and 5 in second or subsequent relapse. Fifteen patients received mini-BEAM (BCNU 60 mg/m2/day, etoposide 300 mg/m2/day, cytarabine 800 mg/m2/day and melphalan 30 mg/m2/day for one day) as first salvage chemotherapy regimen. The remaining nine patients had previously been exposed to a median of one salvage regimen. Patients received a median of 3 cycles of mini-BEAM. Sixteen patients achieved CR and four PR, yielding an overall response rate of 83%.

No significant differences in response were observed between patients who received mini-BEAM as initial salvage  therapy  and  those  who  had  received  a  prior  salvage  regimen.  Eighteen  out  of  the  twenty responding patients went on to intensive therapy and APBSCT. With a median follow-up of 52 months, the cumulative probability of 7-year OS is 71% for the responders and that of the 6- year DFS is 42%. No treatment-related deaths were observed.

Conclusion -mini-BEAM is an effective salvage regimen with moderate toxicity that may be useful for cytoreduction prior to stem cell procedures.

Rodríguez et al., (2007) Nineteen patients with angioimmunoblastic T-cell lymphoma treated with high-dose chemotherapy and ASCT within the GELTAMO co-operative group between 1992 and 2004 were  evaluated.  The  median  age  at  transplantation  was  46  years.  Fifteen  patients  underwent  the procedure as front-line therapy and four patients as salvage therapy. Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%).

A 79% of patients achieved CR, 5% PR and 16% failed the procedure. After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial OS

<div style=\"page-break-after: always\"></div>

and PFS at 3 years was 60% and 55%. Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL.

Conclusion - high-dose chemotherapy and ASCT offers better results than conventional chemotherapy in treating aggressive lymphomas. Although further follow-up is needed to confirm these results, more than half of the patients in this study were in continued remission.

Martín et al. (2001) reported on long-term results of 55 consecutive patients (male/female: 36/19; age: 15 - 60 [median: 33.5] years) with Hodgkin's disease who received mini-BEAM (BCNU 60 mg/m2, etoposide 75 mg/m2, cytarabine 100 mg/m2, melphalan 30 mg/m2) as salvage therapy before ASCT. Eleven patients were refractory to front-line therapy, 17 were PR, and 27 patients had relapsed from Hodgkin's disease.

Results - Twenty-eight patients achieved CR, and 18 achieved PR with a median of two cycles of miniBEAM, giving a total response rate of 84%. Significant factors predicting poor response (p &lt; 0.05) were: initial  treatment  with  MOPP  (mechloroethamine,  oncovin,  procarbazi ne,  prednisolone),  ≥  2  previous chemotherapy  regimens  and  three  disease  characteristics  at  mini-BEAM  treatment:  presence  of  B symptoms, extranodal involvement or low serum albumin. However, only the last two factors retained independent influence on multivariate analysis. In total, 45/55 patients have been transplanted. Median follow-up after mini-BEAM administration for living patients is 68 months. At the time of reporting, 31 out of 55 patients (56.4%) are still alive, 21 patients (38%) have relapsed, three (5.4%) have developed secondary neoplasias, and five have died of other complications not related to disease progression. The actuarial 7-year OS was 52%, the PFS 54% and the EFS 36%. The response to mini-BEAM was the most important prognostic factor for predicting the long-term probability of surviving the disease: none of the eight  patients  who  did  not  respond  to  mini-BEAM  were  alive  at  3  years.  On  multivariate  analysis, response to mini-BEAM and extranodal involvement before mini-BEAM had a significant influence on OS.

Conclusion - Results showed the safety and efficacy of mini-BEAM before ASCT for refractory or relapsed Hodgkin's disease patients.

Raut et al. (2016) reported analysis of all consecutive Hodgkin's disease patients undergoing AHSCT from September 1999 to December 2014. Out of total 38 patients 26 were males and 12 were females. Thirty-two were adults and 6 were paediatric (&lt; 18 years). None were elderly. Median age was 28 years (9 - 61). All received BEAM protocol as conditioning regimen. Median engraftment time for granulocytes was 12 and 14 days for platelets. Thirty three (86.84 %) patients achieved CR out of which 8 (24.24 %) had further relapse. Transplant related mortality occurred in 4 (10 %) patients. Finally, 26 (78.78 %) patients were disease free at median follow up of 60 months and median DFS was 35 months. DFS was 66.66 and 65 %, respectively on 3 and 5 years. While OS was 70.83 and 70 % on 3 and 5 years, respectively.

Esbah et al., (2016) - medical records of 62 patients who had undergone AHCT following BEAM (BCNU, etoposide, cytarabine, and melphalan) and high-dose ICE (hICE; ifosfamide, carboplatin, and etoposide) conditioning  regimens  were  analysed  retrospectively  and  compared  in  terms  of  efficacy.  The  study included a total of 29 and 33 patients diagnosed with relapsed/refractory NHL and HL, respectively. Patients received BEAM (n = 37) or hICE (n = 25) regimens for conditioning. One-year OS was 73 ± 6% in all patients. One-year OS was 71 ± 8% and 74 ± 9% in the BEAM and hICE groups, respectively (p = 0.86).

The investigators concluded that there was no difference in terms of OS between the BEAM and hICE groups. The BEAM regimen has comparable efficacy to hICE in patients with relapsed/refractory NHL and HL.

<div style=\"page-break-after: always\"></div>

Khattry et al. (2016) compared the CCNU (200 mg/m2 orally for 1 day), cytarabine (2000 mg/m2 intravenous over 12 h for 2 days), cyclophosphamide (1800 mg/m2 intravenously over 1 - 2 h for 2 days) and etoposide (1000 mg/m2 intravenous infusion over 10 h for 1 day) (LACE, n = 75 [male/female: 56/19]; age: 4 - 58 [median: 23] years) and BCNU (300 mg/m2 intravenously for 1 day), etoposide (200 mg/m2 intravenously for 2 days), cytarabine (200 mg/m2 intravenously twice daily for 2 days), melphalan (140 mg/m2 intravenously for 1 day) (BEAM, n = 64 [male/female: 51/13]; age: 8 - 57 [median: 25] years) conditioning regimens for toxicity, engraftment kinetics, and efficacy in 139 patients undergoing  AHSCT  for  primary  refractory  or  relapsed  lymphoma.  Ninety-two  patients  with  Hodgkin lymphoma and 47 with non-Hodgkin lymphoma were enrolled. Seventy-five patients received LACE while 64 received BEAM. The incidence of grade 3-4 oral mucositis (9 vs. 38%; p &lt; 0.001) and parenteral nutrition requirement (32 vs. 69%; p &lt; 0.001) were significantly lower in the LACE cohort. The median days to myeloid (10 vs. 11; p = 0.007) and platelet engraftment (13 vs. 15; p = 0.026) were shorter for the LACE cohort. TRM in the LACE group was 9% compared to 13% in patients treated with BEAM (p =  NS).  The  probability  of  OS  and  PFS  at  5  years  for  entire  cohort  was  46  and  41%,  respectively. Probability of OS (LACE 46% vs. BEAM 47%; p = NS) and PFS (LACE 37% vs. BEAM 47%; p = NS) at 5 years was comparable between two groups.

The authors concluded that LACE has better toxicity profile compared to BEAM and results in similar longterm survival in primary refractory or relapsed lymphoma transplant.

Olivieri et al. (2018) - a retrospective cohort study in 18 Italian centers to compare the efficacy of BEAM (BCNU, 300 mg/m2 × 1 day; etoposide, 200 mg/m2 × 4 days; cytarabine, 400 mg/m2 × 4 day; melphalan, 140 mg/m2 × 1 day) and FEAM (fotemustine, 150 mg/m2 × 2 days; etoposide, 200 mg/m2 × 4 days; cytarabine, 400 mg/m2 × 4 day; melphalan, 140 mg/m2 × 1 day) regimens for ASCT in lymphomas performed from 2008 to 2015. In this study, 1038 patients (BEAM = 607 [female 40.2%; age: 16.5 - 79.5 years], FEAM = 431 [female 39.2%; age: 17.2 - 77.8 years]), of which 27% had Hodgkin lymphoma (HL), 14% indolent non-Hodgkin lymphoma (NHL), and 59% aggressive NHL were enrolled.  Baseline  characteristics  including  age,  sex,  stage,  B-symptoms,  extranodal  involvement, previous  treatments,  response  before  ASCT,  and  overall  conditioning  intensity  were  well  balanced between BEAM and FEAM; notable exceptions were median ASCT year (BEAM = 2011 vs. FEAM = 2013, p &lt; 0.001), Sorror score ≥ 3 (BEAM = 15% vs. FEAM = 10%, p = 0.017), and radiotherapy use (BEAM = 18% vs. FEAM = 10%, p &lt; 0.001). Response status at day 100 post-ASCT (overall response: BEAM = 91% vs. FEAM = 88%, p = 0.42), 2-year OS (83.9%; 95% CI, 81.5% to 86.1%) and PFS (70.3%; 95% CI, 67.4% to 73.1%) were not different in the two groups. Mortality from infection was higher in the FEAM group (subhazard ratio, 1.99; 95% CI, 1.02 to 3.88; p = 0.04).

It was concluded that BEAM and FEAM do not appear different in terms of survival and disease control.

Patir et al. (2018) retrospectively analysed 108 relapsed/refractory lymphoma patients who had highdose treatments (TECAM and BEAM regimens) followed by AHSCT between October 2012 and February 2017. TECAM regimen (n = 36 [male/female: 24/12]; age: 28 - 69 [median: 54.5] years) consists of thiotepa 40 mg/m2 × 4 days, etoposide 200 mg/m2 × 4 days, cyclophosphamide 60 mg/kg × 1 day, cytarabine  at  200  mg/m2  ×  4  days,  and  melphalan  60  mg/m2  ×  2  days  whereas  BEAM  (n  =  72 [male/female: 47/25]; age: 20 - 68 [median: 49] years) consists of BCNU 300 mg/m2 × 1 day, etoposide at 200 mg/m2 × 4 days, cytarabine 200 mg/m2 × 4 days, and melphalan 140 mg/m2 × 1 day. At a median follow-up period of 16 months, the estimated 2-year PFS rates for the TECAM and BEAM groups were 55.7% and 52.9%, respectively (p = 0.811). The estimated 2-year OS rate in the TECAM group (55.9%) was relatively inferior to that shown in the BEAM group (67%), but the differences were not significant (p = 0.238). No differences were observed for time to haematopoietic recovery and duration of  hospitalisation.  Incidences  of  transplant-related  infectious  and  noninfectious  complications  were

<div style=\"page-break-after: always\"></div>

similar  for  each  conditioning  regimen.  It  was  concluded  that  both  BEAM  and  TECAM  regimens  have similar efficacy for lymphoma patients before AHSCT.

Singer et al. (2019a) retrospectively compared the outcomes of HL patients treated with BEAM (n = 128 [male/female: 63/65]; age: 19 - 73 [median: 34] years) or BUCYVP16 (n = 105 [male/female: 58/47]; age: 19 - 69 [median: 38] years) followed by AHSCT. Patients treated with BEAM were given BCNU 300 mg/m2 on day -6, etoposide 100 mg/m2 from days -5 to -2, cytarabine 100 mg/m2 from days  -5  to  -2,  and  melphalan  140  mg/m2  on  day  -1.  Patients  treated  with  BUCYVP16  were  given intravenously busulfan 0.8 mg/kg every 6 h for 14 doses on days -8 to -5, etoposide 40 mg/kg on days -5 to -4, and cyclophosphamide 60 mg/kg on days -3 to - 2. Haematopoietic stem cells were infused on day 0. After a median follow-up of 4.2 years for BEAM and 3.8 for BUCYVP16 from AHSCT, the 5-year cumulative incidence of relapse was 29% with BEAM compared with 56% with BUCYVP16 (p &lt; 0.001). Median  PFS  and  OS  were  not  reached  with  BEAM  and  were  2.0  and  7.8  years  with  BUCYVP16, respectively. Improved PFS (p &lt; 0.001) and OS (p = 0.001) were observed with BEAM for patients who needed transplant within 24 months from diagnosis and for patients not in CR (p = 0.001 and p &lt; 0.001, respectively) at AHSCT. In this large retrospective comparison, the use of BEAM conditioning before AHSCT resulted in a statistically  significant  improved  PFS  and  OS  and  lower  relapse  compared  with BUCYVP16. This supports the use of BEAM as a frontline conditioning regimen before AHSCT for early relapsed and non-CR HL.

Similarly, Singer et al. (2019b) compared the outcomes of NHL patients treated with BEAM (n = 269 [male/female: 170/99]; age: 20 - 77 [median: 60] years) at The Ohio State University and BUCYVP16 (n = 409 [male/female: 264/145]; age: 27 - 78 [median: 58] years) at the Cleveland Clinic followed by AHCT between 2006 and 2014. Patients treated with BEAM were given BCNU 300 mg/m2 on day -6, etoposide 100 mg/m2 on days -5 to -2, cytarabine 100 mg/m2 on days -5 to -2, and melphalan 140 mg/m2 on day -1. Patients treated with BUCYVP16 were given intravenous busulfan 0.8 mg/kg every 6 h for 14 doses on days -8 to -5, etoposide 40 mg/kg days -5 to -4, and cyclophosphamide 60 mg/kg on days -3 to -2. Haematopoietic cells were infused on day 0. The primary endpoints were PFS, OS, and cumulative incidence of relapse. Patient characteristics between the two groups were similar. After a median follow-up of 3.9 years for BEAM and 4.3 years for BUCYVP16 from AHCT, the rate of relapse (p = 0.69), PFS (p = 0.52), and OS (p = 0.11) were similar between the two conditioning regimens. No differences in survival outcomes were seen in disease subtypes. Multivariable analysis showed significant association toward improved OS with BEAM (HR: 1.56, 95% CI 1.16 - 2.10) (p &lt; 0.01).

Even though the study is limited by its retrospective nature and some differences in cohort, the findings indicated that BEAM could serve as an alternative conditioning regimen prior to AHCT for NHL.

Weaver et al., (1998) - In a study, 49 patients with low-grade NHL received high-dose chemotherapy with  busulfan  and  cyclophosphamide  (BuCy)  or  BCNU,  etoposide,  cytarabine  and  cyclophosphamide (BEAC) followed by unpurged autologous peripheral blood stem (PBSC) infusion. All patients had failed initial chemotherapy or progressed after an initial remission. PBSCs were mobilised with cyclophosphamide  alone  (n  =  1),  cyclophosphamide,  etoposide  (n  =  19),  or  cyclophosphamide, etoposide and cisplatin (n = 29) followed by G-CSF. Twenty-two patients (73% male; age: 25 - 62 [median: 46] years) received busulfan, 16 mg/kg, and cyclophosphamide, 120 mg/kg. Twenty-seven patients  (41%  male;  age:  22  -  64  [median:  53]  years)  received  BCNU  300  mg/m2,  etoposide  600 mg/m2, cytarabine 600 mg/m2, and cyclophosphamide 140 mg/kg. Four patients (8%) died of nonrelapse causes, two (9%) in the BuCy group and two (7%) in the BEAC group. Twenty-seven patients (55%) relapsed or progressed at a median of 9.4 months (2-38) from PBSC infusion. Ten patients who relapsed are alive a median of 31 months (range, 6-47) after relapse. The probabilities of relapse at 3.6 years for patients receiving BuCy or BEAC were 0.57 and 0.70, respectively (p = 0.92). Twenty-seven patients (55%) are alive at a median of 3.6 years (range: 1 - 5). The probabilities of survival at 3.6

<div style=\"page-break-after: always\"></div>

years for patients receiving BuCy or BEAC were 0.58 and 0.55, respectively (p = 0.72). The probabilities of EFS at 3.6 years for patients receiving BuCy or BEAC were 0.36 and 0.28, respectively (p = 0.82). It was concluded that BuCy and BEAC are an active regimen for the treatment of patients with low-grade NHL.

Zaucha  et  al.  (2008) -  In  retrospective  comparison  study,  treatment  results  of  two  high-dose regimens:  BEAM  (n  =48)  and  BuMelTT  (n  =  59)  in  autologous  transplant  patients  with  NHL  were analysed. Patients received BEAM (BCNU 150 mg/m2 intravenously for 60 min infusion on days -6 to -5 [total dose 300 mg/m2], etoposide 100 mg/m2 intravenously twice daily for 120 min infusion on days5 to -2 [total dose 800 mg/m2], cytarabine 200 mg/m2 intravenously for 60 min infusion twice daily on days-5 to -2 [total dose 1600 mg/m2] and melphalan 140 mg/m2 intravenously for 120 min infusion on day-2) or BuMelTT (busulfan 1 mg/kg/dose orally every 6 h on days-8 to -6 [total dose 12 mg/kg], melphalan 50 mg/m2 intravenously for 120 min infusion on days-5 to -4 [total dose 100 mg/m2] and thiotepa 250 mg/m2 intravenously for 120 min infusion on days-3 to -2 [total dose 500 mg/m2] from 1998 to 2005. BEAM group patients were older (mean 59.7 vs. 50.1 years), more advanced (stage ≥ III 88 vs. 61 %), had higher IPI/FLIPI scores (score ≥ 3, 65 vs. 19%), and a higher comorbidity index (HCT -CI) (score ≥ 2, 40 vs. 19%). Grade 3 -4 complications occurred in 10 patients (17%), with six deaths in the BuMelTT group vs. none in the BEAM group. CR was achieved in 20 of 36 (56%) BuMelTT vs. 12 of 39 (31%) BEAM patients. After adjusting for IPI/FLIPI, HCT-CI, age and stage of disease, the hazards of death, relapse and treatment failure were similar in both groups.

It was concluded that BEAM regimen appeared to be equally effective but less toxic than BuMelTT.

In study by Caballero et al (1997) carmustine was used as part of the BEAM (carmustine, etoposide, cytarabine and melphalan) regimen for the preparation of HSCT. This was a prospective uncontrolled trial in 148 in patients with poor prognosis non-Hodgkin's lymphoma (NHL) and Hodgkin's disease. The median numbers of days to reach engraftment were 20 (range, 11-51), 12 (9-27) and 16 (13- followup of 30 months (3-70 months) for patients receiving BM, PBSC or both, respectively. Overall, at 3 months, 88 out of the 112 NHL patients were in CR (81%) and 12 had progressed. In the group of patients with HD (n = 36), 83% were in CR at 3 months after the transplant.

Kasenda et al.(2017) - To investigate safety and efficacy of high-dose chemotherapy followed by ASCT in  relapsed/refractory  PCNSL,  a  single-arm  multicentre  study  was  conducted  for  immunocompetent patients (&lt;66 years [51.3% female]) with PCNSL failing high-dose methotrexate-based chemotherapy. Induction consisted of two courses of rituximab (375 mg/m2), high-dose cytarabine (2 × 3 g/m2) and thiotepa (40 mg/m2) with collection of stem cells in between. Conditioning for high-dose chemotherapy with ASCT consisted of rituximab 375 mg/m2, BCNU 400 mg/m2 and thiotepa (4 × 5 mg/kg). Patients commenced high-dose chemotherapy followed by ASCT irrespective of response after induction. Patients not achieving CR after high-dose chemotherapy-ASCT received whole-brain radiotherapy. Primary endpoint was CR after high-dose chemotherapy-ASCT. Thirteen nine patients were enrolled; median age and Karnofsky performance score are 57 years and 90%, respectively. About 28 patients had relapsed and 8 refractory disease. About 22 patients responded to induction and 32 patients commenced highdose chemotherapy-ASCT. About 22 patients (56.4%) achieved CR after high-dose chemotherapy-ASCT.

Respective 2-year PFS and OS rates were 46.0% (median PFS 12.4 months) and 56.4%; median OS not reached. Four treatment-related deaths were recorded. BCNU, thiotepa, and rituximab based high-dose chemotherapy-ASCT is an effective treatment option in eligible patients with relapsed/refractory PCNSL.

Comenzo et al., (2006) - ASCT with high-dose melphalan (200 mg/m2) is the most effective therapy for  multiple  myeloma. To determine the feasibility of combining BCNU (300 mg/m2) with high-dose melphalan, 49 patients with previously treated Durie-Salmon stage II/III myeloma (32 male/17 female, median age: 53 years) were enrolled on a phase I/II trial involving escalating doses of melphalan (160,

<div style=\"page-break-after: always\"></div>

180, 200 mg/m2). The median β2 -microglobulin was 2.5 (0 - 9.3); marrow karyotypes were normal in 88%. The phase I doselimiting toxicity was ≥ grade 2 pulmonary toxicity 2 months post -SCT. Other endpoints  were  response  rate  and  PFS.  High-dose  melphalan  was  safely  escalated  to  200  mg/m2; treatmentrelated mortality was 2% and ≥ grade 2 pulmonary toxicity 10%. The CR and near CR rate was 49%. With a median post-SCT follow-up of 2.9 years, the PFS and OS post-SCT were 2.3 and 4.7 years. PFS for those with CR or near CR was 3.1 years while for those with stable disease it was 1.3 years (p = 0.06).

The investigators concluded that BCNU can be combined with high-dose melphalan for myeloma with minimal pulmonary toxicity and a high response rate.

Child et al., (2003) -  In a multicenter study, the Medical Research Council Myeloma VII Trial, 407 patients  with  previously  untreated  multiple  myeloma  who  were  younger  than  65  years  of  age  were randomised to receive either standard conventional-dose combination chemotherapy (short infusion of 30 mg/m2 doxorubicin intravenously, and 30 mg/m2 BCNU intravenously on day 1 followed by 100 mg/m2 cyclophosphamide/day orally and 6 mg/m2 melphalan/day orally on days 22, 23, 24, and 25) or high-dose therapy (continuous infusion of 9 mg/m2 doxorubicin/day and 0.4 mg vincristine/day on days 1 through 4, 1 g/m2 methylprednisolone/day intravenously or orally [maximum 1.5 g] on days 1 through 5, and 500 mg/cyclophosphamide/day intravenously on days 1, 8, and 15) and an autologous stem-cell transplant. Among the 401 patients who could be evaluated (standard therapy, n = 200 [male/female: 110/90], age: 35 - 64 years; intensive therapy, n = 2001 [male/female: 113/88], age: 33 - 66 years), the rates of CR were higher in the intensive-therapy group than in the standard-therapy group (44% vs. 8%, p &lt; 0.001).

The rates of PP were similar (42% and 40%, respectively; p = 0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3% vs. 18%, p &lt; 0.001). Intention-to-treat analysis showed a higher rate of OS (p = 0.04 by the log-rank test) and PFS (p &lt; 0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95% CI, 44.9 to 65.2] vs. 42.3 months [95% CI, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high β2 -microglobulin level (&gt; 8 mg/L).

The authors concluded that high-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.

## Carmustine with total body irradiation

The Applicant referred to 5 publication. A total of 334 patients with haematological diseases received BCNU intravenously  in  combination  with  TBI/IFR  and  other  chemotherapeutic  drugs  as  conditioning treatment before allogenic or autologous HPCT.

There are one reference related for each of the following malignant haematological disease :NHL, mantle cell lymphoma, multiple myeloma, Hodgkin's disease, lymphoma.

The efficacy endpoints used to evaluate efficacy of conditioning treatment were disease control (relapse rate); progression-free survival (PFS)/ disease free-survival (DFS) and overall survival (OS).

The Applicant provided following summary table.

<div style=\"page-break-after: always\"></div>

| Characteristic        | Conditioningtreatment             |   No. of patinets | Reference            |
|-----------------------|-----------------------------------|-------------------|----------------------|
| Multiple myeloma      | BEM/TBI                           |                14 | Fermandetal.,1989    |
| NHL/Hodgkin's disease | CBV/BEAM/BEAC/TBI                 |                24 | Briceetal.,1992      |
| MCL                   | BCNU/cytoxan/etoposide /TBI       |                02 | Milpied et al., 1998 |
| NHL                   | BEP/IFR                           |                70 | Wadhwaet al.,2005    |
| Lymphoma              | Tositumoma-BEAM/ Rituxi- mab-BEAM |               224 | Voseetal.,2013       |
| Total                 | Total                             |               334 | 334                  |

BCNU, carmustine; BEAC, carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM, carmustine, etoposide, cytarabine and melphalan; BEM, carmustine, etoposide and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; MCL, mantle cell lymphoma; IFR, involved-field radiotherapy; NHL, non-Hodgkin lymphoma; TBI, total body inradiation.

In study by Fermand et al. (1989) carmustine was used as a part of high dose chemotherapy (BCNU 120 mg/m2, etoposide 250 mg/m2 and melphalan 140 mg/m2) together with TBI in patients with stage III aggressive multiple myeloma. This was retrospective study. Study population was 14 young patients (male/female: 8/6; age: 29 - 56 [median: 42.5] years). tumour mass reduction (over 90% in 12 cases). Two patients relapsed and died 12 and 15 months after the graft; another one relapsed but is still alive at 24 months. Two to 23 months (median 12 months) after the autograft, 10 patients are well either in apparent CR (2 cases) or with a state of stable minimal residual disease. Autologous blood-derived haematopoietic stem cells induced successful and sustained engraftment in the 13 evaluable patients. No OS, DFS or PFS data were reported.

The study by Brice at al (1992) was prospective, uncontrolled study in 24 patients with refractory or relapsed NHL or Hodgkin's disease. Conditioning regimens were CBV, BEAM, BEAC and cyclophosphamide + TBI.

In study by Wadhwa et al (2005) carmustine was used as part of the BEP (carmustine, etoposide, cisplatin) regimen for the preparation of HSCT. This was a prospective uncontrolled trial in 101 relapsed or refractory non-Hodgkin lymphoma patients. Kaplan-Meier 5-year probabilities of overall survival (OS) and disease-free survival (DFS) were 58.6% and 51.1%, respectively.

Study by Vose et al (2013) was a Phase III randomized study of rituximab/carmustine, etoposide, cytarabine,and  melphalan  (BEAM)  compared  with  Iodine131  tositumomab/BEAM  with  autologous hematopoietic cell transplantation for chemotherapy-sensitive persistent or relapsed diffuse large B-cell lymphoma. The carmustine was used as a part of conditioning regimens B-BEAM and R-BEAM. 113 patients were randomly assigned to R-BEAM and 111 patients assigned to B-BEAM. B-BEAM consisted of 131 I tositumomab (dosimetric dose of 5 mCi on day -19 and therapeutic dose of 0.75 Gy on day -12), BCNU 300 mg/m2 (day -6), etoposide 100 mg/m2 twice daily (days -5 to -2), cytarabine 100 mg/m2 twice daily (days -5 to -2), and melphalan 140 mg/m2 (day -1) R-BEAM consisted of rituximab 375 mg/m2 on days -19 and -12 and the same chemotherapy regimen. Two-year PFS rates, the primary end point, were 48.6% (95% CI, 38.6 - 57.8%) for R-BEAM and 47.9% (95% CI, 38.2 - 57%; p = 0.94) for B-BEAM, and the 2-year OS rates were 65.6% (95% CI, 55.3 - 74.1%) for R-BEAM and 61% (95% CI, 50.9 - 69.9%; p = 0.38) for B-BEAM. The 100-day treatment-related mortality rates were 4.1% (95% CI, 0.2 - 8.0%) for R-BEAM and 4.9% (95% CI, 0.8 - 9.0%; p = 0.97) for B-BEAM.

## Carmustine without total body irradiation

In 6 publications, a total of 750 patients with HL, NHL, lymphomas received BCNU intravenously and other  chemotherapeutic  drugs  without  TBI  as  conditioning  treatment  before  autologous  HPCT.  The efficacy  endpoints  used  to  evaluate  efficacy  of  conditioning  treatment  were  disease  control  (relapse rate); progression-free survival (PFS)/ disease free-survival (DFS) and overall survival (OS).

Table 3: summary table of studies without TBI.

<div style=\"page-break-after: always\"></div>

| Characteristic    | Conditioning treatment   |   No. of patinets | Reference                     |
|-------------------|--------------------------|-------------------|-------------------------------|
| Hodgkin's disease | BCNU                     |                63 | Nademaneeetal.,1995           |
| Hodgkin's disease | CBV                      |                74 | Horning et al., 1997          |
| Lymphomas         | BEAM/BEAC/ CBV           |               373 | Caballeroetal..2003           |
| NHL               | BEAM                     |                47 | Liu et al., 2010              |
| NHL               | CBV                      |                87 | Stockerl-Goldsteinetal., 1996 |
| NHL/HL            | BEM/BEAM                 |               106 | Mahendra et al., 1996         |
| Total             | Total                    |               750 | 750                           |

BCNU, carmustine; BEAC, carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM, carmustine, etoposide, cytarabine and melphalan; BEM, carmustine, etoposide and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.

Nademanee et al. (1995) - In a retrospective study, 85 consecutive patients (male/female: 44/41) with relapsed or refractory Hodgkin's disease underwent high-dose chemotherapy or chemo/radiotherapy followed  by  autologous  bone  marrow  (ABMT)  and/or  peripheral  blood  stem  cell (PBSC) transplantation. Two preparative regimens were used. Twenty-two patients (26%) without prior radiation received fractionated TBI 1,200 Gy in combination with high-dose etoposide 60 mg/kg and cyclophosphamide 100 mg/kg. Sixty-three patients (74%) with prior radiotherapy received BCNU 450 mg/m2 instead of fractionated TBI. The median age was 32 years (range: 16 to 56). The median number of  prior  chemotherapy  regimens  was  three  (range:  1  to  7).  Forty-three  patients  (51%)  received transplants  in  first  relapse  or  second  CR,  whereas  33  (39%)  received  transplants  after  second  or subsequent  relapse.  All  relapsed  patients,  except  one,  received  conventional  salvage  chemotherapy and/or radiotherapy in an attempt to reduce tumour bulk before transplant. At the time of analysis in April 1994, 57 patients (67%) are alive, including 44 (52%) in continuous CR, with a median follow-up for the surviving patients of 28 months (range: 7 to 66). Thirty patients (35%) relapsed at a median of 9 months (range: 1 to 43). At a median follow-up of 25 months (range: 0.6 to 66), the cumulative probability of 2-year overall and DFS of all 85 patients is 75% (95% CI 64 - 84%) and 58% (95% CI 47 - 69%), respectively. Multivariate stepwise Cox regression identified the number of prior chemotherapy regimens as the only significant prognostic factor predicting for both relapse and DFS. There were no significant differences in the outcome of the treatment between the two preparative regimens.

Caballero et al. (2003) was a retrospective study in 452 patients (male/female: 257/195) diagnosed with diffuse large cell lymphomas (DLCL) treated with high-dose therapy included in the Grupo Español de  Linfomas/Trasplante  Autólogo  de  Médula  Osea  (GEL-TAMO)  Spanish  registry.  At  transplantation, median age was 42 years (range, 15 - 73), 146 patients (32%) were transplanted in first CR (1st CR), 19% in second CR (2nd CR) and 47% had active disease: sensitive disease in 157 (35%) patients [95 were in first PR (1st PR) and 62 in second PR (2nd PR)] and refractory disease in 55 (12%) patients. Age-adjusted International Prognostic Index (IPI) was 2 or 3 in 51 patients (12%). Conditioning regimen consisted  of  BEAM  (BCNU,  etoposide,  cytarabine  and  melphalan)  in  39%  of  patients,  BEAC  (BCNU, etoposide, cytarabine and cyclophosphamide) in 33%, CBV (BCNU, etoposide and cyclophosphamide) in 10% and cyclophosphamide plus TBI in 12%. Estimated OS and DFS at 5 years were 53% and 43%, respectively.  The  TRM  was  11%  (53  cases).  By  multivariate  analysis  three  variables  significantly influenced OS and DFS: number of protocols to reach 1st CR, disease status at transplant and TBI in the conditioning regimen. Age-adjusted IPI at transplantation also influenced OS.

Liu  et  al.,  2010 was  a  retrospective  cohort  study  performed  at  a  Canadian  cancer  centre  for  NHL patients to compare the acute and long-term toxicities, disease RFS, and OS. The TBI regimen consisted of CY/E/TBI (cyclophosphamide 100 mg/kg × 1 dose on day -2, etoposide 60 mg/kg × 1 dose on day 4, and cytarabine 30 mg/m2 (to a maximal dose of 70 mg) given intrathecally on day - 7 and TBI 12 Gy in six fractions). The chemotherapy-alone regimen consisted of BEAM (BCNU 300 mg/m2 × 1 dose on day -6, etoposide 200 mg/m2 every 12 h × 8 on days -5 to -2, cytarabine 200 mg/m2 every 12 h × 8

<div style=\"page-break-after: always\"></div>

on days -5 to -2, melphalan 140 mg/m2 × 1 dose on day - 1). Of 73 patients, 26 (male/female: 21/5; age: 24 - 65 [median: 45] years) received CY/E/TBI and 47 (male/female: 29/18; age: 24 - 65 [median: 48] years) received BEAM. The median follow-up for the CY/E/TBI group was 12.0 years and for the BEAM group was 7.3 years. After PBSCT, no differences in acute toxicity were seen between the two groups.  The  5-year  disease  RFS  rate  was  50.0%  and  50.7%  in  the  CY/E/TBI  and  BEAM  groups, respectively (p = 0.808). The 5-year OS rate was 53.9% and 63.8% for the CY/E/TBI and BEAM groups, respectively  (p  =  0.492).  The  univariate  analysis  results  indicated  that  patients  with  Stage  IV,  with chemotherapy-resistant disease, and who had received PBSCT before 2000 had inferior OS. A 3-way categorical analysis revealed that transplantation before 2000, rather than the conditioning regimen, was  a  more  important  predictive  factor  of  long-term  outcome  (p  =  0.034).  The  12-Gy  TBI-based conditioning regimen for PBSCT for NHL resulted in diseases RFS and OS similar to those after BEAM. PBSCT  before  2000,  and  not  the  conditioning  regimen,  was  an  important  predictor  of  long-term outcomes. TBI was not associated with more acute toxicity or pneumonitis. The TBI regimen was similar to BEAM.

Stockerl-Goldstein et al. (1996) - A study in 221 patients with high-risk, relapsed or refractory NHL who were treated with either chemotherapy alone (n = 87 [male/female: 36/51]; age: 9 - 61 [median: 48] years) or radiochemotherapy (n = 134 [male/female: 47/87]; age: 5 - 59 [median: 42] years) followed by ABMT or PBPCT. The patients were assigned preparatory regimens in a non-randomised manner and this  analysis  was  performed  to  evaluate  differences  in  outcome  with  the  two  preparatory  regimens. Actuarial 5-year  EFS  was  similar in patients receiving fractionated (TBI) plus  etoposide  and cyclophosphamide  compared  with  chemotherapy  alone  consisting  of  BCNU  plus  identical  doses  of etoposide  and  cyclophosphamide  (52%  vs.  46%,  p  =  0.08).  OS  favored  radiochemotherapy  (61%) compared with chemotherapy alone (53%, p = 0.02). The relapse rate was the same in both groups (41%),  whereas  the  transplantation-related mortality (TRM)  was  similar in patients receiving chemotherapy  alone  and  those  receiving  radiochemotherapy  (13%  vs.  7%  respectively,  p  =  0.30). Proportional  hazards  analysis  of  significant  variables  including  preparatory  regimen  found  only  the number of prior relapses to be predictive of EFS. Fewer number of prior relapses, radiochemotherapy and PBPCT were significant predictors of favorable OS. In additional analyses, the improved OS of the radiochemotherapy regimen was confirmed only for patients receiving ABMT but was not a significant predictor of outcome in patients transplanted with PBPCT.

## Summary of main studies

## Main studies of efficacy in autologous HCT

## Table 1. The Summary of efficacy for Chen et al. (2015)

<div style=\"page-break-after: always\"></div>

| Title: Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation   | Title: Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation   | Title: Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation   | Title: Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation                                                                                                                                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                               | Chen et al., 2015                                                                                                                                              | Chen et al., 2015                                                                                                                                              | Chen et al., 2015                                                                                                                                                                                                                                                                                                                                                                         |
| Design                                                                                                                                                         | Retrospective registry study                                                                                                                                   | Retrospective registry study                                                                                                                                   | Retrospective registry study                                                                                                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                         | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                 | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                 | 14-17 months Not applicable Not applicable                                                                                                                                                                                                                                                                                                                                                |
| Hypothesis                                                                                                                                                     | To analyse the impact of several commonly used HDT regimens on clinical outcomes                                                                               | To analyse the impact of several commonly used HDT regimens on clinical outcomes                                                                               | To analyse the impact of several commonly used HDT regimens on clinical outcomes                                                                                                                                                                                                                                                                                                          |
| Treatments groups!                                                                                                                                             | BEAM                                                                                                                                                           | BEAM                                                                                                                                                           | BCNU. etoposide. cytarabine. and melphalan. 3-year, 1730                                                                                                                                                                                                                                                                                                                                  |
| Treatments groups!                                                                                                                                             | CBVlow                                                                                                                                                         | CBVlow                                                                                                                                                         | Low dose of cyclophosphamide, BCNU, and etoposide. 3-year, 1249                                                                                                                                                                                                                                                                                                                           |
| Treatments groups!                                                                                                                                             | CBVhigh                                                                                                                                                        | CBVhigh                                                                                                                                                        | High dose of cyclophosphamide, BCNU, and etoposide. 3-year, 604                                                                                                                                                                                                                                                                                                                           |
| Treatments groups!                                                                                                                                             | BuCy                                                                                                                                                           | BuCy                                                                                                                                                           | busulphan and cyclophosphamide 3-year, 789                                                                                                                                                                                                                                                                                                                                                |
| Treatments groups!                                                                                                                                             | TBI                                                                                                                                                            | TBI                                                                                                                                                            | Total body irradiation. 3-year, 545                                                                                                                                                                                                                                                                                                                                                       |
| Endpoints and definitions                                                                                                                                      | Primary endpoint                                                                                                                                               | OS                                                                                                                                                             | The primary endpoint of this analysis was OS among  the different conditioning regimens.                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                      | Secondary endpoint                                                                                                                                             | IPS, TRM, relapse/progression and PFS                                                                                                                          | Secondary endpoints include IPS, TRM, relapse or progression, and PFS. TRM was defined as any death without fecurrent lymphoma. Relapse or progression was defined as evidence of disease fecurrence censored at the date of last contact and using death in remission as the competing hazard PFS was defined as survival without death or relapse censored at the date of last contact. |
| Database lock                                                                                                                                                  | 1995-2008                                                                                                                                                      | 1995-2008                                                                                                                                                      | 1995-2008                                                                                                                                                                                                                                                                                                                                                                                 |
| Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                      |
| Analysis description Analysis                                                                                                                                  | Primary Analysis 4,917 patients (NHL, n=3.905; HL, n=1,012) who underwent AHCT from 1995-2008 using                                                            | Primary Analysis 4,917 patients (NHL, n=3.905; HL, n=1,012) who underwent AHCT from 1995-2008 using                                                            | Primary Analysis 4,917 patients (NHL, n=3.905; HL, n=1,012) who underwent AHCT from 1995-2008 using                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PFS Others: Mortality (FL) Mortality (B-cell lymphoma) Mortality (HL)   | P-value           | [0.002           |
|-------------------------------------------------------------------------|-------------------|------------------|
|                                                                         | Comparison groups | CBVtih and CBVlw |
|                                                                         | HR (95% CI)       | 1.75 (1.14-2.70) |
|                                                                         | P-value           | 0.01             |
|                                                                         | Comparison groups | BuCy and CBVlow  |
|                                                                         | HR (95% CI)       | 1.17 (0.75-1.84) |
|                                                                         | P-value           | 0.489            |
|                                                                         | Comparison groups | TBI and CBVbw    |
|                                                                         | HR (95% CI)       | 1.90 (1.19-3.04) |
|                                                                         | P-value           | 0.008            |
|                                                                         | Comparison groups | BuCy and CBV     |
|                                                                         | HR (95% CI)       | 0.67 (0.42-1.06) |
|                                                                         | P-value           | 0.085            |
|                                                                         | Comparison groups | TBI and CBV      |
|                                                                         | HR (95% CI)       | 1.08 (0.67-1.76) |
|                                                                         | P-value           | 0.746            |
|                                                                         | Comparison groups | TBI and BuCy     |
|                                                                         | HR (95% CI)       | 1.62 (0.99-2.65) |
|                                                                         | P-value           | 0.055            |
|                                                                         | Comparison groups | BuCy and BEAM    |
|                                                                         | HR (95% CI)       | 1.51 (1.15-1.97) |
|                                                                         | P-value           | 0.003            |
|                                                                         | Comparison groups | TBI and BEAM     |
|                                                                         | HR (95% CI)       | 2.01 (1.21-3.34) |
|                                                                         | P-value           | 0.007            |
|                                                                         | Comparison groups | BEAM and CBVbw   |
|                                                                         | HR.               | 0.63             |
|                                                                         | P-value           | -0.001           |
|                                                                         | Comparison groups | BEAM and CBV     |
|                                                                         | HR.               | 1.44             |
|                                                                         | P-value           | 0.001            |
|                                                                         | Comparison groups | CBVand BEAM      |
|                                                                         | HR                | 1.54             |
|                                                                         | P-value           | -0.001           |
|                                                                         | Comparison groups | CBVow and BEAM   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                 | HR.                                                                                                                                                                                                                                                                                                                                                                                                                             | 1.53                                                                                                                                                                                                                                                                                                                                                                                                                            |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                 | P-value                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.001                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                 | Comparisongroups                                                                                                                                                                                                                                                                                                                                                                                                                | BuCy and BEAM                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                 | HR                                                                                                                                                                                                                                                                                                                                                                                                                              | 1.77                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                 | P-value                                                                                                                                                                                                                                                                                                                                                                                                                         | -0.001                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                               | TBI and BEAM                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                 | HR.                                                                                                                                                                                                                                                                                                                                                                                                                             | 3.39                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                 | P-value                                                                                                                                                                                                                                                                                                                                                                                                                         | -0.001                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Notes!               | The dose distibution of BCNU varied widely among recipients of CBV, clustering approximately aroumd 300 mg/m² (median 296 mg/m² [225-374 mg/m²]) and at 450 mg/m (median 453 mg/m² [376-807 mg/m²]), which were then separated into CBVlow and CBV/hig respectively. Among recipients of BEAM, the BCNU dose distibution was approximately aroumd 300 mg/m² (median 293 mg/m² [227-347 mg/m²]).                                 | The dose distibution of BCNU varied widely among recipients of CBV, clustering approximately aroumd 300 mg/m² (median 296 mg/m² [225-374 mg/m²]) and at 450 mg/m (median 453 mg/m² [376-807 mg/m²]), which were then separated into CBVlow and CBV/hig respectively. Among recipients of BEAM, the BCNU dose distibution was approximately aroumd 300 mg/m² (median 293 mg/m² [227-347 mg/m²]).                                 | The dose distibution of BCNU varied widely among recipients of CBV, clustering approximately aroumd 300 mg/m² (median 296 mg/m² [225-374 mg/m²]) and at 450 mg/m (median 453 mg/m² [376-807 mg/m²]), which were then separated into CBVlow and CBV/hig respectively. Among recipients of BEAM, the BCNU dose distibution was approximately aroumd 300 mg/m² (median 293 mg/m² [227-347 mg/m²]).                                 |
| Analysis description | Secondary: IPS, TRM and mortality                                                                                                                                                                                                                                                                                                                                                                                               | Secondary: IPS, TRM and mortality                                                                                                                                                                                                                                                                                                                                                                                               | Secondary: IPS, TRM and mortality                                                                                                                                                                                                                                                                                                                                                                                               |
|                      | The 1-year incidence of IPS was 3-6%; highest in recipients of CBVhigh (HR, 1.9) and TBI (HR 2.0) compared to BEAM. The 1-year-TRM was 4-8%; similar between regimens. Compared to BEAM, CBVkw (HR, 0.63) was associated with lower mortality in FL (P<0.001), T  s 1 =      (t1 A p CBV/μi≠ (HR,1.54), CBV/low (HR 1.53), BuCy (HR, 1.77) and TBI (HR, 3.39) were associated with higher mortality compared to BEAM (P-0.001). | The 1-year incidence of IPS was 3-6%; highest in recipients of CBVhigh (HR, 1.9) and TBI (HR 2.0) compared to BEAM. The 1-year-TRM was 4-8%; similar between regimens. Compared to BEAM, CBVkw (HR, 0.63) was associated with lower mortality in FL (P<0.001), T  s 1 =      (t1 A p CBV/μi≠ (HR,1.54), CBV/low (HR 1.53), BuCy (HR, 1.77) and TBI (HR, 3.39) were associated with higher mortality compared to BEAM (P-0.001). | The 1-year incidence of IPS was 3-6%; highest in recipients of CBVhigh (HR, 1.9) and TBI (HR 2.0) compared to BEAM. The 1-year-TRM was 4-8%; similar between regimens. Compared to BEAM, CBVkw (HR, 0.63) was associated with lower mortality in FL (P<0.001), T  s 1 =      (t1 A p CBV/μi≠ (HR,1.54), CBV/low (HR 1.53), BuCy (HR, 1.77) and TBI (HR, 3.39) were associated with higher mortality compared to BEAM (P-0.001). |

AHCT: autologous haematopoietic cell transplantation; BCNU: carmustine; BEAM: BCNU, etoposide, cytarabine, and melphalan;  BuCy:  busulphan  and  cyclophosphamide;  CBVlow:  low  dose  of  cyclophosphamide,  BCNU,  etoposide; CBVhigh: high dose of cyclophosphamide,  BCNU, etoposide;  CI:  confidence  interval;  DLBCL:  diffuse  large  B-cell lymphoma;  FL:  follicular  lymphoma;  HDT:  high-dose  therapy;  HL:  hodgkin  lymphoma;  HR:  hazard  ratio;  IPS: idiopathic pulmonary syndrome; MCL: mentle cell lymphoma; NHL: non-Hodgkin lymphoma; OS: overall survival; PFS: progression free survival; TRM: transplant-related mortality; TBI: total body irradiation.

<div style=\"page-break-after: always\"></div>

Table 2. The Summary of efficacy for Sellner et al. (2016)

<!-- image -->

| Title: Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT   | Title: Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Title: Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Title: Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Title: Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                    | Sellner et al., 2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Sellner et al., 2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Sellner et al., 2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Sellner et al., 2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Design                                                                                                                              | Registy-based retrospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Registy-based retrospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Registy-based retrospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Registy-based retrospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                                                                                                     | Duuation ofmain phase: Duuation of Rum-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Duuation ofmain phase: Duuation of Rum-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 36 months Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 36 months Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                                                                     | Duuation of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Duuation of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hypothesis                                                                                                                          | To evaluate the potential risks and benefits of thiotepa-based preparative regimens compared with BEAM in AHCT for diffiuse large B-cell lymphoma (DLBCL, excluding PCNSL), FL or HL                                                                                                                                                                                                                                                                                                                                                                                                            | To evaluate the potential risks and benefits of thiotepa-based preparative regimens compared with BEAM in AHCT for diffiuse large B-cell lymphoma (DLBCL, excluding PCNSL), FL or HL                                                                                                                                                                                                                                                                                                                                                                                                            | To evaluate the potential risks and benefits of thiotepa-based preparative regimens compared with BEAM in AHCT for diffiuse large B-cell lymphoma (DLBCL, excluding PCNSL), FL or HL                                                                                                                                                                                                                                                                                                                                                                                                            | To evaluate the potential risks and benefits of thiotepa-based preparative regimens compared with BEAM in AHCT for diffiuse large B-cell lymphoma (DLBCL, excluding PCNSL), FL or HL                                                                                                                                                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                   | BEAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | BEAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | BCNU, etoposide, cytarabine, melphalan. 36 months, n=1031                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | BCNU, etoposide, cytarabine, melphalan. 36 months, n=1031                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                     | Thiotepa (TT based)-based                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Thiotepa (TT based)-based                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Thiotepa,36 months, n=535                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Thiotepa,36 months, n=535                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                     | TEAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | TEAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Thiotepa, etoposide, cytarabine. melphalan. 36 months, n=110                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Thiotepa, etoposide, cytarabine. melphalan. 36 months, n=110                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Endpoints and definitions                                                                                                           | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PFS and OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Primary endpoints werePFSamd OS calculated from auto-HCT in each of the four lymphoma subtypes ( DLBCL, excluding PCNSL, FL, HL or PTCL).                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Primary endpoints werePFSamd OS calculated from auto-HCT in each of the four lymphoma subtypes ( DLBCL, excluding PCNSL, FL, HL or PTCL).                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                     | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | NRM, RI and toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Secondary endpoints were NRM amd RI in each of the subsets and as Dooled data of all four subsets. Early toxicity (mucositis, nausea, yomiting duuring conditioning and early post-hransplamt phase; pneumonia and other infectious complications up to day +100; pneumonitis amd other non- nfectious complications up to day +100) was additionally evaluated as al secondary end point.                                                                                                                                                                                                      | Secondary endpoints were NRM amd RI in each of the subsets and as Dooled data of all four subsets. Early toxicity (mucositis, nausea, yomiting duuring conditioning and early post-hransplamt phase; pneumonia and other infectious complications up to day +100; pneumonitis amd other non- nfectious complications up to day +100) was additionally evaluated as al secondary end point.                                                                                                                                                                                                      |
| Database lock                                                                                                                       | 2003-2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2003-2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2003-2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2003-2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Results and Analysis                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Analysis description                                                                                                                | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Analysis population and time point description                                                                                      | A total of 14544 patients (589 thiotepa and 13955 BEAM) met the eligibility critenia, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. For a more detailed analysis, 47 TEAM-treated patients were compared with 75matched BEAMpatients with additional collection of toxicity data. Treatment duuation was 36 months and median follow up of all alive patientswere 18 months for BEAM group and 13 months for TT-base group. For additional collection of data, median follow up was 28 months for BEAM group and 18 months for TEAM group. | A total of 14544 patients (589 thiotepa and 13955 BEAM) met the eligibility critenia, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. For a more detailed analysis, 47 TEAM-treated patients were compared with 75matched BEAMpatients with additional collection of toxicity data. Treatment duuation was 36 months and median follow up of all alive patientswere 18 months for BEAM group and 13 months for TT-base group. For additional collection of data, median follow up was 28 months for BEAM group and 18 months for TEAM group. | A total of 14544 patients (589 thiotepa and 13955 BEAM) met the eligibility critenia, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. For a more detailed analysis, 47 TEAM-treated patients were compared with 75matched BEAMpatients with additional collection of toxicity data. Treatment duuation was 36 months and median follow up of all alive patientswere 18 months for BEAM group and 13 months for TT-base group. For additional collection of data, median follow up was 28 months for BEAM group and 18 months for TEAM group. | A total of 14544 patients (589 thiotepa and 13955 BEAM) met the eligibility critenia, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. For a more detailed analysis, 47 TEAM-treated patients were compared with 75matched BEAMpatients with additional collection of toxicity data. Treatment duuation was 36 months and median follow up of all alive patientswere 18 months for BEAM group and 13 months for TT-base group. For additional collection of data, median follow up was 28 months for BEAM group and 18 months for TEAM group. |
| Descriptive statistics and estimate vaniability                                                                                     | Ireatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | BEAM (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | BEAM (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | TT-based regimen (95% (1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                                                                     | NRM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                     | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1031                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 1031                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 535                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                     | At 12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 4% (3-6%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 4% (3-6%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2% (1-4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                     | Subset analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                               | Treatment group                   | BEAM (95% CI)     | TEAM (95% CD)            |
|-------------------------------|-----------------------------------|-------------------|--------------------------|
|                               | No. of subjects                   | 199               | 110                      |
|                               | OS                                |                   |                          |
|                               | At 30 months                      | 77%               | 77%                      |
|                               |                                   | (71-84%)          | (67-88%)                 |
|                               | PFS                               |                   |                          |
|                               | At 30 months                      | 62%               | 49%                      |
|                               | R                                 | (54-70%)          | (38-63%)                 |
|                               | At 30 months                      | 37% (29-45%)      | 50% (37-61%)             |
| Effect estimate per compaison | Primary endpoint For whole sample |                   |                          |
|                               | OS                                | Comparison groups | TT-base regimen vs. BEAM |
|                               |                                   | HR (95% CD)       | 1.16 (0.88-1.52)         |
|                               |                                   | P-value           | 0.29                     |
|                               | PFS                               | Comparison groups | TT-base regimen vs. BEAM |
|                               |                                   | HR (95% CD)       | 1.2 (0.96-1.51)          |
|                               |                                   | P-value           | 0.12                     |
|                               | Disease enty subsets              |                   |                          |
|                               | DLBCL OS                          | Comparison groups | IT-base regimen vs. BEAM |
|                               |                                   | HR (95% CD)       | 1.24 (0.91-1.69)         |
|                               |                                   | P-value           | 0.17                     |
|                               | PFS                               | Comparison groups | IT-base regimen Vs. BEAM |
|                               |                                   | HR (95% CI)       | 1.2 (0.91-1.58)          |
|                               |                                   | P-value           | 0.19                     |
|                               | EL                                |                   |                          |
|                               | OS                                | Comparison groups | IT-base regimen vs. BEAM |
|                               |                                   | HR. (95% CD)      | 0.82 (0.28-2.43)         |
|                               |                                   | P-value           | p.72                     |
|                               | PFS                               | Comparison groups | TT-base regimen Vs. BEAM |
|                               |                                   | HR (95% CD)       | 1.09 (0.48-2.49)         |
|                               | HL                                | P-value           | 0.83                     |
|                               | OS                                | Comparison groups | IT-base regimen vs. BEAM |
|                               |                                   | HR (95% CD)       | 0.91 (0.43-1.91)         |
|                               |                                   | P-value           | 0.8                      |
|                               | PFS                               | Comparison groups | IT-base regimen Vs. BEAM |
|                               |                                   | HR (95% CD)       | 1.15 (0.7-1.87)          |
|                               | DLBCL with CR/PR>1                |                   |                          |
|                               |                                   | P-value           | 0.59                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

AEs adverse events; AHCT: autologous haematopoietic stem cell transplantation; BEAM: BCNU, etoposide, cytarabine, and melphalan; BCNU: carmustine; CI: confidence interval; CR/PR: complete remission/partial remission; DLBCL: diffuse  large  B-cell  lymphoma;  EBMT:  European  Society  for  Blood  and  Marrow  Transplantation;  FL:  follicular lymphoma;  HCT:  mortality;  OS:  overall  survival;  PFS:progression  free  survival  PCNSL:  primary  central  nervous system  lymphoma;  PTCL:  peripheral  T-cell  lymphoma;  RI:  incidence  of  relapse;  TEAM:  thiotepa,  etoposide, cytarabine, melphalan;TT: thiotepa based.

<div style=\"page-break-after: always\"></div>

Table 3. The Summary of efficacy for Olivieri et al. (2018)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Analysis population and time point description   | 1,038 patients (BEAM=607,FEAM=431), of which 27%had HL, 14% ndolent NHL, and 59% aNHL Median follow-up was 42 months for both groups, and it was longer for                                                                                                                                                                                                            | 1,038 patients (BEAM=607,FEAM=431), of which 27%had HL, 14% ndolent NHL, and 59% aNHL Median follow-up was 42 months for both groups, and it was longer for   | 1,038 patients (BEAM=607,FEAM=431), of which 27%had HL, 14% ndolent NHL, and 59% aNHL Median follow-up was 42 months for both groups, and it was longer for   |
|--------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                                                                                                                                                                                                                                        | BEAM-treated patients (BEAM=50 months and FEAM=34 months). BEAM (95% CI)                                                                                      | FEAM (95% CI)                                                                                                                                                 |
|                                                  | SIEs                                                                                                                                                                                                                                                                                                                                                                   | 607                                                                                                                                                           | 431                                                                                                                                                           |
|                                                  | Number of subjects Gastrointestinal toxicity Mucositis (grade ≥3)                                                                                                                                                                                                                                                                                                      | 31%                                                                                                                                                           | 44%                                                                                                                                                           |
|                                                  | Nausea (grade ≥3)                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                               | 17%                                                                                                                                                           |
|                                                  | Vomiting (gade ≥3)                                                                                                                                                                                                                                                                                                                                                     | 12% 21%                                                                                                                                                       | 28%                                                                                                                                                           |
|                                                  | Diamhoea (grade ≥4)                                                                                                                                                                                                                                                                                                                                                    | 2.4%                                                                                                                                                          | 5%                                                                                                                                                            |
|                                                  | Overall SIEs Grade =3 Grade _4                                                                                                                                                                                                                                                                                                                                         | ORR 2.6% (1.6-4.2%) p-value                                                                                                                                   | 71% 11%                                                                                                                                                       |
|                                                  | Others Early death rate                                                                                                                                                                                                                                                                                                                                                | 71% 5%                                                                                                                                                        |                                                                                                                                                               |
|                                                  | Overall SIES Secondary endpoints Platelet engrafment (=0.5×10/L) Neutrophils engrafiment (=0.5×10²/L)                                                                                                                                                                                                                                                                  | 91 84.1% (80.9-86.8%)                                                                                                                                         | 83.7% (79.6-87%) 1.99 (1.02-3.88)                                                                                                                             |
|                                                  | OS At 2-year PFS At 2-year RI At l-year NRM                                                                                                                                                                                                                                                                                                                            | At 100 post AHCT                                                                                                                                              | 38                                                                                                                                                            |
|                                                  | At l-year Primary endpoint                                                                                                                                                                                                                                                                                                                                             | 71.9% (68-75.4%)                                                                                                                                              | 68% (63.1-72.4%)                                                                                                                                              |
|                                                  |                                                                                                                                                                                                                                                                                                                                                                        | 18.4% (15.4-21.6%)                                                                                                                                            | 20.7% (16.9-24.7%)                                                                                                                                            |
| Effect estimate per comparison                   | Mortality from infection                                                                                                                                                                                                                                                                                                                                               | Comparisongroups Sub-HR (95% CI)                                                                                                                              | 3.8% (2.2-5.9%) BEAM vs.FEAM                                                                                                                                  |
|                                                  |                                                                                                                                                                                                                                                                                                                                                                        | Comparison groups Grade 3 P-value                                                                                                                             | 0.04 BEAM vs. FEAM 71% vs. 71% 0.94 BEAM vs. FEAM                                                                                                             |
|                                                  |                                                                                                                                                                                                                                                                                                                                                                        | Grade _4 P-value                                                                                                                                              | 5% vs. 11% 0.001                                                                                                                                              |
|                                                  |                                                                                                                                                                                                                                                                                                                                                                        | Comparison groups                                                                                                                                             |                                                                                                                                                               |
|                                                  |                                                                                                                                                                                                                                                                                                                                                                        | Comparison groups Day                                                                                                                                         | BEAM vs. FEAM 12 vs. 13 0.001                                                                                                                                 |
|                                                  |                                                                                                                                                                                                                                                                                                                                                                        | P-value Companison groups Day                                                                                                                                 | BEAM vs. FEAM 10 vs.10 0.09                                                                                                                                   |
|                                                  |                                                                                                                                                                                                                                                                                                                                                                        | P-value Comparison groups At 100 day P-value                                                                                                                  | BEAM vs. FEAM 3.5% VS 5.3% 0.14                                                                                                                               |
| Analysis description                             | Secondary: OS, PFS, RL, NRM BEAM=0.1 vs. FEAM=0.19, P-0.001). to 73.1%) were not different in the two groups.                                                                                                                                                                                                                                                          | Primary: Frequency of severe infections events (grade ≥3 and 4):                                                                                              |                                                                                                                                                               |
|                                                  | FEAM resulted in higher rates of gastrointestinal and infectious toxicities, including severe oral mucositis grade ≥3 (BEAM=31% vs. FEAM=44%, P=0.001), and sepsis from Gram-negative bacteria (mean isolates/patient: 2-year-0S (83.9%; 95% CI, 81.5% to 86.1%) amd PFS (70.3%; 95% CI, 67.4% Mortality from infection was higher in the FEAM group (sub-hazard ratio |                                                                                                                                                               |                                                                                                                                                               |
|                                                  | 1.99: 95% CI, 1.02 to 3.88; P=0.04)                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                               |                                                                                                                                                               |

AHCT: autologous  haematopoetic  (stem)  cell  transplantation;  aNHL:  aggressive  NHL;  BCNU:  carmustine;  BEAM: BCNU, etoposide, cytarabine, and melphalan; CI: confidence interval; FEAM: fotemustine, etoposide, cytarabine, and melphalan  HL:  hodgkin  lymphoma;  HR:  hazard  ratio;  i.v.:  intravenous;  NHL:  non-Hodgkin  lymphoma;  PFS:

<div style=\"page-break-after: always\"></div>

progression free survival; ORR: overall response rate; OS: overall survival; NRM: non-relapse mortality; RI: incidence of relapse; SIE: severe infectious events.

Table 4. The Summary of efficacy for Marchesi et al. (2018)

<!-- image -->

| Title: BEAM vs. FEAM high-dose chemotherapy: retrospective study in lymphoma patients umdergoing autologous stem cell transplant   | Title: BEAM vs. FEAM high-dose chemotherapy: retrospective study in lymphoma patients umdergoing autologous stem cell transplant   | Title: BEAM vs. FEAM high-dose chemotherapy: retrospective study in lymphoma patients umdergoing autologous stem cell transplant   | Title: BEAM vs. FEAM high-dose chemotherapy: retrospective study in lymphoma patients umdergoing autologous stem cell transplant                                                                             | Title: BEAM vs. FEAM high-dose chemotherapy: retrospective study in lymphoma patients umdergoing autologous stem cell transplant                                                                             |
|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                   | Marchesi et al., 2018                                                                                                              | Marchesi et al., 2018                                                                                                              | Marchesi et al., 2018                                                                                                                                                                                        | Marchesi et al., 2018                                                                                                                                                                                        |
| Design                                                                                                                             | Retrospective study Duration of main phase: 2-year                                                                                 | Retrospective study Duration of main phase: 2-year                                                                                 | Retrospective study Duration of main phase: 2-year                                                                                                                                                           | Retrospective study Duration of main phase: 2-year                                                                                                                                                           |
| Hypothesis                                                                                                                         | Comparison between BEAM and FEAM regimen in terms of efficacy and safety in                                                        | lymphoma patients mdergoing AHCT.                                                                                                  | Comparison between BEAM and FEAM regimen in terms of efficacy and safety in                                                                                                                                  | Comparison between BEAM and FEAM regimen in terms of efficacy and safety in                                                                                                                                  |
| Treatments groups                                                                                                                  | BEAM                                                                                                                               | BEAM                                                                                                                               | BCNU 300 mg/m² on day-6, etoposide and cytarabine 100 mg/m² twice daily on days-5, -4 -3, and -2, and melphalan 140 mg/m² on day-1. 100 days, n=200                                                          | BCNU 300 mg/m² on day-6, etoposide and cytarabine 100 mg/m² twice daily on days-5, -4 -3, and -2, and melphalan 140 mg/m² on day-1. 100 days, n=200                                                          |
| Treatments groups                                                                                                                  | FEAM                                                                                                                               | FEAM                                                                                                                               | Fotemustine 150 mg/m on days-7 and-6 etoposide 100 mg/m² twice daily and cytarabine 200 mg/m² twice daily on days-5, -4,-3, and -2 and melphalam 140 mg/m² on day -1 100 days, n=162                         | Fotemustine 150 mg/m on days-7 and-6 etoposide 100 mg/m² twice daily and cytarabine 200 mg/m² twice daily on days-5, -4,-3, and -2 and melphalam 140 mg/m² on day -1 100 days, n=162                         |
| Endpoints and definitions                                                                                                          | Primary endpoint                                                                                                                   | TRR.                                                                                                                               | Primary endpoint was the TRR assessed at day- 100 after AHCT                                                                                                                                                 | Primary endpoint was the TRR assessed at day- 100 after AHCT                                                                                                                                                 |
| Endpoints and definitions                                                                                                          | Secondary endpoint                                                                                                                 | CR, PFS, OS. TRM, CIR, AEs                                                                                                         | Secondary endpoints were conversion rate into CR from a worst disease status (PR, SD, and PD) assessed at day +100 after AHCT, PFS and OS, cumulative IR, engrafhment, AEs, days of hospitalisation, and TRM | Secondary endpoints were conversion rate into CR from a worst disease status (PR, SD, and PD) assessed at day +100 after AHCT, PFS and OS, cumulative IR, engrafhment, AEs, days of hospitalisation, and TRM |
| Database lock                                                                                                                      | 2007-2017                                                                                                                          | 2007-2017                                                                                                                          | 2007-2017                                                                                                                                                                                                    | 2007-2017                                                                                                                                                                                                    |
| Results and Analysis                                                                                                               | Results and Analysis                                                                                                               | Results and Analysis                                                                                                               | Results and Analysis                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                         |
| Analysis description                                                                                                               | Primary Analysis                                                                                                                   | Primary Analysis                                                                                                                   | Primary Analysis                                                                                                                                                                                             | Primary Analysis                                                                                                                                                                                             |
| Descriptive statistics and estimate variability                                                                                    |                                                                                                                                    |                                                                                                                                    |                                                                                                                                                                                                              |                                                                                                                                                                                                              |
| description                                                                                                                        | Treatment group                                                                                                                    | Treatment group                                                                                                                    | BEAM                                                                                                                                                                                                         | FEAM                                                                                                                                                                                                         |
| description                                                                                                                        | All Patients                                                                                                                       | All Patients                                                                                                                       | All Patients                                                                                                                                                                                                 | All Patients                                                                                                                                                                                                 |
| description                                                                                                                        | Number of subject                                                                                                                  | Number of subject                                                                                                                  | 200                                                                                                                                                                                                          | 162                                                                                                                                                                                                          |
| description                                                                                                                        | CR                                                                                                                                 | CR                                                                                                                                 | CR                                                                                                                                                                                                           | CR                                                                                                                                                                                                           |
| description                                                                                                                        | At post-transplant day-100) 174 (87%) PR. At post-transplant day-100                                                               | At post-transplant day-100) 174 (87%) PR. At post-transplant day-100                                                               | 11 (5.5%)                                                                                                                                                                                                    | 15 (9.3%)                                                                                                                                                                                                    |
| description                                                                                                                        | SD/PD                                                                                                                              | SD/PD                                                                                                                              | SD/PD                                                                                                                                                                                                        | SD/PD                                                                                                                                                                                                        |
| description                                                                                                                        | At post-transplant day-100                                                                                                         | At post-transplant day-100                                                                                                         | 10 (5%)                                                                                                                                                                                                      | 19 (11.7%)                                                                                                                                                                                                   |
| description                                                                                                                        | OS                                                                                                                                 | OS                                                                                                                                 | OS                                                                                                                                                                                                           | OS                                                                                                                                                                                                           |
| description                                                                                                                        | At 2-year                                                                                                                          | At 2-year                                                                                                                          | 87%                                                                                                                                                                                                          | 84%                                                                                                                                                                                                          |
| description                                                                                                                        | PFS                                                                                                                                | PFS                                                                                                                                | PFS                                                                                                                                                                                                          | PFS                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | At 2-year                  | 76%                             | 74%                |
|---------------------|----------------------------|---------------------------------|--------------------|
|                     | CIR.                       |                                 |                    |
|                     | At 2-year                  | 12%                             | 14%                |
|                     | TRM                        | 2%                              | 3.7%               |
|                     | HL                         |                                 |                    |
|                     | Number of subjects         | 55                              | 45                 |
|                     | CR                         |                                 |                    |
|                     | At post-transplant day-100 | 48 (87.3%)                      | 34 (75.5%)         |
|                     | PR.                        |                                 |                    |
|                     | At post-tansplant day-100  | 5 (9.1%)                        | 4 (8.9%)           |
|                     | SD/PD                      |                                 |                    |
|                     | At post-transplant day-100 | 2 (3.6%)                        | 7 (15.6%)          |
|                     | PFS                        |                                 |                    |
|                     | At 2-year                  | 77%                             | 78%                |
|                     | DLBCL                      |                                 |                    |
|                     | Number of subjects         | 87                              | 44                 |
|                     | CR                         |                                 |                    |
|                     | At post-transplant day-100 | 72 (82.8%)                      | 28 (63.6%)         |
|                     | PR                         |                                 |                    |
|                     | At post-transplant day-100 | 6 (6.9%)                        | 8 (18.2%)          |
|                     | SD/PD                      |                                 |                    |
|                     | At post-transplant day-100 | 8 (18.2%)                       | 6 (13.6%)          |
|                     | PFS                        |                                 |                    |
|                     | At 2-year                  | 75%                             | 67%                |
| Effect estimate per | Primary endpoint           |                                 |                    |
| comparison          | All patients               |                                 |                    |
|                     | CR                         | Comparison groups               | BEAM vs. FEAM      |
|                     |                            | Post-transplant day-100 P-value | 87% vs. 74.7% 0.01 |
|                     | HL                         |                                 |                    |
|                     | CR                         | Comparison groups               | BEAM vs. FEAM      |
|                     |                            | Post-tramsplant day-100         | 87.3% vs. 75.6%    |
|                     |                            | P-value                         | 0.11               |
|                     | DLBCL                      |                                 |                    |
|                     | CR                         | Comparison groups               | BEAM vs. FEAM      |
|                     |                            | Post-tramsplant day-100         | 82.8% Vs. 63.6%    |
|                     |                            | P-value                         | 0.03               |
|                     | Secondary endpoint         |                                 |                    |
|                     | All patients               |                                 |                    |
|                     | CR                         | Comparison groups               | BEAM vs. FEAM      |
|                     |                            | OR (95% CI)                     | 2.26 (1.28-3.99)   |
|                     |                            | P-value                         | 0.01               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                      | OS                                                                                                                                                                                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                   | BEAM vs. FEAM                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | OS                                                                                                                                                                                                                                                                                                                                                                                                                                  | At 2-year                                                                                                                                                                                                                                                                                                                                                                                                                           | 87% vs. 84%                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                      | OS                                                                                                                                                                                                                                                                                                                                                                                                                                  | P-value                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.578                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                   | BEAM vs. FEAM                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                 | At 2-year                                                                                                                                                                                                                                                                                                                                                                                                                           | 76% vs. 74%                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.211                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                      | CR                                                                                                                                                                                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                   | BEAM vs. FEAM                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | At 2-year                                                                                                                                                                                                                                                                                                                                                                                                                           | 12% vs. 14%                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.235                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                      | TRM                                                                                                                                                                                                                                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                   | BEAM vs. FEAM                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2% vs. 3.7%                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.321                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                      | HL                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                      | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                   | BEAM vs. FEAM                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | At 2-year                                                                                                                                                                                                                                                                                                                                                                                                                           | 77% vs. 78%                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.744                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                      | DLBCL                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                      | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                   | BEAM vs.FEAM                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | At 2-year                                                                                                                                                                                                                                                                                                                                                                                                                           | 75% vs. 67%                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.237                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                      | Others:                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                      | Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                            | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                   | BEAM vs. FEAM                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | Oral mucositis (grade 3- 4)                                                                                                                                                                                                                                                                                                                                                                                                         | 30.5% vs. 51.9%                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                             | c0.0001                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | Infectious complications                                                                                                                                                                                                                                                                                                                                                                                                            | 30.5% vs. 51.9%                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                             | 0.05                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | Absolute neutrophils coumt                                                                                                                                                                                                                                                                                                                                                                                                          | 10 vs. 10 days (similar)                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                     | Platelets recover                                                                                                                                                                                                                                                                                                                                                                                                                   | 13 vs. 14 days (similar)                                                                                                                                                                                                                                                                                                                                                                                                            |
| Notes                |                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Analysis description | Secondary analysis: PFS, OS, RI; Others: CR                                                                                                                                                                                                                                                                                                                                                                                         | Secondary analysis: PFS, OS, RI; Others: CR                                                                                                                                                                                                                                                                                                                                                                                         | Secondary analysis: PFS, OS, RI; Others: CR                                                                                                                                                                                                                                                                                                                                                                                         |
|                      | A significantly higher probability of being in a CR status at post-transplant day-100 assessment in the BEAM group compared with FEAM (87% vs. 74.7%; P=0.01) No sigmificant difference between the two cohorts in PFS (2-year-PFS BEAM: 76% vs. FEAM: 74%; P=0.211), cumulative incidence of relapse (2-year cumulative imcidence of relapse BEAM: 12% vs. FEAM: 14%; P=0.235), and 0S (2-year 0S BEAM: 87% vs. FEAM: 84%;P=0.578) | A significantly higher probability of being in a CR status at post-transplant day-100 assessment in the BEAM group compared with FEAM (87% vs. 74.7%; P=0.01) No sigmificant difference between the two cohorts in PFS (2-year-PFS BEAM: 76% vs. FEAM: 74%; P=0.211), cumulative incidence of relapse (2-year cumulative imcidence of relapse BEAM: 12% vs. FEAM: 14%; P=0.235), and 0S (2-year 0S BEAM: 87% vs. FEAM: 84%;P=0.578) | A significantly higher probability of being in a CR status at post-transplant day-100 assessment in the BEAM group compared with FEAM (87% vs. 74.7%; P=0.01) No sigmificant difference between the two cohorts in PFS (2-year-PFS BEAM: 76% vs. FEAM: 74%; P=0.211), cumulative incidence of relapse (2-year cumulative imcidence of relapse BEAM: 12% vs. FEAM: 14%; P=0.235), and 0S (2-year 0S BEAM: 87% vs. FEAM: 84%;P=0.578) |

AHCT: autologous haematopoetic stem cell transplantation; AE: adverse events; BCNU: carmustine; BEAM: BCNU, etoposide,  cytarabine,  and  melphalan;  CR:  complete  remission;  DLBCL:  diffuse  large  B-cell  lymphoma;  FEAM: fotemustine, etoposide, cytarabine, and melphalan; HL: Hodgkin lymphoma; IR: incidence of relapse; OR: odds ratio; OS:  overall  survival;  PD:  progressive  disease;  PFS:  progression  free  survival;  PR:  partial  remission;  SD:  stable disease; TRR: treatment response rate; TRM: transplant related mortality.

<div style=\"page-break-after: always\"></div>

Table 5. The Summary of efficacy for Khattry et al. (2016)

<!-- image -->

| Title: LACE versus BEAM conditioning inrelapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.   | Title: LACE versus BEAM conditioning inrelapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.   | Title: LACE versus BEAM conditioning inrelapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.                       | Title: LACE versus BEAM conditioning inrelapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.                       | Title: LACE versus BEAM conditioning inrelapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                   | Study identifier                                                                                                                                   | Khatty et al, 2016                                                                                                                                                     | Khatty et al, 2016                                                                                                                                                     | Khatty et al, 2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Design                                                                                                                                             | Design                                                                                                                                             | A retrospective study                                                                                                                                                  | A retrospective study                                                                                                                                                  | A retrospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                    |                                                                                                                                                    | Duuation of main phase: Duuation of Rum-in phase: Duuation of Extension phase:                                                                                         | Duuation of main phase: Duuation of Rum-in phase: Duuation of Extension phase:                                                                                         | 2.08 years (range 0.17-17 years) Not applicable Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Hypothesis                                                                                                                                         | Hypothesis                                                                                                                                         | To compare the LACE and BEAM conditioning regimens for toxicity, engrafhment kinetics, and efficacy in 139 patients umdergoing AHCT for primary refractory or relapsed | To compare the LACE and BEAM conditioning regimens for toxicity, engrafhment kinetics, and efficacy in 139 patients umdergoing AHCT for primary refractory or relapsed | To compare the LACE and BEAM conditioning regimens for toxicity, engrafhment kinetics, and efficacy in 139 patients umdergoing AHCT for primary refractory or relapsed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Treatments groups                                                                                                                                  | Treatments groups                                                                                                                                  | BEAM                                                                                                                                                                   | BEAM                                                                                                                                                                   | BCNU 300 mg/m² i.v. on day -6, etoposide at 200 mg/m² i.v. on days -5 to -2, cytarabine at 200 mg/m² i.v. twice daily on days -5 to -2 and melphalan at 140 mg/m² iv.on day -1 2001-2011,n=64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                    |                                                                                                                                                    | LACE                                                                                                                                                                   | LACE                                                                                                                                                                   | Lomustine at 200 mg/m² oral on day -7. etoposide at 1000 mg/m² i.v. infusion over 10 h on day -7, cytarabine at 2000 mg/m² i.v. 0ver 12 h on days -6 and -5,cyclophosphamide at 1800 mg/m² i.v. over 1-2 h on days -4 to -2 and mesna 1800 mg/m² i.v. over 12 h twice daily on days 4 to -2. 2016-2011,n=75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Endpoints                                                                                                                                          | and                                                                                                                                                | Primary endpoint                                                                                                                                                       |                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| definitions                                                                                                                                        | definitions                                                                                                                                        | Secondary endpoint                                                                                                                                                     |                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                    |                                                                                                                                                    | Others                                                                                                                                                                 | CR, PR, SD, PD, TRM, PFS, OS                                                                                                                                           | Other endpoint CR was defined as complete disappearance of allmeasuurable lesions climically and radiologically for >30 days. PR was defined as reduction of >50% of all measiuable lesions.SD was defined as reduction of less than 50%of measiuable disease without appearance of new lesions. PD was defined as increase of >25% in the size of measiuable disease or appearance of new lesions.TRM was defined as any death urelated to relapse or disease progression dhuing the first 100 days after transplant. PFS was defined as the time interval from the date of transplant to the date of disease progression, relapse, and death due to any cause or last follow-up. OS was defined as the time interval between date of transplant to date of death due to any cause or date of last follow-up. |
| Database lock                                                                                                                                      | Database lock                                                                                                                                      | 30th November 2014                                                                                                                                                     | 30th November 2014                                                                                                                                                     | 30th November 2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Results and Analysis                                                                                                                               | Results and Analysis                                                                                                                               | Results and Analysis                                                                                                                                                   | Results and Analysis                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Analysis description                                                                                                                               | Analysis description                                                                                                                               | Primary Analysis                                                                                                                                                       | Primary Analysis                                                                                                                                                       | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Analysis population and time point description   | One humdred and thirty-nine patients (107 male and 32 female) umderwent HDT followed by HCT for refractory/relapsed lymphoma at three transplant centres duuing the study period. Seventy-five (54%) patients received LACE while 64 (46%) patients received BEAM. Median follow-up: 4.1 years   | One humdred and thirty-nine patients (107 male and 32 female) umderwent HDT followed by HCT for refractory/relapsed lymphoma at three transplant centres duuing the study period. Seventy-five (54%) patients received LACE while 64 (46%) patients received BEAM. Median follow-up: 4.1 years   | One humdred and thirty-nine patients (107 male and 32 female) umderwent HDT followed by HCT for refractory/relapsed lymphoma at three transplant centres duuing the study period. Seventy-five (54%) patients received LACE while 64 (46%) patients received BEAM. Median follow-up: 4.1 years   |
|--------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                                                                                                                                                                  | BEAM                                                                                                                                                                                                                                                                                             | LACE                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability  | Nuumber of subject                                                                                                                                                                                                                                                                               | 64                                                                                                                                                                                                                                                                                               | 75                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability  | CR n (%)                                                                                                                                                                                                                                                                                         | 21 (33)                                                                                                                                                                                                                                                                                          | 43 (57)                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability  | PR n (%)                                                                                                                                                                                                                                                                                         | 31 (48)                                                                                                                                                                                                                                                                                          | 26 (35)                                                                                                                                                                                                                                                                                          |
| Effect estimate per companison                   | Primary endpoint                                                                                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                  |
| Effect estimate per companison                   | PR                                                                                                                                                                                                                                                                                               | P-value                                                                                                                                                                                                                                                                                          | 0.007 BEAM vs. LACE                                                                                                                                                                                                                                                                              |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  | Comparison groups P-value                                                                                                                                                                                                                                                                        | 48% vs. 35% 0.141                                                                                                                                                                                                                                                                                |
| Effect estimate per companison                   | Refractory OS (at 5 years)                                                                                                                                                                                                                                                                       | Comparison groups P-value                                                                                                                                                                                                                                                                        | BEAM vs. LACE 11% vs. 7% 0.141 BEAM vs. LACE 47% vs. 46% (32.98-60.82) Vs.                                                                                                                                                                                                                       |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                  |
| Effect estimate per companison                   | All patients                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  |
| Effect estimate per companison                   | HL patients                                                                                                                                                                                                                                                                                      | 95% CI P-value                                                                                                                                                                                                                                                                                   | (31.69- 59.91) 0.389                                                                                                                                                                                                                                                                             |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  | Comparison groups 95% CI P-value                                                                                                                                                                                                                                                                 | BEAM vs. LACE 48% vs. 49% (29.96-65.24) VS. (30.97-                                                                                                                                                                                                                                              |
| Effect estimate per companison                   | NHL                                                                                                                                                                                                                                                                                              | Comparison groups 95% CI P-value                                                                                                                                                                                                                                                                 | 67.43) 0.279 BEAMvs.LACE 46% vs. 37%                                                                                                                                                                                                                                                             |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  | (23.37-69.23) Vs. (16.72- 57.49) 0.907                                                                                                                                                                                                                                                           |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  | Comparison groups 95% CI                                                                                                                                                                                                                                                                         | BEAM vs. LACE 47% vs. 37%                                                                                                                                                                                                                                                                        |
| Effect estimate per companison                   | PFS (at 5 years)2 All patients                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  | (33.58-61.42) Vs. (21.81- 52.39)                                                                                                                                                                                                                                                                 |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  | P-value                                                                                                                                                                                                                                                                                          | 0.938                                                                                                                                                                                                                                                                                            |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  |
| Effect estimate per companison                   |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                      | HL                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                 | BEAM vs. LACE                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 48% vs. 39%                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | (30.76-65.64) Vs. (18.70- 58.3)                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.747                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                      | NHL                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                 | BEAM vs.LACE                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 46% vs. 34%                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (23.37-69.23) Vs. (13.70- 53.3)                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.709                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                      | TRM                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      | All patients                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Comparisongroups                                                                                                                                                                                                                                                                                                                                                                                                                                                  | BEAM vs.LACE                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 8 (13%) vs. 7 (9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                      | HL                                                                                                                                                                                                                                                                                                                                                                                                                                                                | P-value Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.7448 BEAM vs.LACE 4 vs.5                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.7502                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      | NHL                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | BEAM vs. LACE                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 4 vs.2                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 0.5851                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      | Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                 | BEAM vs. LACE                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Grade 3-4 oral mucositis                                                                                                                                                                                                                                                                                                                                                                                                                                          | 38% vs. 9%                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Parenteral muthition requirement                                                                                                                                                                                                                                                                                                                                                                                                                                  | 69% vs. 32%                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Myeloid engraftment                                                                                                                                                                                                                                                                                                                                                                                                                                               | 11% vs. 10%                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Platelet engrafhment                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14.5% vs. 13%                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Notes                | 1 Probability of OS at 5 years 2 Probability of PFS at 5 years                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis description | Others: OS, PFS, TRMI and TPN The imcidence of grade 3-4 oral mucositis (9 vs. 38%; P-0.001) and TPN (32 vs. 69%; P=0.001) were sigmificantly lower in the LACE cohort. The median days to myeloid (10 vs. 11; P=0.007) and platelet engrafhment (13 vs. 15; P=0.026) were shorter for the LACE cohort. The probability of 0S and PFS at 5 years for entire cohort was 46 and 41%, respectively. TRM was non-significantly higher in BEAM group compared to LACE. | Others: OS, PFS, TRMI and TPN The imcidence of grade 3-4 oral mucositis (9 vs. 38%; P-0.001) and TPN (32 vs. 69%; P=0.001) were sigmificantly lower in the LACE cohort. The median days to myeloid (10 vs. 11; P=0.007) and platelet engrafhment (13 vs. 15; P=0.026) were shorter for the LACE cohort. The probability of 0S and PFS at 5 years for entire cohort was 46 and 41%, respectively. TRM was non-significantly higher in BEAM group compared to LACE. | Others: OS, PFS, TRMI and TPN The imcidence of grade 3-4 oral mucositis (9 vs. 38%; P-0.001) and TPN (32 vs. 69%; P=0.001) were sigmificantly lower in the LACE cohort. The median days to myeloid (10 vs. 11; P=0.007) and platelet engrafhment (13 vs. 15; P=0.026) were shorter for the LACE cohort. The probability of 0S and PFS at 5 years for entire cohort was 46 and 41%, respectively. TRM was non-significantly higher in BEAM group compared to LACE. |

BCNU: carmustine; BEAM: BCNU, etoposide, cytarabine, and melphalan; CR: complete remission; HCT: hematopoietic (stem) cell transplantation; HDT: high-dose therapy; HL: Hodgkin lymphoma; i.v.: intravenous; LACE: lomustine, etoposide, cytarabine, cyclophosphamide; OS: overall survival; PFS: progression free survival; PR: partial remission; PD: progressive disease; SD: stable disease; TRM: transplant related mortality; TPN: total parenteral nutrition.

<div style=\"page-break-after: always\"></div>

Table 6. The Summary of efficacy for Sakellari et al. (2015)

<!-- image -->

| Title: Canmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas   | Title: Canmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas   | Title: Canmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas   | Title: Canmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas                                                                                                                    | Title: Canmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                     | Sakellani et al., 2015                                                                                                                                                                                                                                                                               | Sakellani et al., 2015                                                                                                                                                                                                                                                                               | Sakellani et al., 2015                                                                                                                                                                                                                                                                                                                                                                                                | Sakellani et al., 2015                                                                                                                                                                                                                                                                                                                                                                                                |
| Design                                                                                                                                                                                                                                                                                               | A retrospective matched-pair analysis                                                                                                                                                                                                                                                                | A retrospective matched-pair analysis                                                                                                                                                                                                                                                                | A retrospective matched-pair analysis                                                                                                                                                                                                                                                                                                                                                                                 | A retrospective matched-pair analysis                                                                                                                                                                                                                                                                                                                                                                                 |
| Design                                                                                                                                                                                                                                                                                               | Duuration of main phase:                                                                                                                                                                                                                                                                             | Duuration of main phase:                                                                                                                                                                                                                                                                             | [Not applicable Not applicable                                                                                                                                                                                                                                                                                                                                                                                        | [Not applicable Not applicable                                                                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                                                                                               | Duuation of Extension phase:                                                                                                                                                                                                                                                                         | Duuation of Extension phase:                                                                                                                                                                                                                                                                         | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                        | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hypothesis                                                                                                                                                                                                                                                                                           | To evaluate the outcome of patients conditioned with BEAM and a novel BuEMregimen, in terms of toxicity and efficacy, in a retrospective matched-pair analysis                                                                                                                                       | To evaluate the outcome of patients conditioned with BEAM and a novel BuEMregimen, in terms of toxicity and efficacy, in a retrospective matched-pair analysis                                                                                                                                       | To evaluate the outcome of patients conditioned with BEAM and a novel BuEMregimen, in terms of toxicity and efficacy, in a retrospective matched-pair analysis                                                                                                                                                                                                                                                        | To evaluate the outcome of patients conditioned with BEAM and a novel BuEMregimen, in terms of toxicity and efficacy, in a retrospective matched-pair analysis                                                                                                                                                                                                                                                        |
| Treatments groups                                                                                                                                                                                                                                                                                    | BEAM BuEM                                                                                                                                                                                                                                                                                            | BEAM BuEM                                                                                                                                                                                                                                                                                            | BCNU (300 mg/m²) on day -6, etoposide (200 mg/m2/day) and cytarabine (200 mg/m²/day) on days -5, -4, -3, -2 and melphalan (140 mg/m) on day -1. n=87 Busulfex 9.6 mg/kg (0.8 mg/kg/6 h per day, days -                                                                                                                                                                                                                | BCNU (300 mg/m²) on day -6, etoposide (200 mg/m2/day) and cytarabine (200 mg/m²/day) on days -5, -4, -3, -2 and melphalan (140 mg/m) on day -1. n=87 Busulfex 9.6 mg/kg (0.8 mg/kg/6 h per day, days -                                                                                                                                                                                                                |
| Treatments groups                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                      | 6,-5.-4), 20 h rest, etoposide 800 mg/m² (400 mg/m²/day, days -3, -2) and melphalan 140 mg/m² (day -1). duuation=,n=50                                                                                                                                                                                                                                                                                                | 6,-5.-4), 20 h rest, etoposide 800 mg/m² (400 mg/m²/day, days -3, -2) and melphalan 140 mg/m² (day -1). duuation=,n=50                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                                                            | Primary endpoint                                                                                                                                                                                                                                                                                     | PFS                                                                                                                                                                                                                                                                                                  | Primary endpoint PFS defined as the time in months from the transplant date umtil the occuurence of death or relapse/progression duuing the study period                                                                                                                                                                                                                                                              | Primary endpoint PFS defined as the time in months from the transplant date umtil the occuurence of death or relapse/progression duuing the study period                                                                                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                                                                                                                            | Secondary endpoint                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Endpoints and definitions                                                                                                                                                                                                                                                                            | Other                                                                                                                                                                                                                                                                                                | OS, CR, PR, SD                                                                                                                                                                                                                                                                                       | Secondary endpoint CR was defined as complete disappearance of all detectable climical evidence of disease and disease-related symptoms if present before therapy. The designation of PR required at least a 50% decrease of the diameter of the largest mass. A patient was considered to have SD when he/she failed to attain the criteria needed for a CR or PR but did not fiulfil those for progressive disease. | Secondary endpoint CR was defined as complete disappearance of all detectable climical evidence of disease and disease-related symptoms if present before therapy. The designation of PR required at least a 50% decrease of the diameter of the largest mass. A patient was considered to have SD when he/she failed to attain the criteria needed for a CR or PR but did not fiulfil those for progressive disease. |
| Database lock                                                                                                                                                                                                                                                                                        | 2000-2013                                                                                                                                                                                                                                                                                            | 2000-2013                                                                                                                                                                                                                                                                                            | 2000-2013                                                                                                                                                                                                                                                                                                                                                                                                             | 2000-2013                                                                                                                                                                                                                                                                                                                                                                                                             |
| Results and Analysis                                                                                                                                                                                                                                                                                 | Results and Analysis                                                                                                                                                                                                                                                                                 | Results and Analysis                                                                                                                                                                                                                                                                                 | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                  |
| Analysis description                                                                                                                                                                                                                                                                                 | Primary Analvsis                                                                                                                                                                                                                                                                                     | Primary Analvsis                                                                                                                                                                                                                                                                                     | Primary Analvsis                                                                                                                                                                                                                                                                                                                                                                                                      | Primary Analvsis                                                                                                                                                                                                                                                                                                                                                                                                      |
| Analysis population and time point description                                                                                                                                                                                                                                                       | Eighty-seven patients treated with BEAM who fulfilled the matching criteria were randomly selected Follow up: Median follow-up of64.7 (0.9-129.0) months for BEAM treated patients and 42.7 (1.4-54.0) months for the BuEM cohort                                                                    | Eighty-seven patients treated with BEAM who fulfilled the matching criteria were randomly selected Follow up: Median follow-up of64.7 (0.9-129.0) months for BEAM treated patients and 42.7 (1.4-54.0) months for the BuEM cohort                                                                    | Eighty-seven patients treated with BEAM who fulfilled the matching criteria were randomly selected Follow up: Median follow-up of64.7 (0.9-129.0) months for BEAM treated patients and 42.7 (1.4-54.0) months for the BuEM cohort                                                                                                                                                                                     | Eighty-seven patients treated with BEAM who fulfilled the matching criteria were randomly selected Follow up: Median follow-up of64.7 (0.9-129.0) months for BEAM treated patients and 42.7 (1.4-54.0) months for the BuEM cohort                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                      | Treatment group Number of subject PFS                                                                                                                                                                                                                                                                | BEAM 87                                                                                                                                                                                                                                                                                              | BEAM 87                                                                                                                                                                                                                                                                                                                                                                                                               | BuEM 50                                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                      | At 2-years (%)                                                                                                                                                                                                                                                                                       | 63.2                                                                                                                                                                                                                                                                                                 | 63.2                                                                                                                                                                                                                                                                                                                                                                                                                  | 65.6                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                                                                                                                                                      | OS                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

BCNU: carmustine; BEAM: BCNU, etoposide, cytarabine, and melphalan; BuEM: busulfex, etoposide, melphalan; CI: confidence interval; CR: complete remission; HL: Hodgkin lymphoma; HR: hazard ratio NHL: non-Hodgkin lymphoma; OS: overall survival; PFS: progression free survival; PR: partial remission; SD: stable disease.

<div style=\"page-break-after: always\"></div>

Table 7. The Summary of efficacy for Joffe et al. (2018)

<!-- image -->

| Title: Replacing carmustine by tlhiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma   | Title: Replacing carmustine by tlhiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma   | Title: Replacing carmustine by tlhiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma   | Title: Replacing carmustine by tlhiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                        | Joffe et al., 2018                                                                                                                                      | Joffe et al., 2018                                                                                                                                      | Joffe et al., 2018                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                  | Retrospective study                                                                                                                                     | Retrospective study                                                                                                                                     | Retrospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                         | Duuation of main phase:                                                                                                                                 | Duuation of main phase:                                                                                                                                 | 3 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hypothesis                                                                                                                                              | To compare the outcomes ofBEAM and TECAM in patients transplanted for relapsed or reffractory Hodgkin's and non-Hodgkin's B-cell lymphomas.             | To compare the outcomes ofBEAM and TECAM in patients transplanted for relapsed or reffractory Hodgkin's and non-Hodgkin's B-cell lymphomas.             | To compare the outcomes ofBEAM and TECAM in patients transplanted for relapsed or reffractory Hodgkin's and non-Hodgkin's B-cell lymphomas.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                       | BEAM                                                                                                                                                    | BEAM                                                                                                                                                    | BCNU (300 mg/m² i.v. day -7), etoposide (200 mg/m² days -6 to -3), cytarabine (200 mg/m² days -6 to -3), and melphalan (140 mg/m² day -2). 3 years, n=60                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                         | TECAM                                                                                                                                                   | TECAM                                                                                                                                                   | Thiotepa (40 mg/m² days -5 to -2), etoposide (200 mg/m² days -6 to -3), cytarabine (200 mg/m² days -4 to -1), cyclophosphamide (60 mg/kg day -3). and melphalan (60 mg/m² days -2 to - 1). 3 years, n=65                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                               | Primary endpoint                                                                                                                                        |                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                                         | Secondary endpoint                                                                                                                                      |                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                                         | Others                                                                                                                                                  | TRM, OS, PFS, neutrophil engrafiment, platelet engrafiment, length of stay                                                                              | Disease assessment was perfonmed prior to transplant, and at three months intervals for the first 2 years post-transplant, and at 6 months intervals thereafter. Disease response was defined according to standard lymphoma response criteria. Neutrophil engrafhment was defined as the first of three consecutive days with a neutrophil count 4500 cell/uL and platelet engrafiment as the first of three consecutive days with supported platelets coumt >20 000 cells/μL. Length of stay was defined as the time from admission for transplantation uutil discharge. TRM was defined as non-relapse death within 100 days firom transplantation. OS and PFS were defined from the time of stem cell infusion umtil death from any cause, relapse (for PFS) or end of follow-up. |
| Database lock                                                                                                                                           | 1999-2014                                                                                                                                               | 1999-2014                                                                                                                                               | 1999-2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Results and Analysis                                                                                                                                    | Results and Analysis                                                                                                                                    | Results and Analysis                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Analysis description                                                                                                                                    | Primary Analysis                                                                                                                                        | Primary Analysis                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

BCNU: carmustine; BEAM: BCNU, etoposide, cytarabine, and melphalan; CI: confidence interval; OS: overall survival; PFS:  progression  free  survival;  TRM:  treatment  related  mortality  TECAM:  thiotepa,  etoposide,  cytarabine, cyclophosphamide, melphalan.

Table 8. The Summary of efficacy for Patir et al. (2018)

<!-- image -->

| Title: A retrospective comparison of TECAM and BEAM conditioning regimens before autologous hematopoietic stem cell transplant in lymphoma patients: efficacy and toxicity.   | Title: A retrospective comparison of TECAM and BEAM conditioning regimens before autologous hematopoietic stem cell transplant in lymphoma patients: efficacy and toxicity.   | Title: A retrospective comparison of TECAM and BEAM conditioning regimens before autologous hematopoietic stem cell transplant in lymphoma patients: efficacy and toxicity.   | Title: A retrospective comparison of TECAM and BEAM conditioning regimens before autologous hematopoietic stem cell transplant in lymphoma patients: efficacy and toxicity.   | Title: A retrospective comparison of TECAM and BEAM conditioning regimens before autologous hematopoietic stem cell transplant in lymphoma patients: efficacy and toxicity.      | Title: A retrospective comparison of TECAM and BEAM conditioning regimens before autologous hematopoietic stem cell transplant in lymphoma patients: efficacy and toxicity.      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Stuidy identifier                                                                                                                                                             | Patir et al., 2018                                                                                                                                                            | Patir et al., 2018                                                                                                                                                            | Patir et al., 2018                                                                                                                                                            | Patir et al., 2018                                                                                                                                                               | Patir et al., 2018                                                                                                                                                               |
| Design                                                                                                                                                                        | A. retrospective, single-center, non-interventional study                                                                                                                     | A. retrospective, single-center, non-interventional study                                                                                                                     | A. retrospective, single-center, non-interventional study                                                                                                                     | A. retrospective, single-center, non-interventional study                                                                                                                        | A. retrospective, single-center, non-interventional study                                                                                                                        |
| Design                                                                                                                                                                        | Duration of main phase:                                                                                                                                                       | Duration of main phase:                                                                                                                                                       | Duration of main phase:                                                                                                                                                       | Not applicable Not applicable                                                                                                                                                    | Not applicable Not applicable                                                                                                                                                    |
| Design                                                                                                                                                                        | Duration of Rum-in phase:                                                                                                                                                     | Duration of Rum-in phase:                                                                                                                                                     | Duration of Rum-in phase:                                                                                                                                                     | Not applicable                                                                                                                                                                   | Not applicable                                                                                                                                                                   |
| Design                                                                                                                                                                        | Duuation of Extension phase:                                                                                                                                                  | Duuation of Extension phase:                                                                                                                                                  | Duuation of Extension phase:                                                                                                                                                  |                                                                                                                                                                                  |                                                                                                                                                                                  |
| Hypothesis                                                                                                                                                                    | To evaluate the efficacy and toxicity of TECAM and BEAM conditioning regimens before AHCT in patients with lymphoma.                                                          | To evaluate the efficacy and toxicity of TECAM and BEAM conditioning regimens before AHCT in patients with lymphoma.                                                          | To evaluate the efficacy and toxicity of TECAM and BEAM conditioning regimens before AHCT in patients with lymphoma.                                                          | To evaluate the efficacy and toxicity of TECAM and BEAM conditioning regimens before AHCT in patients with lymphoma.                                                             | To evaluate the efficacy and toxicity of TECAM and BEAM conditioning regimens before AHCT in patients with lymphoma.                                                             |
| Treatments groups                                                                                                                                                             | BEAM                                                                                                                                                                          | BEAM                                                                                                                                                                          | BEAM                                                                                                                                                                          | BCNU at 300 mg/m² × 1 day, etoposide at 200 mg/m² x 4 days, cytarabine at 200 mg/m² x 4 days, and melphalan at 140 mg/m² x 1 day. n=72                                           | BCNU at 300 mg/m² × 1 day, etoposide at 200 mg/m² x 4 days, cytarabine at 200 mg/m² x 4 days, and melphalan at 140 mg/m² x 1 day. n=72                                           |
| Treatments groups                                                                                                                                                             | TECAM                                                                                                                                                                         | TECAM                                                                                                                                                                         | TECAM                                                                                                                                                                         | Thiotepa at 40 mg/m² x 4 days, etoposide at 200 mg/m2 x 4 days, cyclophosphamide at 60 mg/kg x 1 day, cytarabine at 200 mg/m² x 4 days, and melphalan at 60 mg/m² × 2 days. n=36 | Thiotepa at 40 mg/m² x 4 days, etoposide at 200 mg/m2 x 4 days, cyclophosphamide at 60 mg/kg x 1 day, cytarabine at 200 mg/m² x 4 days, and melphalan at 60 mg/m² × 2 days. n=36 |
| Endpoints and definitions                                                                                                                                                     | Primary endpoint                                                                                                                                                              | PFS and OS                                                                                                                                                                    | PFS and OS                                                                                                                                                                    | PFS was measured fom the date of the HDT/AHCT umtil either disease progression or death from any cause. OS was measuured from                                                    | PFS was measured fom the date of the HDT/AHCT umtil either disease progression or death from any cause. OS was measuured from                                                    |
| Endpoints and definitions                                                                                                                                                     | Secondary endpoint                                                                                                                                                            | NRM and                                                                                                                                                                       | NRM and                                                                                                                                                                       | NRM and relapse rate were defined as the time to death without relapse/progression and time to relapse, respectively.                                                            | NRM and relapse rate were defined as the time to death without relapse/progression and time to relapse, respectively.                                                            |
| Database lock                                                                                                                                                                 | October 2012-Febnuary 2017 (final follow-up was completed on May 15, 2017)                                                                                                    | October 2012-Febnuary 2017 (final follow-up was completed on May 15, 2017)                                                                                                    | October 2012-Febnuary 2017 (final follow-up was completed on May 15, 2017)                                                                                                    | October 2012-Febnuary 2017 (final follow-up was completed on May 15, 2017)                                                                                                       | October 2012-Febnuary 2017 (final follow-up was completed on May 15, 2017)                                                                                                       |
| Results and Amalysis Analysis description                                                                                                                                     | Primary Analysis                                                                                                                                                              | Primary Analysis                                                                                                                                                              | Primary Analysis                                                                                                                                                              | Primary Analysis                                                                                                                                                                 | Primary Analysis                                                                                                                                                                 |
| Analysis population and time point description                                                                                                                                | 108 relapsed/refractory lymphoma patients who had high-dose treatments followed by AHCT were analysed.                                                                        | 108 relapsed/refractory lymphoma patients who had high-dose treatments followed by AHCT were analysed.                                                                        | 108 relapsed/refractory lymphoma patients who had high-dose treatments followed by AHCT were analysed.                                                                        | 108 relapsed/refractory lymphoma patients who had high-dose treatments followed by AHCT were analysed.                                                                           | 108 relapsed/refractory lymphoma patients who had high-dose treatments followed by AHCT were analysed.                                                                           |
| Descriptive statistics and estimate variability                                                                                                                               | Median follow-up: 16 months Treatment group                                                                                                                                   | Median follow-up: 16 months Treatment group                                                                                                                                   | BEAM                                                                                                                                                                          | BEAM                                                                                                                                                                             | TECAM                                                                                                                                                                            |
| Descriptive statistics and estimate variability                                                                                                                               | Number of subject                                                                                                                                                             | Number of subject                                                                                                                                                             | 72                                                                                                                                                                            | 72                                                                                                                                                                               | 36                                                                                                                                                                               |
| Descriptive statistics and estimate variability                                                                                                                               | OS                                                                                                                                                                            | OS                                                                                                                                                                            |                                                                                                                                                                               |                                                                                                                                                                                  |                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                               | At 2-years (%)                                                                                                                                                                | At 2-years (%)                                                                                                                                                                | 67                                                                                                                                                                            | 67                                                                                                                                                                               | 55.9                                                                                                                                                                             |
| Descriptive statistics and estimate variability                                                                                                                               | PFS                                                                                                                                                                           | PFS                                                                                                                                                                           |                                                                                                                                                                               |                                                                                                                                                                                  |                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                               | At 2-years (%)                                                                                                                                                                | At 2-years (%)                                                                                                                                                                | 52.9                                                                                                                                                                          | 52.9                                                                                                                                                                             | 55.7                                                                                                                                                                             |
| Descriptive statistics and estimate variability                                                                                                                               | NRM                                                                                                                                                                           | NRM                                                                                                                                                                           |                                                                                                                                                                               |                                                                                                                                                                                  |                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                               | At 1-year (%). (95% CI)                                                                                                                                                       | At 1-year (%). (95% CI)                                                                                                                                                       | 12.5 (7-33.3)                                                                                                                                                                 | 12.5 (7-33.3)                                                                                                                                                                    | 18.1 (7-33.3)                                                                                                                                                                    |
| Descriptive statistics and estimate variability                                                                                                                               | Relapse rate                                                                                                                                                                  | Relapse rate                                                                                                                                                                  |                                                                                                                                                                               |                                                                                                                                                                                  |                                                                                                                                                                                  |
| Descriptive statistics and estimate variability                                                                                                                               | At 1-year (%) (95% CI)                                                                                                                                                        | At 1-year (%) (95% CI)                                                                                                                                                        | 25.5 (16-36.2)                                                                                                                                                                | 25.5 (16-36.2)                                                                                                                                                                   | 26.2 (12.7-41.8)                                                                                                                                                                 |
| Descriptive statistics and estimate variability                                                                                                                               | Primary endpoint                                                                                                                                                              | Primary endpoint                                                                                                                                                              |                                                                                                                                                                               |                                                                                                                                                                                  |                                                                                                                                                                                  |
| Effect estimate per comparison                                                                                                                                                | OS (2-years)                                                                                                                                                                  | OS (2-years)                                                                                                                                                                  | Comparison groups                                                                                                                                                             | Comparison groups                                                                                                                                                                | BEAM vs. TECAM                                                                                                                                                                   |
| Effect estimate per comparison                                                                                                                                                |                                                                                                                                                                               |                                                                                                                                                                               |                                                                                                                                                                               |                                                                                                                                                                                  | 67% vs. 55.9%                                                                                                                                                                    |
| Effect estimate per comparison                                                                                                                                                |                                                                                                                                                                               |                                                                                                                                                                               | P-value                                                                                                                                                                       | P-value                                                                                                                                                                          | 0.238                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                      | PFS                                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                               | BEAM vs. TECAM                                                                                                                                                                                                                                                                                  |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | PFS                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                 | 52.9% vs 55.7%                                                                                                                                                                                                                                                                                  |
|                      | PFS                                                                                                                                                                                                                                                                                             | P-value                                                                                                                                                                                                                                                                                         | 0.811                                                                                                                                                                                                                                                                                           |
|                      | Secondary endpoint                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                 |
|                      | NRM (1-year)                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                               | BEAM vs. TECAM 12.5% vs. 18.1%                                                                                                                                                                                                                                                                  |
|                      | NRM (1-year)                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                          | 6.1-21.3 vs. 7-33.3                                                                                                                                                                                                                                                                             |
|                      | NRM (1-year)                                                                                                                                                                                                                                                                                    | P-value                                                                                                                                                                                                                                                                                         | 0.545                                                                                                                                                                                                                                                                                           |
|                      | Relapse rate (l-year)                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                               | BEAM vs. TECAM                                                                                                                                                                                                                                                                                  |
|                      | Relapse rate (l-year)                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                 | 25.5% vs. 26.2%                                                                                                                                                                                                                                                                                 |
|                      | Relapse rate (l-year)                                                                                                                                                                                                                                                                           | 10 %56                                                                                                                                                                                                                                                                                          | 16-36.2 vs. 12.7-41.8                                                                                                                                                                                                                                                                           |
|                      | Relapse rate (l-year)                                                                                                                                                                                                                                                                           | P-value                                                                                                                                                                                                                                                                                         | 0.844                                                                                                                                                                                                                                                                                           |
|                      | Oihers                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                 |
|                      | Bacterial infection                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                               | BEAM vs. TECAM 43.1% vs. 36.1%                                                                                                                                                                                                                                                                  |
|                      | Bacterial infection                                                                                                                                                                                                                                                                             | P-value                                                                                                                                                                                                                                                                                         | 0.48                                                                                                                                                                                                                                                                                            |
|                      | Invasivefimgal infection                                                                                                                                                                                                                                                                        | Comparison groups                                                                                                                                                                                                                                                                               | BEAM vs. TECAM                                                                                                                                                                                                                                                                                  |
|                      | Cytomegalovinus infection                                                                                                                                                                                                                                                                       | Comparison groups                                                                                                                                                                                                                                                                               | BEAM vs. TECAM                                                                                                                                                                                                                                                                                  |
|                      | Cytomegalovinus infection                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                 | 9.7% vs. 16.7%                                                                                                                                                                                                                                                                                  |
|                      | Cytomegalovinus infection                                                                                                                                                                                                                                                                       | P-value                                                                                                                                                                                                                                                                                         | 0.35                                                                                                                                                                                                                                                                                            |
|                      | Cardiotoxicity                                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                                               | BEAM vs. TECAM                                                                                                                                                                                                                                                                                  |
|                      | Cardiotoxicity                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                 | 9.7% vs. 5.6%                                                                                                                                                                                                                                                                                   |
|                      | Cardiotoxicity                                                                                                                                                                                                                                                                                  | P-value                                                                                                                                                                                                                                                                                         | 0.71                                                                                                                                                                                                                                                                                            |
|                      | Venous thrombosis                                                                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                                                                               | BEAM vs. TECAM 1.4% vs. 8.3                                                                                                                                                                                                                                                                     |
|                      | Intracranial haemonhage                                                                                                                                                                                                                                                                         | Comparison groups                                                                                                                                                                                                                                                                               | BEAM vs. TECAM                                                                                                                                                                                                                                                                                  |
|                      | Intracranial haemonhage                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                 | 2.8% vs. 2.8%                                                                                                                                                                                                                                                                                   |
|                      | Elevated ALT/AST                                                                                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                                                                               | BEAMvs. TECAM                                                                                                                                                                                                                                                                                   |
|                      | Elevated ALT/AST                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                 | 0% vs. 5.6%                                                                                                                                                                                                                                                                                     |
|                      | TRM at day-100                                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                                               | BEAM vs. TECAM                                                                                                                                                                                                                                                                                  |
|                      | TRM at day-100                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                 | 8.3% vs. 11.1%                                                                                                                                                                                                                                                                                  |
|                      |                                                                                                                                                                                                                                                                                                 | P-value                                                                                                                                                                                                                                                                                         | 0.72                                                                                                                                                                                                                                                                                            |
| Notes                |                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                 |
| Analysis description | Primary endpoint: OS and PFS; Secondary endpoint: NRM and RR At a median follow-up period of 16 months, the estimated 2-year progression-free suvival rates for the TECAM and BEAM groups were 55.7% and 52.9%. respectively (P=0.811). The estimated 2-year OS rate in the TECAM group (55.9%) | Primary endpoint: OS and PFS; Secondary endpoint: NRM and RR At a median follow-up period of 16 months, the estimated 2-year progression-free suvival rates for the TECAM and BEAM groups were 55.7% and 52.9%. respectively (P=0.811). The estimated 2-year OS rate in the TECAM group (55.9%) | Primary endpoint: OS and PFS; Secondary endpoint: NRM and RR At a median follow-up period of 16 months, the estimated 2-year progression-free suvival rates for the TECAM and BEAM groups were 55.7% and 52.9%. respectively (P=0.811). The estimated 2-year OS rate in the TECAM group (55.9%) |

ALT:  alanine  transaminase;  AST:  aspartate  aminotransferase;  AHCT:  autologous  haematopoietic  (stem)  cell transplant; BCNU: carmustine; BEAM: BCNU, etoposide, cytarabine, and melphalan; CI: confidence interval; HDT: high dose therapy; NRM: non-relapse mortality; OS: overall survival; PFS: progression free survival; TRM: treatment related mortality; TECAM: thiotepa, etoposide, cytarabine, cyclophosphamide, melphalan.

Table 9. The Summary of efficacy for Kothari et al. (2016)

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Title: A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM   | Title: A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM   | Title: A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM                                    | Title: A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM                                    | Title: A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM                                                                                                                                                                                                                                                              | Title: A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM                                                                                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                       | Kothari et al, 2016                                                                                                                                                    | Kothari et al, 2016                                                                                                                                                                                     | Kothari et al, 2016                                                                                                                                                                                     | Kothari et al, 2016                                                                                                                                                                                                                                                                                                                                                                                                               | Kothari et al, 2016                                                                                                                                                                                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                 | Retrospective study                                                                                                                                                    | Retrospective study                                                                                                                                                                                     | Retrospective study                                                                                                                                                                                     | Retrospective study                                                                                                                                                                                                                                                                                                                                                                                                               | Retrospective study                                                                                                                                                                                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                 | Duration of main phase.                                                                                                                                                | Duration of main phase.                                                                                                                                                                                 | Duration of main phase.                                                                                                                                                                                 | Not applicable Not applicable                                                                                                                                                                                                                                                                                                                                                                                                     | Not applicable Not applicable                                                                                                                                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                 | Duuation of Rum-in phase:                                                                                                                                              | Duuation of Rum-in phase:                                                                                                                                                                               | Duuation of Rum-in phase:                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Design                                                                                                                                                                 | Duuation of Extension phase:                                                                                                                                           | Duuation of Extension phase:                                                                                                                                                                            | Duuation of Extension phase:                                                                                                                                                                            | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                    | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hypothesis                                                                                                                                                             | Comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma.                                        | Comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma.                                                                         | Comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma.                                                                         | Comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma.                                                                                                                                                                                                                                                                                                   | Comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma.                                                                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                      | BEAM                                                                                                                                                                   | BEAM                                                                                                                                                                                                    | BEAM                                                                                                                                                                                                    | BCNU 300 mg/m², etoposide 800 mg/m² (in divided doses), cytarabine 1600 mg/m² (in divided doses) and melphalan 140mg/m². Time period covered December 1999-September 2011, n=50                                                                                                                                                                                                                                                   | BCNU 300 mg/m², etoposide 800 mg/m² (in divided doses), cytarabine 1600 mg/m² (in divided doses) and melphalan 140mg/m². Time period covered December 1999-September 2011, n=50                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                      | LEAM                                                                                                                                                                   | LEAM                                                                                                                                                                                                    | LEAM                                                                                                                                                                                                    | Lomustine 200 mg/m², etoposide 800 mg/m² (inm divided doses), cytarabine 1600 mg/m² (in divided doses) and melphalam140 mg/m? Time period covered August 2008-Jume 2013, n=50                                                                                                                                                                                                                                                     | Lomustine 200 mg/m², etoposide 800 mg/m² (inm divided doses), cytarabine 1600 mg/m² (in divided doses) and melphalam140 mg/m? Time period covered August 2008-Jume 2013, n=50                                                                                                                                                                                                                                                     |
| Endpoints definitions                                                                                                                                                  | Primary endpoint                                                                                                                                                       |                                                                                                                                                                                                         |                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Endpoints definitions                                                                                                                                                  | Secondary endpoint                                                                                                                                                     |                                                                                                                                                                                                         |                                                                                                                                                                                                         | Toxicities were assessed retrospectively for each                                                                                                                                                                                                                                                                                                                                                                                 | Toxicities were assessed retrospectively for each                                                                                                                                                                                                                                                                                                                                                                                 |
| Endpoints definitions                                                                                                                                                  | Others                                                                                                                                                                 |                                                                                                                                                                                                         | Toxicity. OS, PFS and NRM                                                                                                                                                                               | cohort, using the musing and medical notes, according to CTCAEv4.0 criteria. OS was defined as the time from the date of transplant to death from any cause. PFS was defined as the date of transplant to the date of documented progression/relapse or death from any cause. Cuumulative incidence was estimated for NRM and relapse risk, with relapse as a competing risk for the NRM and death in remission for relapse risk. | cohort, using the musing and medical notes, according to CTCAEv4.0 criteria. OS was defined as the time from the date of transplant to death from any cause. PFS was defined as the date of transplant to the date of documented progression/relapse or death from any cause. Cuumulative incidence was estimated for NRM and relapse risk, with relapse as a competing risk for the NRM and death in remission for relapse risk. |
| Database lock                                                                                                                                                          | July 2015                                                                                                                                                              | July 2015                                                                                                                                                                                               | July 2015                                                                                                                                                                                               | July 2015                                                                                                                                                                                                                                                                                                                                                                                                                         | July 2015                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Results and Analysis                                                                                                                                                   | Results and Analysis                                                                                                                                                   | Results and Analysis                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                              |
| Analysis description                                                                                                                                                   | Analysis description                                                                                                                                                   | Primary Analysis                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                  | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Analysis population and time point description                                                                                                                         | Analysis population and time point description                                                                                                                         | Two cohorts of patients (n=50, each cohort) umdergoing AHCT for relapsed/refiactory B-cell lymphoma was compared. Follow up: For LEAM (August 2008-Juue 2013); For BEAM (December 1999- September 2011) | Two cohorts of patients (n=50, each cohort) umdergoing AHCT for relapsed/refiactory B-cell lymphoma was compared. Follow up: For LEAM (August 2008-Juue 2013); For BEAM (December 1999- September 2011) | Two cohorts of patients (n=50, each cohort) umdergoing AHCT for relapsed/refiactory B-cell lymphoma was compared. Follow up: For LEAM (August 2008-Juue 2013); For BEAM (December 1999- September 2011)                                                                                                                                                                                                                           | Two cohorts of patients (n=50, each cohort) umdergoing AHCT for relapsed/refiactory B-cell lymphoma was compared. Follow up: For LEAM (August 2008-Juue 2013); For BEAM (December 1999- September 2011)                                                                                                                                                                                                                           |
| Descniptive statistics and                                                                                                                                             | Descniptive statistics and                                                                                                                                             | Treatment group BEAM                                                                                                                                                                                    | Treatment group BEAM                                                                                                                                                                                    | Treatment group BEAM                                                                                                                                                                                                                                                                                                                                                                                                              | LEAM                                                                                                                                                                                                                                                                                                                                                                                                                              |
| estimate variability                                                                                                                                                   | estimate variability                                                                                                                                                   | Number of subject 50                                                                                                                                                                                    | Number of subject 50                                                                                                                                                                                    | Number of subject 50                                                                                                                                                                                                                                                                                                                                                                                                              | 50                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                        |                                                                                                                                                                        | Median time to discharge from hospital                                                                                                                                                                  | 23 days                                                                                                                                                                                                 | 23 days                                                                                                                                                                                                                                                                                                                                                                                                                           | 23 days                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                        |                                                                                                                                                                        | NRM                                                                                                                                                                                                     |                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                                        |                                                                                                                                                                        | At 100 days                                                                                                                                                                                             | 2%                                                                                                                                                                                                      | 2%                                                                                                                                                                                                                                                                                                                                                                                                                                | 4%                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                        |                                                                                                                                                                        | At 12-months                                                                                                                                                                                            | 4%                                                                                                                                                                                                      | 4%                                                                                                                                                                                                                                                                                                                                                                                                                                | 4%                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                        |                                                                                                                                                                        | OS                                                                                                                                                                                                      |                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

AHCT: Autologous haematopoetic stem cell transplantation; BCNU: Carmustine; BEAM: BCNU, etoposide, cytarabine, and melphalan; CI: Confidence interval; LEAM: Lomustine, etoposide, cytarabine, and melphalan; GI: Gastrointestinal; NRM: Non-relapse mortality; OS: Overall survival PFS: Progression free survival.

<div style=\"page-break-after: always\"></div>

## Main studies in allogenic HCT

Table 10. The Summary of efficacy for Robinson et al. (2002)

| Title: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working Party of the European Group for Blood and Bone Marrow Transplantation   | Title: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working Party of the European Group for Blood and Bone Marrow Transplantation   | Title: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working Party of the European Group for Blood and Bone Marrow Transplantation   | Title: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working Party of the European Group for Blood and Bone Marrow Transplantation   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                               | Robinson et al., 2002                                                                                                                                                                                                                                          | Robinson et al., 2002                                                                                                                                                                                                                                          | Robinson et al., 2002                                                                                                                                                                                                                                          |
| Design                                                                                                                                                                                                                                                         | A retrospective study                                                                                                                                                                                                                                          | A retrospective study                                                                                                                                                                                                                                          | A retrospective study                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                | Duuation of main phase:                                                                                                                                                                                                                                        | Not applicable                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Dhuation of Rum-in phase:                                                                                                                                                                                                                                      | Not applicable                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Dhuation of Extension phase:                                                                                                                                                                                                                                   | Not applicable                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                |
| Hypothesis                                                                                                                                                                                                                                                     | To repot the outcome of RIT in 188 patients with lymphoma reported to the EBMT registy                                                                                                                                                                         | To repot the outcome of RIT in 188 patients with lymphoma reported to the EBMT registy                                                                                                                                                                         | To repot the outcome of RIT in 188 patients with lymphoma reported to the EBMT registy                                                                                                                                                                         |
| Treatments groups                                                                                                                                                                                                                                              | ≤ that of BEAM plus fludarabine                                                                                                                                                                                                                                | ≤ that of BEAM plus fludarabine                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Not applicable                                                                                                                                                                                                                                                 | Fludarabine (90-150 mg/m²) + cyclophosphamide (20-120 mg/kg) n=41                                                                                                                                                                                              |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Not applicable                                                                                                                                                                                                                                                 | Fludarabine (150-300 mg/m²) + busulphan (4-10 mg/kg).n=31                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Not applicable Not applicable                                                                                                                                                                                                                                  | melphalan(140 mg/m-)± alemhuzumab (100 mg/m²).n=63 Fludarabine (150 mg/m²) + thiotepa                                                                                                                                                                          |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Not applicable                                                                                                                                                                                                                                                 | Fludarabine (100 mg/m²) + busulphan (8 mg/kg) + etoposide(30 mg/kg). n=3                                                                                                                                                                                       |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Not applicable                                                                                                                                                                                                                                                 | Fludarabine (150 mg/m²) + BCNU (300 mg/m²) + melphalan (140 mg/m²)                                                                                                                                                                                             |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Not applicable                                                                                                                                                                                                                                                 | BCNU (300 mg/m²) + etoposide (800 mg/m-) + cytarabine (800 mg/m²) + melphalan (140 mg/m²) ± Campath-IG antibody.n=18 BCNU (300 mg/m²) + etoposide (800                                                                                                         |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Not applicable                                                                                                                                                                                                                                                 | mg/m²) + cytarabine (800 mg/m²) + melphalan (140 mg/m²) + fludarabine (150 mg/m²). n=1 Cyclophosphamide (60-120 mg/kg) ±                                                                                                                                       |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Not applicable Not applicable                                                                                                                                                                                                                                  | thiotepa (300-600 mg/m²). n=10 Fludarabine (150 mg/m²) + cytarabine (800 mg/m²) ± idanubicin (15 mg/m²).                                                                                                                                                       |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Not applicable                                                                                                                                                                                                                                                 | Not applicable                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Not applicable                                                                                                                                                                                                                                                 | TBI (2 Gy). n=1                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                      | Primary endpoint                                                                                                                                                                                                                                               | Primary endpoint                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                | Secondary endpoint                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                     | Others                                                                                       | Response to the last therapy, OS, PFS, TRM, GVHD                                             | Response to the last therapy, OS, PFS, TRM, GVHD                                             | A response to the last therapy prior to transplantation PR, CR umconfinmed and CR; chemoresistant disease included those with primary refractory disease or refractory relapse pnior to transplantation. OS. PFS was measiued in months as the time from the day of transplantation umtil disease relapse/progression or death from any cause. Both relapse and progression were defined as disease progression with transplantation-related deaths being censored. TRM included all causes of death other than disease progression/relapse occuring at any time after reduced-intensity progenitor cell transplants . Patients with progressive disease who died from transplantation-related causes were classified as TRM deaths. For the puuposes of uuivariate and multivariate analysis the following groups were defined: no GVHD vs. GVHD (acute GVHD grade I-IV.   | A response to the last therapy prior to transplantation PR, CR umconfinmed and CR; chemoresistant disease included those with primary refractory disease or refractory relapse pnior to transplantation. OS. PFS was measiued in months as the time from the day of transplantation umtil disease relapse/progression or death from any cause. Both relapse and progression were defined as disease progression with transplantation-related deaths being censored. TRM included all causes of death other than disease progression/relapse occuring at any time after reduced-intensity progenitor cell transplants . Patients with progressive disease who died from transplantation-related causes were classified as TRM deaths. For the puuposes of uuivariate and multivariate analysis the following groups were defined: no GVHD vs. GVHD (acute GVHD grade I-IV.   |
|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Database lock                                                       | 1996-2000                                                                                    | 1996-2000                                                                                    | 1996-2000                                                                                    | 1996-2000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1996-2000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Results and Analysis                                                | Results and Analysis                                                                         | Results and Analysis                                                                         | Results and Analysis                                                                         | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis description Analysis population and time point description | Primary Analysis 188 patients with lymphoma reported to the EBMT registy. Follow-up:283 days | Primary Analysis 188 patients with lymphoma reported to the EBMT registy. Follow-up:283 days | Primary Analysis 188 patients with lymphoma reported to the EBMT registy. Follow-up:283 days | Primary Analysis 188 patients with lymphoma reported to the EBMT registy. Follow-up:283 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary Analysis 188 patients with lymphoma reported to the EBMT registy. Follow-up:283 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate vaniability                     | Treatment group                                                                              | Treatment group                                                                              | Equivalent to or less than that of BEAM plus fludarabine                                     | Equivalent to or less than that of BEAM plus fludarabine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Equivalent to or less than that of BEAM plus fludarabine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate vaniability                     | Nuumber of subjects                                                                          | Nuumber of subjects                                                                          | 188                                                                                          | 188                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 188                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate vaniability                     | Regimen intentsity                                                                           | Regimen intentsity                                                                           | Low                                                                                          | Intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | High                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate vaniability                     | OS                                                                                           | OS                                                                                           |                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate vaniability                     | At 1-year, n                                                                                 | At 1-year, n                                                                                 | 61                                                                                           | 62                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 63                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate vaniability                     | PFS                                                                                          | PFS                                                                                          |                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate vaniability                     | At 1-year, n                                                                                 | At 1-year, n                                                                                 | 40                                                                                           | 50                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 51                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate vaniability                     | TRM                                                                                          | TRM                                                                                          |                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate vaniability                     | At 1-year, n                                                                                 | At 1-year, n                                                                                 | 24                                                                                           | 28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate vaniability                     | Progression                                                                                  | Progression                                                                                  |                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate vaniability                     | At 1-year, n                                                                                 | At 1-year, n                                                                                 | 44                                                                                           | 29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate vaniability                     | GVHD                                                                                         | GVHD                                                                                         |                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate vaniability                     |                                                                                              |                                                                                              | 48                                                                                           | 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                                      | Primary endpoint                                                                             | Primary endpoint                                                                             | Comparison groups                                                                            | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison                                      | Secondary endpoint                                                                           |                                                                                              |                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Effect estimate per comparison                                      | Others:                                                                                      | Comparison groups                                                                            | Comparison groups                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                      | Multivariate amalysis                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | os                                                                                                                                                                                                                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | Chemosensitive RR (CI)                                                                                                                                                                                                                                                                                                                                                                                            | 2.4 (1.4-4.2)                                                                                                                                                                                                                                                                                                                                                                                                     |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                           | 0.002                                                                                                                                                                                                                                                                                                                                                                                                             |
|                      | PFS                                                                                                                                                                                                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | Chemosensitive                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | RR (CI)                                                                                                                                                                                                                                                                                                                                                                                                           | 2.3 (1.4-3.7)                                                                                                                                                                                                                                                                                                                                                                                                     |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                           | 0.007                                                                                                                                                                                                                                                                                                                                                                                                             |
|                      | TRM                                                                                                                                                                                                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | Age >50-year                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | RR (CI)                                                                                                                                                                                                                                                                                                                                                                                                           | 2.02 (1.03-4.0)                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                           | 0.041                                                                                                                                                                                                                                                                                                                                                                                                             |
|                      | Progression                                                                                                                                                                                                                                                                                                                                                                                                       | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | Chemoresistant                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | RR (CI)                                                                                                                                                                                                                                                                                                                                                                                                           | 3.3 (1.69-6.35)                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                           | 0.0004                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      | GVHD                                                                                                                                                                                                                                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | MUD RR (CI)                                                                                                                                                                                                                                                                                                                                                                                                       | 3.7 (1.37-9.9)                                                                                                                                                                                                                                                                                                                                                                                                    |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                           | 0.0098                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | TCD                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | RR (CI)                                                                                                                                                                                                                                                                                                                                                                                                           | 0.4 (0.21-0.78)                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0071                                                                                                                                                                                                                                                                                                                                                                                                            |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                      | TRM                                                                                                                                                                                                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                 | TRM =50 years old vs. =50 years old                                                                                                                                                                                                                                                                                                                                                                               |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | For older patients                                                                                                                                                                                                                                                                                                                                                                                                | 39% vs. 22%,                                                                                                                                                                                                                                                                                                                                                                                                      |
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                                                                                                                                                                                                           | 0.04                                                                                                                                                                                                                                                                                                                                                                                                              |
| Notes                |                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis description | Other: OS, PFS, TRM, GVHD The estimated 0S at 2 years was 65%, 46.7%, 56.3%,12.8% for LGNHL, HGNHL, HD, and MCL respectively. The 1-year PFS rates for LGNHL, HGNHL, HD, and MCL were 61%, 32%, 55%, and 31%, respectively (P=0.009) Acute GVHD occured as Grade I and Grade II to IV occured in 12% and 24% patients while chronic GVHD occuured as limited chromic and extensive chromic in 7% and 9% patients. | Other: OS, PFS, TRM, GVHD The estimated 0S at 2 years was 65%, 46.7%, 56.3%,12.8% for LGNHL, HGNHL, HD, and MCL respectively. The 1-year PFS rates for LGNHL, HGNHL, HD, and MCL were 61%, 32%, 55%, and 31%, respectively (P=0.009) Acute GVHD occured as Grade I and Grade II to IV occured in 12% and 24% patients while chronic GVHD occuured as limited chromic and extensive chromic in 7% and 9% patients. | Other: OS, PFS, TRM, GVHD The estimated 0S at 2 years was 65%, 46.7%, 56.3%,12.8% for LGNHL, HGNHL, HD, and MCL respectively. The 1-year PFS rates for LGNHL, HGNHL, HD, and MCL were 61%, 32%, 55%, and 31%, respectively (P=0.009) Acute GVHD occured as Grade I and Grade II to IV occured in 12% and 24% patients while chronic GVHD occuured as limited chromic and extensive chromic in 7% and 9% patients. |

BCNU:  carmustine;  BEAM:  BCNU,  etoposide,  cytarabine,  and  melphalan;  CI:  confidence  interval;  CR:  complete remission;  EBMT:  European  Bone  Marrow  Transplant;  GVHD:  graft  versus  host  disease;  LGNHL:  low-grade  nonHodgkin lymphoma; HGNHL: high-grade non- Hodgkin lymphoma; MCL: Mantle cell lymphomas; MUD: matched unrelated donor; OS: overall survival; PFS: progression free survival; RR: Relative risk; TRM: Transplantation related mortality; TCD: T-cell depletion.

Table 11. The Summary of efficacy for Bertz et al. (2016)

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Title: Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced- intensity conditioning for patients ≥60 years with advanced AML/MDS   | Title: Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced- intensity conditioning for patients ≥60 years with advanced AML/MDS   | Title: Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced- intensity conditioning for patients ≥60 years with advanced AML/MDS   | Title: Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced- intensity conditioning for patients ≥60 years with advanced AML/MDS   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                             | Bertz et al., 2016                                                                                                                                                           | Bertz et al., 2016                                                                                                                                                           | Bertz et al., 2016                                                                                                                                                           |
| Design                                                                                                                                                                       | A report on detailed multivariable analyses of a phase II prospective shudy                                                                                                  | A report on detailed multivariable analyses of a phase II prospective shudy                                                                                                  | A report on detailed multivariable analyses of a phase II prospective shudy                                                                                                  |
| Design                                                                                                                                                                       | Duuation of main phase:                                                                                                                                                      | Duuation of main phase:                                                                                                                                                      | 13-years                                                                                                                                                                     |
| Design                                                                                                                                                                       | Duuation of Rum-in phase:                                                                                                                                                    | Duuation of Rum-in phase:                                                                                                                                                    | Not applicable                                                                                                                                                               |
| Design                                                                                                                                                                       | Duuation of Extension phase:                                                                                                                                                 | Duuation of Extension phase:                                                                                                                                                 | Not applicable                                                                                                                                                               |
| Hypothesis                                                                                                                                                                   | A report on detailed multivariable amalyses of a phase II prospective study                                                                                                  | A report on detailed multivariable amalyses of a phase II prospective study                                                                                                  | A report on detailed multivariable amalyses of a phase II prospective study                                                                                                  |
| Treatments groups                                                                                                                                                            | FBM                                                                                                                                                                          | FBM                                                                                                                                                                          | Fludarabine, bis-chlorethyl-mitroso-uurea/BCNU, melphalan; 13-year, n=250                                                                                                    |
| Endpoints and definitions                                                                                                                                                    | Primary endpoint                                                                                                                                                             |                                                                                                                                                                              |                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                    | Secondary endpoint                                                                                                                                                           |                                                                                                                                                                              |                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                    | Other                                                                                                                                                                        | CR, OS, DFS, RI, GVHD                                                                                                                                                        | CR, OS and DFS, cimulative RI; GVHD: acute GVHD and chronic GVHD                                                                                                             |
| Database lock                                                                                                                                                                | 1999-2012                                                                                                                                                                    | 1999-2012                                                                                                                                                                    | 1999-2012                                                                                                                                                                    |
| Results and Analysis                                                                                                                                                         | Results and Analysis                                                                                                                                                         | Results and Analysis                                                                                                                                                         | Results and Analysis                                                                                                                                                         |
| Analysis description                                                                                                                                                         | Primary Analysis                                                                                                                                                             | Primary Analysis                                                                                                                                                             | Primary Analysis                                                                                                                                                             |
| Analysis population and time point description Descriptive statistics                                                                                                        | 250 patients treated with allo-HCT Follow up: 4.8 years                                                                                                                      | 250 patients treated with allo-HCT Follow up: 4.8 years                                                                                                                      | 250 patients treated with allo-HCT Follow up: 4.8 years                                                                                                                      |
| and estimate variability                                                                                                                                                     | Treatment group                                                                                                                                                              | Treatment group                                                                                                                                                              | FBM (95% CI)                                                                                                                                                                 |
| and estimate variability                                                                                                                                                     | Number of subject                                                                                                                                                            | Number of subject                                                                                                                                                            | [250                                                                                                                                                                         |
| and estimate variability                                                                                                                                                     | Haematological CR                                                                                                                                                            | Haematological CR                                                                                                                                                            |                                                                                                                                                                              |
| and estimate variability                                                                                                                                                     | At day +30                                                                                                                                                                   | At day +30                                                                                                                                                                   | 96%                                                                                                                                                                          |
| and estimate variability                                                                                                                                                     | OS                                                                                                                                                                           | OS                                                                                                                                                                           |                                                                                                                                                                              |
| and estimate variability                                                                                                                                                     | At l-year                                                                                                                                                                    | At l-year                                                                                                                                                                    | 60.5% (54.6-66.9%)                                                                                                                                                           |
| and estimate variability                                                                                                                                                     | At 2-year                                                                                                                                                                    | At 2-year                                                                                                                                                                    | 48.5% (2.4-55.2%)                                                                                                                                                            |
| and estimate variability                                                                                                                                                     | At 5-year                                                                                                                                                                    | At 5-year                                                                                                                                                                    | 36.8% (30.8-43.8%)                                                                                                                                                           |
| and estimate variability                                                                                                                                                     | OS (AML patients not mdergone allo-HCT)                                                                                                                                      | OS (AML patients not mdergone allo-HCT)                                                                                                                                      |                                                                                                                                                                              |
| and estimate variability                                                                                                                                                     | 6month                                                                                                                                                                       | 6month                                                                                                                                                                       | 50.1%                                                                                                                                                                        |
| and estimate variability                                                                                                                                                     | At l-year                                                                                                                                                                    | At l-year                                                                                                                                                                    | 33.4%                                                                                                                                                                        |
| and estimate variability                                                                                                                                                     | At 2-year                                                                                                                                                                    | At 2-year                                                                                                                                                                    | 17.1%                                                                                                                                                                        |
| and estimate variability                                                                                                                                                     | At 5-year                                                                                                                                                                    | At 5-year                                                                                                                                                                    | 5.3%                                                                                                                                                                         |
| and estimate variability                                                                                                                                                     | DFS                                                                                                                                                                          | DFS                                                                                                                                                                          |                                                                                                                                                                              |
| and estimate variability                                                                                                                                                     | At 1-year                                                                                                                                                                    | At 1-year                                                                                                                                                                    | 48.7% (42.8-55.4%)                                                                                                                                                           |
| and estimate variability                                                                                                                                                     | At 2-year                                                                                                                                                                    | At 2-year                                                                                                                                                                    | 40.5% (4.7-47.2%)                                                                                                                                                            |
| and estimate variability                                                                                                                                                     | At 5-year                                                                                                                                                                    | At 5-year                                                                                                                                                                    | 33.7% (27.9-40.6%)                                                                                                                                                           |
| and estimate variability                                                                                                                                                     | Cumulative incidence of RI                                                                                                                                                   | Cumulative incidence of RI                                                                                                                                                   |                                                                                                                                                                              |
| and estimate variability                                                                                                                                                     | At 1-year                                                                                                                                                                    | At 1-year                                                                                                                                                                    | 28.1% (22.5-33.7%)                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                                | At 2-year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 32.0% (26.2-37.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 32.0% (26.2-37.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                | At 5-year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 34.8% (28.7-40.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 34.8% (28.7-40.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                | GVHD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                | Acute                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                | Grade II -IV (At day +100)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                | Grade II-IV (At day +100)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 11.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                | Grade II -IV (at day +365)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 24%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                | Grade III-IV (at day +365)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 12%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 12%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                | Chronic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                | 1-year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 36.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 36.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                | 2-year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 37.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 37.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                | 5-year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 39.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 39.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                | Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                | OS (umivariate analysis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | HR (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 1.96 (1.35-2.84)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                | DFS (uivariate analysis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | HR (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 1.99 (1.38-2.87)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                | OS (multivariate analysis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | HR (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 1.65 (1.08-2.52)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                | DFS (multivariate amalysis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | HR. (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 1.73 (1.08-2.76)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Notes                          | There is no clear infonmation about posology used.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | There is no clear infonmation about posology used.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | There is no clear infonmation about posology used.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Analysis description           | Other: CR, OS, DFS, RI, GIHD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Other: CR, OS, DFS, RI, GIHD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Other: CR, OS, DFS, RI, GIHD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                | At day +30, haematological CR was achieved in 96% Probabilities for 0S at 1, 2 and 5 years were 60.5% (95% CI: 54.6-66.9%), 48.5% (95% CI: 42.4-55.2%) and 36.8% (95% CI: 30.8-43.8%), respectively. DFS at 1, 2 and 5 years Were 48.7% (95% CI: 42.855.4%), 40.5% (95% CI: 34.7- 47.2%) and 33.7% (95% CI: 27.940.6%), respectively. Clinically relevant acute GVHD II-IV and III-IV with cumulative incidences at day +100 of 22.8 and 11.6%, and at day +365 of 24% and 12%, respectively. Cumulative incidence rates of overall chronic GVHD after 1, 2 or 5 years were 36.1%, 37.4% and 39.1%, respectively. The cumulative imcidence of RI was at 1, 2 and 5 years were 28.1% (95% CI: 22.5- 33.7%), 32.0% (95% CI: 26.2-37.9%) and 34.8% (95% CI: 28.7-40.9%). | At day +30, haematological CR was achieved in 96% Probabilities for 0S at 1, 2 and 5 years were 60.5% (95% CI: 54.6-66.9%), 48.5% (95% CI: 42.4-55.2%) and 36.8% (95% CI: 30.8-43.8%), respectively. DFS at 1, 2 and 5 years Were 48.7% (95% CI: 42.855.4%), 40.5% (95% CI: 34.7- 47.2%) and 33.7% (95% CI: 27.940.6%), respectively. Clinically relevant acute GVHD II-IV and III-IV with cumulative incidences at day +100 of 22.8 and 11.6%, and at day +365 of 24% and 12%, respectively. Cumulative incidence rates of overall chronic GVHD after 1, 2 or 5 years were 36.1%, 37.4% and 39.1%, respectively. The cumulative imcidence of RI was at 1, 2 and 5 years were 28.1% (95% CI: 22.5- 33.7%), 32.0% (95% CI: 26.2-37.9%) and 34.8% (95% CI: 28.7-40.9%). | At day +30, haematological CR was achieved in 96% Probabilities for 0S at 1, 2 and 5 years were 60.5% (95% CI: 54.6-66.9%), 48.5% (95% CI: 42.4-55.2%) and 36.8% (95% CI: 30.8-43.8%), respectively. DFS at 1, 2 and 5 years Were 48.7% (95% CI: 42.855.4%), 40.5% (95% CI: 34.7- 47.2%) and 33.7% (95% CI: 27.940.6%), respectively. Clinically relevant acute GVHD II-IV and III-IV with cumulative incidences at day +100 of 22.8 and 11.6%, and at day +365 of 24% and 12%, respectively. Cumulative incidence rates of overall chronic GVHD after 1, 2 or 5 years were 36.1%, 37.4% and 39.1%, respectively. The cumulative imcidence of RI was at 1, 2 and 5 years were 28.1% (95% CI: 22.5- 33.7%), 32.0% (95% CI: 26.2-37.9%) and 34.8% (95% CI: 28.7-40.9%). |

allo-HCT: allogenous Haematologic cell transplantation AML: acute myeloblastic leukaemia; BCNU: carmustine; CI: confidence interval; CR: complete remission; DFS: disease free survival; GVHD: graft versus host disease; HR: hazard ratio; OS: overall survival; FBM: fludarabine, BCNU, melphalan; MDS: myelodysplastic syndrome; RI: incidence rates of relapse.

<div style=\"page-break-after: always\"></div>

Table 11. The Summary of efficacy for Marks et al. (2008)

<!-- image -->

| Title: Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies   | Title: Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies                                                       | Title: Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies                                                       | Title: Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies                                                                                                                                                                                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                             | Marks et al., 2008                                                                                                                                                                                                                               | Marks et al., 2008                                                                                                                                                                                                                               | Marks et al., 2008                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Desig                                                                                                                                                                                        | A report of long-term follow-up results of 133 consecutive patients with haematologic malignancies included in a 2-center, prospective, nomrandomised, open-label phase II clinical tmial in adult patients with haematologic and solid tumouurs | A report of long-term follow-up results of 133 consecutive patients with haematologic malignancies included in a 2-center, prospective, nomrandomised, open-label phase II clinical tmial in adult patients with haematologic and solid tumouurs | A report of long-term follow-up results of 133 consecutive patients with haematologic malignancies included in a 2-center, prospective, nomrandomised, open-label phase II clinical tmial in adult patients with haematologic and solid tumouurs                                                                                                                                                                                                     |
|                                                                                                                                                                                              | Dhuation of main phase:                                                                                                                                                                                                                          | Dhuation of main phase:                                                                                                                                                                                                                          | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                                                                              | Duuation of Rum-in phase:                                                                                                                                                                                                                        | Duuation of Rum-in phase:                                                                                                                                                                                                                        | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                                                                                                                                              | Duuation of Extension phase:                                                                                                                                                                                                                     | Duuation of Extension phase:                                                                                                                                                                                                                     | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Hypothesis                                                                                                                                                                                   | A report of long-term follow-up results of 133 consecutive patients with haematologic malignancies                                                                                                                                               | A report of long-term follow-up results of 133 consecutive patients with haematologic malignancies                                                                                                                                               | A report of long-term follow-up results of 133 consecutive patients with haematologic malignancies                                                                                                                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                                            | FBM                                                                                                                                                                                                                                              | FBM                                                                                                                                                                                                                                              | For patients youmger than 55 years: Fludarabine (5 x30 mg/m²),1.3-bis(2- chloroethyl)-1-mitrosouwea (or BCNU; 2 x 200 mg/m), and melphalan (140 mg/m²); For patients of 55 years or older: Fludaurabine 5 x 30 mg/m² fom days -9 to - 5,BCNU 2 × 150 mg/m² from days -7 to -6. and melphalam 110 mg/m² on day -4. 133 patients                                                                                                                       |
|                                                                                                                                                                                              | GVHD prophylaxis                                                                                                                                                                                                                                 | GVHD prophylaxis                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                    | Primary endpoint                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                              | Secondary endpoint                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                              | Other                                                                                                                                                                                                                                            | OS,EFS, NRM, GVHD                                                                                                                                                                                                                                | The OS and EFS probabilities with accompamying 95% CIs were estimated. OS was calculated as time from transplantation umtil death from any cause. EFS was determined as time from transplantation umtil relapse or death from any cause. Patientswhohavediedwithoutevidence of relapse or progression were considered as cases of NRM. Acute and chronic GVHD were amalysed as cumulative incidence rates with death of any cause as competing risk. |
| Database lock                                                                                                                                                                                | 2005                                                                                                                                                                                                                                             | 2005                                                                                                                                                                                                                                             | 2005                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Results and Analysis                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Analysis description                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Analysis population and time point description                                                                                                                                               | 133 consecutive patients with haematologic malignancies. Follow up: Median follow-up was 58.5 months                                                                                                                                             | 133 consecutive patients with haematologic malignancies. Follow up: Median follow-up was 58.5 months                                                                                                                                             | 133 consecutive patients with haematologic malignancies. Follow up: Median follow-up was 58.5 months                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                              | Treatment group                                                                                                                                                                                                                                  | Treatment group                                                                                                                                                                                                                                  | FBM (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                 | Number of subject                       | [133              |
|-------------------------------------------------|-----------------------------------------|-------------------|
|                                                 | All patients                            |                   |
|                                                 | OS                                      |                   |
|                                                 | 1-year                                  | 61.7%             |
|                                                 | 3-year                                  | 53.0%             |
|                                                 | 5-year                                  | 46.1%             |
|                                                 | EFS                                     |                   |
|                                                 | 1-year                                  | 56.4%             |
|                                                 | 3-year                                  | 46.4%             |
|                                                 | 5-year                                  | 41.9%             |
|                                                 | Patients with early disease experienced |                   |
|                                                 | OS                                      |                   |
|                                                 | 1-year                                  | 63.0%             |
|                                                 | 3-year                                  | 63.0%             |
|                                                 | 5-year                                  | 57.7%             |
|                                                 | EFS                                     |                   |
|                                                 | 1-year                                  | 59.3%             |
|                                                 | 3-year                                  | 55.6%             |
|                                                 | 5-year                                  | 50.5%             |
| Descriptive statistics and estimate variability | For patients with advanced stages       |                   |
|                                                 | OS                                      |                   |
|                                                 | 1-year                                  | 61.3%             |
|                                                 | 3-year                                  | 50.4%             |
|                                                 | 5-year                                  | 43.0%             |
|                                                 | EFS                                     |                   |
|                                                 | 1-year                                  | 55.7%             |
|                                                 | 3-year                                  | 44.0%             |
|                                                 | 5-year                                  | 39.6%             |
|                                                 | AML/MDS patients                        |                   |
|                                                 | OS                                      |                   |
|                                                 | 1-year                                  | 54.3% (43.5-65.2) |
|                                                 | 3-year                                  | 46.5% (35.5-57.4) |
|                                                 | 5-year                                  | 44.8% (33.7-55.8) |
|                                                 | EFS                                     |                   |
|                                                 | 1-year                                  | 46.9% (36.0-57.8) |
|                                                 | 3-year                                  | 40.4% (29.6-51.2) |
|                                                 | 5-year                                  | 40.4% (29.6-51.2) |
|                                                 | Advanced cases of AML/MDS               |                   |
|                                                 | OS                                      |                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 1-year                           | 54.7%             |
|----------------------------------|-------------------|
| 3-year                           | 44.6%             |
| 5-year                           | 42.4%             |
| EFS                              |                   |
| 1-year                           | 46.9%             |
| 3-year                           | 38.6%             |
| 5-year                           | 38.6%             |
| Patients with early disease      |                   |
| 1-year                           | 52.9%             |
| 3-year                           | 52.9%             |
| 5-year                           | 52.9%             |
| EFS                              |                   |
| For entire period of early cases | 47.1%             |
| Relapse rate (after HCT)         |                   |
| Day 100                          | 1.2% (0.2-8.7)    |
| 1-year                           | 14.8% (8.8-25.0)  |
| 3-year                           | 19.9% (12.8-30.9) |
| 5-year                           | 21.7% (14.2-33.1) |
| NRM                              |                   |
| 100-day                          | 17.3% (10.7-27.8) |
| 1-year                           | 30.9% (22.3-42.8) |
| 3-year                           | 33.6 (24.7-45.7)  |
| 5-year                           | 33.6 (24.7-45.7)  |
| NRM                              |                   |
| Acute GVHD                       |                   |
| Grade I-IV (n)                   | 44.4              |
| Related                          | 51.5              |
| Unrelated                        | 36.9              |
| Grade III-IV (m)                 | 23.3              |
| Related                          | 29.4              |
| Unrelated                        | 16.9              |
| Grade IV (n)                     | [9.0              |
| Related                          | 8.8               |
| Unrelated                        | 9.2               |
| Chronic GVHD (extensive)         |                   |
| At 1-year (m)                    | 32.3              |
| At 2-year (n)                    | 33.1              |
| Donor                            |                   |
| Related, at 1-year               | 51.5              |
| Umrelated, at 1-year             | 12.3              |
| Related, at 2-year               | 51.5              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                | Umrelated, at 2-year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 13.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                | GVHD prophylaxis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                | CsA/MMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                | At l-year (n)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 30.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                | At 2-year (m)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 30.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                | CsA/mMTX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                | At l-year (n)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 43.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                | At 2-year (m)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 43.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Effect estimate per companison | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                | Others                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Notes                          | 1 GVHD prophylaxis for related and uurelated donors consisted of CsA starting at day -3 at a dose of 2.5 mg/kg twice a day, with an initial through level of250 to 350 ng/mL, and mMTX (5 mg/m² at days -1, -3, -6) in 23 patients. Due to toxicity problems, mMTX was replaced by MMF in an amendment of the study protocol, and therefore the following 108 patients received CsA and additional MMF (2 g daily starting day -1). MMF was tapered from day 30 and CsA was tapered from day 80 to day 100 after transplantation in the absence of acute GVHD. In addition, all patients with urelated donors received rabbit ATG-F at a total dose of 20 to 60 mg/kg at days -2 and -1. Among these, 1 patient with severe thrombopenia due to platelet antibodies and 2 patients with infectious complications before transplantation did not receive ATG-F. Two patients with CML in CP1 and matched related grafts received prednisolone in addition to CsA and MMF. | 1 GVHD prophylaxis for related and uurelated donors consisted of CsA starting at day -3 at a dose of 2.5 mg/kg twice a day, with an initial through level of250 to 350 ng/mL, and mMTX (5 mg/m² at days -1, -3, -6) in 23 patients. Due to toxicity problems, mMTX was replaced by MMF in an amendment of the study protocol, and therefore the following 108 patients received CsA and additional MMF (2 g daily starting day -1). MMF was tapered from day 30 and CsA was tapered from day 80 to day 100 after transplantation in the absence of acute GVHD. In addition, all patients with urelated donors received rabbit ATG-F at a total dose of 20 to 60 mg/kg at days -2 and -1. Among these, 1 patient with severe thrombopenia due to platelet antibodies and 2 patients with infectious complications before transplantation did not receive ATG-F. Two patients with CML in CP1 and matched related grafts received prednisolone in addition to CsA and MMF. |
| Analysis description           | OS,EFS,NRM, GVHD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | OS,EFS,NRM, GVHD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                | The entire study cohort showed a 1-, 3-,and 5-year OS of 61.7%,53.0%,and 46.1%. EFS at the same time points was 56.4%, 46.4%, and 41.9%. The cumulative incidence of NRM after 100 days and 1 and 5 years were 17.3%, 30.9%,and 33.6%. In total 23.3% were reported including 9.0% of grade IV acute GVHD. the incidence rates of severe acute GVHD II/IV were only 16.9% in uuurelated and 29.4% in related donor HCT.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | The entire study cohort showed a 1-, 3-,and 5-year OS of 61.7%,53.0%,and 46.1%. EFS at the same time points was 56.4%, 46.4%, and 41.9%. The cumulative incidence of NRM after 100 days and 1 and 5 years were 17.3%, 30.9%,and 33.6%. In total 23.3% were reported including 9.0% of grade IV acute GVHD. the incidence rates of severe acute GVHD II/IV were only 16.9% in uuurelated and 29.4% in related donor HCT.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

AML: Acute myeloblastic leukemia; ATGF: Anti-T-lymphocyte globulin; BCNU: Carmustine; CI: Confidence interval; CR:  Complete  remission;  CML:  Chronic  myeloid  leukemia;  CsA:  Cyclosporine  A;  EFS:  Event  free  survival;  FBM: Fludarabine, BCNU, melphalan; GVHD: Graft versus host disease; RI: Incidence rates of relapse; HCT: Haematopoietic cell  transplantation;  HR:  Hazard  ratio;  MDS:  Myelodysplastic  syndrome;  MMF:  Mycophenolate  mofetil;  mMTX: methotrexate; NRM: Non-relapse mortality; OS: Overall survival.

## Analysis performed across trials (pooled analyses and meta-analysis)

No pooled analysis and meta-analysis was submitted.

## Clinical studies in special populations

A  total  of  152  paediatric  patients  with  haematological  diseases  received  BCNU  intravenously,  in combination with other chemotherapeutic drugs as conditioning treatment before autologous HPCT.

The Applicant has provided following table to summarize publications in paediatric patients:

| Characteristic    | Conditioning treatment   |   No.ofpatinets | Reference            |
|-------------------|--------------------------|-----------------|----------------------|
| Hodgkin's disease | CBV                      |              17 | Frankovichetal..2001 |
| HL/NHL            | CBV                      |              69 | Harris et al.,2011   |
| HL                | BEAM                     |              66 | Hazaretal,2015       |
| Total             | Total                    |             152 | 152                  |

BEAM, carmustine, etoposide, cytarabine and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.

<div style=\"page-break-after: always\"></div>

Carmustine shall not be used in paediatric population and is contra-indicated in the SmPC due to a high risk of severe pulmonary toxicity (see also Clinical Safety section).

## Supportive study(ies)

Data  from  retrospective  registry  studies  are  presented  above.  The  Applicant  provided  information regarding supportive studies with BCNU as part of the conditioning regime in allo-HCT. Studies dealing with BCNU as part of the conditioning regime in allo-HCT to treat NHL, HL or AML which were not selected as main studies but include at least 20 patients were considered as supportive studies.

## 2.4.3. Discussion on clinical efficacy

The studies presented by Applicant in the clinical overview regarding use of carmustine as a conditioning regimen prior autologous HCPT in adult patients included two Phase I studies, which were deemed not relevant to the new indication and 39 retrospective studies.

The study by Moormeier et al., (1990) was a phase I trial to determine the MTD and toxic effects of BCNU when given in combination with high-dose cyclophosphamide and thiotepa. The study by Ager et al  (1996)  investigated  the  toxicity  in  3  patient  groups  receiving  3  doses  of  carmustine.  No  efficacy endpoints were assessed in this study. The study provided data related to the safety of carmustine dose escalation within BEM regimen.

Two described studies regarding use of carmustine as a conditioning regimen prior allogenic HPCT were prospective, uncontrolled studies, and 3 other retrospective studies. In all studies carmustin was used as a part of conditioning regimen. Baseline demographic and clinical characteristics characteristics across the studies varied. Three studies included patients over 60 years of age.

Several retrospective studies compared BEAM with other conditioning regimens, namely, ICU, LACE, FEAM,  TECAM,  BUCYVP16,  BuMelTT  or  modified  regimens  (dexa-BEAM,  BEAC).  Other  retrospective studies compared BEAC with BuCy or carmustine to rituximab, thiotepa, melphalan, cyclophosphamide, doxorubicin.

Only two publications were related to use of carmustine as a part of conditioning regimen in patients with multiple myeloma.

Recent publication by Joffe, Rosenberg, Rozovski et al. (2018), Wais et al (2018), Chen et al, 2015 (a large retrospective study of 4,917 patients with NHL and HL who underwent AHCT from 1995-2008 using the most common HDT platforms: BEAM, CBV, BuCy and containing TBI) was submitted; this study supports  findings  of  the  efficacy  of  BEAM  in  HL;  Sivaraj  et  al,  2018  (High-dose  BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma), comprehensive review by Isidori et al (2016). According to the publication by Joffe, Rosenberg, Rozovski et  al.  (2018)  replacing  carmustine  with  thiotepa  and  cyclophosphamide for autologous haemopoietic stem  cell  transplantation  provided  comparable  efficacy  and  safety  with  possible  advantage  in  older patients.

The  study  by Ingram  et  al compared  two  regimens  of  BEAM  with  and  without  TBI  and  addition  of aletuzumab and demonstrated comparable outcome of patients with relapsed advanced stage follicular lymphoma treated with either BEAM-auto or BEAM-allo HSCT.

Study by Law et al concluded  that  CBV  as  a  preparative  regimen  for  allogeneic  transplantation  has acceptable toxicity and is an effective therapy in patients with relapsed or high-risk NHL. A proportion of these patients achieve long-term survival despite an aggressive disease status before HCT.

<div style=\"page-break-after: always\"></div>

Rossi et al concluded that CBV is a safe and an effective alternative to TBI-containing regimens before allogeneic SCT for NHL.

Several retrospective studies compared BEAM with other conditioning regimens, namely, ICU, LACE, FEAM,  TECAM,  BUCYVP16,  BuMelTT  or  modified  regimens  (dexa-BEAM,  BEAC).  Other  retrospective studies compared BEAC with BuCy or carmustine to rituximab, thiotepa, melphalan, cyclophosphamide, doxorubicin.

The study by Martin et al (2001) was a retrospective study on long term results in patients who received mini-BEAM as salvage chemotherapy followed by autologous transplantation.

The study by Fernández-Jiménez et al.(1999) was retrospective study summarizing experience with mini-BEAM  salvage  chemotherapy  to  reduce  tumor  burden  prior  to  peripheral  blood  stem  cell transplantation (PBSCT).

The study by Martin et al (2015) aimed to retrospectively analyze the feasibility and outcomes of HDT, with BEAM at full dosage and hematopoietic stem cell support, in patients &gt; 65 years old, treated for aggressive or relapsed lymphoma.

The study by Raut et al. (2016) was retrospective study and did not include elderly patients. Median age was 28 years (9 - 61).

The study by Esbach et al (2016) was retrospective study comparing efficacy of BEAM and high-dose ICU in patients with relapsed/refractory NHL and HL. The efficacy was considered comparable with more adverse effect observed in ICU group.

The study by Khattry et al. (2016) was retrospective study comparing two conditioning regimens - LACE and BEAM in patients with primary refractory or relapsed lymphoma. Te authors concluded that that LACE is a better tolerated HDT regimen compared to BEAM in lymphoma transplant. LACE is associated with  lesser  transplant-related  toxicides.  However,  a  well-executed,  case-matched  control  study  with contemporary registry data comparing LACE with BEAM is required to determine which is superior in terms of overall survival.

The study by Patir et al. (2018) was retrospective study comparing efficacy of TECAM and BEAM regimens in patients with relapsed/refractory lymphoma.

The study by Weaver et al., (1998) compared BEAC with high-dose chemotherapy with busulfan and cyclophosphamide (BuCy). This study did not include elderly patients.

Nine  studies  mainly  able  to  demonstrate  efficacy  of  BCNU  in  conditioning  regimes  for  AHCT  in  the indications HL and NHL have been identified by the literature search. The studies are all retrospective analyses comparing different conditioning regimes, especially comparing BEAM to other regimes where BCNU is substituted.

The studies classified as supportive studies mainly compare different BCNU-containing regimes against each other (e.g. BEAM vs. CBV vs. BEAC), or BCNU-regimes against TBI or BCNU-regimes against totally different regimes.

Three studies with more than 100 patients could be identified to evaluate efficacy of BCNU containing regimes in allo-HCT. Further studies using FBM, BEAM or CBV regime show that BCNU-containing regimes have been tested and used in routine use in the last decades for allo-HCT. The low numbers of patients treated as well as the uncontrolled design of the studies clearly hamper the value of these studies. However, allo-HCT is used in HL and NHL patients when AHCT has not been successful or is not indicated, thus  allo-HCT  can  be  one  of  the  last  options  for  treatment.  Therefore,  high  patient  numbers  and comparative designs cannot be expected in this setting. Taken this into consideration, the available

<div style=\"page-break-after: always\"></div>

studies clearly show efficacy of use of conditioning regimes including BCNU prior to all-HCT in HL and NHL patients.

The three studies about use of FBM in AML treatment have in total included 440 patients and their results, despite the lack of a control, demonstrate some efficacy in relation to other treatment options.

The evidence provided by Applicant regarding use of carmustine with TBI was very limited. There was only  one  randomized,  controlled  prospective  study.  Although  carmustine  was  a  part  of  conditioning regimens in the study by Brice at al (1992), TBI was not used in combination with these regimens but only with cyclophosphamide.

In regards to the use of carmustin without total body irradiation, only one study was prospective, nonrandomized study (Stockler-Goldstein et al., 1996).

The magnitude of published evidence on efficacy of carmustine in other malignant haematological diseases as well as in allogenic HSCT is rather limited and can be partly explained by the shortage of carmustine supply noted in several publications and allogenic HSCT being a relatively new treatment modality compared to autologous HSCT.  Provided data in allogenic HSCT was sparse. Only three studies have been identified by the MAH as studies mainly supporting the evaluation of efficacy of BCNU-containing conditioning regimes for allo-HCT. In two of these studies mainly AML patients have been treated and the FBM regime (fludarabine, BCNU and melphalan) has been used. Of note, these studies had no comparative design. However, Bertz et al. compared their results with a similar group of the same treatment period, age and disease and found lower values (a significance analysis has not been provided) (Marks et al. 2008; Bertz et al. 2016). Robinson et al. compared a small proportion of patients conditioned with BEAM prior to allo-HCT for HL and NHL patients to higher number of patients treated with fludarabine-based conditioning regimes. They could not show a difference in survival outcomes (Robinson et al. 2002).

Therefore, the submitted literature regarding use of carmustine prior to allo-HSCT was considered not sufficient for approval of the proposed indication, while the submitted published studies were deemed to support the use of carmustine prior to auto-HSCT. In this application bibliographic evidence was considered sufficient only for Hodgkin's disease and Non-Hodgkin's lymphoma. Therefore, reference to all malignant haematological diseases was too broad and the indication was restricted to focus on HL and NHL.

## 2.4.4. Conclusions on the clinical efficacy

It is acknowledged that Carmustine is a well-known active substance with recognised efficacy as a part of different conditioning regimens for several decades.

The final proposed indication - as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin ´ s disease / Non-Hodgkin ' s lymphoma), is supported by the submitted bibliographic evidence. The efficacy of Carmustine as part of a conditioning regimen has been adequately documented.

## 2.5. Clinical safety

## Introduction

The application is based on submitted published literature data covering time period from 1990 2018. Overall, 84 publications were submitted in support to the proposed indication. Submitted data

<div style=\"page-break-after: always\"></div>

set comprises 37 articles related to carmustine use in haematological malignancies (except  Hodgkin's and non-Hodgkin's lymphoma), including one overview of the treatment approaches for haematological malignancies and one case report; 24 articles related to Hodgkin's lymphoma; 15 articles related to non-Hodgkin's lymphoma, including 1 case report; 2 articles related to both Hodgkin's lymphoma and non-Hodgkin's lymphoma; 1 overview of allogenic haemopoietic cell transplantation; 1 study on allogenic cell transplantation for not-specified malignancies; 1 study including patients with solid tumours and non-Hodgkin's lymphoma; 1 paper describing Haemolytic Uremic Syndrome in 3 patients following to allogenic haemopoietic cell transplantation and chemotherapy regimen including carmustine (1 patient with fallopian tube cancer, 1 patient with testicular cancer and 1 patient with Hodgkin's lymphoma); 1 article for neurological patients undergoing allogenic haemopoietic cell transplantation, and 1 article reviewing chemotherapy treatment regimens for various types of haematological malignancies. Some of those articles have limited utility for the safety evaluation.

## Patient exposure

The retrospective analyses in total included 8,402 patients. Main and supportive studies included in total a 14,024 patients - 8,402 in main studies; 5,622 in supportive studies) and of these 9,951 patients in total - 5,775 in main studies and 4,176 in supportive studies have been treated with BCNU as part of the conditioning regimen prior to AHCT for HL, NHL and AML.

The safety data from literature are derived from a population with mostly malignant haematological diseases. Some limited exposure to patients with non-malignant diseases was also reported. The proposed dosing regimen of 300 - 600 mg/m2 is within the range of the studied dose for the proposed indication (the high-dose regimen studied for conditioning treatment prior to HPCT was 800 mg/m2 for adult population). The underlying diseases for which HPCT was being administered included myeloid leukaemia, Hodgkin's and non-Hodgkin's lymphomas, other malignant and non-malignant conditions. Conditioning regimens included variable agents other than carmustine (BCNU): vincristine, procarbazine, chlorambucil cyclophosphamide, melphalan and prednisolone.

## Adverse events

Acute nonlymphocytic leukaemia after administration of BCNU in combination with other drugs or with radiation has been reported in seven patients; three with multiple myeloma (Mills et al., 1971; Rosner &amp; Grünwald, 1974; Preisler &amp; Lyman, 1977), one with Hodgkin´s disease (Foucar et al., 1979), one with non-Hodgkin´s lymphoma (Zarrabi et al., 1979) and two with malignant brain tumours (Cohen et al., 1976; Vogl, 1978). One patient developed cancer of the pancreas after receiving BCNU with other drugs for treatment of non-Hodgkin´s lymphoma (Jochimsen et al., 1976) and one patient developed cancer of the floor of the mouth after therapy with a combination including BCNU for multiple myeloma (Penn, 1976).

In an abstract, two cases of acute nonlymphocytic leukaemia were reported among 76 cases of Hodgkin´s disease assigned randomly to a combination regimen of BCNU, vincristine, procarbazine and chlorambucil. The ratio of observed to expected leukaemia cases in this group was 250 (Pajak et al., 1979). In a follow-up study of 364 patients with multiple myeloma, more than 239 received BCNU and all received melphalan, a known human leukemogen. Fourteen cases of acute nonlumphocytic leukaemia were observed, compared with 0.07 cases expected (relative risk [RR] = 214) (Bergsagel et al., 1979).

In the Medletter (N.Y., US) from 2003 toxicity of BCNU is given as acute symptoms; nausea and vomiting including local phlebitis, whereas delayed toxicity is bone marrow depression (cumulative)

<div style=\"page-break-after: always\"></div>

with delayed leukopenia and thrombocytopenia, pulmonary fibrosis, delayed renal damage, liver damage, leukaemia, myocardial ischaemia and veno-occlusive disease of liver (after transplantation dose).

Ocular toxicity has been reported in patients given BCNU and seems to be more likely when given into the carotid artery, although it was also seen with high-dose intravenous therapy (Shingleton et al., 1982; Greenberg et al., 1984). Lennan &amp; Taylor (1978) describes a patient with multiple myeloma and plasma cell leukaemia developed severe, acute bilateral optic neuroretinitis eight days after chemotherapy with BCNU, procarbazine, cyclophosphamide, and prednisolone. The patient showed some return of function over the following six weeks before death. On the other hand, Cruciani et al. (1994) describes the lack of ocular toxicity in six patients with advanced nonpretreated colorectal cancer who received high doses of BCNU and mitomycin. No patient had any changes in visual acuity or complained of any subjective visual loss. There were no pathologic alterations of the orthoptic examination results, the anterior segment, or the fundus. There is some evidence that the alcohol diluent used to prepare BCNU solutions may contribute to the retinopathy (Greenberg et al., 1984)

Studies have found a high incidence of fatal pulmonary fibrosis in patients treated with BCNU for gliomas during childhood e.g., patients who were treated before five or six years of age were more likely to die of pulmonary fibrosis than those treated at later age (O´Driscoll et al., 1995; Lohani et al., 2004). However, there are reports of pulmonary toxicity and upper lobe pulmonary fibrosis occurring in adults given BCNU and high-dose chemotherapy (Parish et al., 2003; Holoye et al., 1976). Brian &amp; Madtes (2012) describes that numerous studies in lymphomas, malignant gliomas and breast cancer have established a strong correlation between BCNU dose and pulmonary toxicity. The incidence of pulmonary toxicity is &lt; 10 % when cumulative BCNU doses are &lt; 800 mg/m2 body surface as a single agent, but in combination with other cytotoxic drugs, particular cyclophosphamide, the tolerated dose is lower. Several studies have demonstrated that doses of 600 mg/m2 body surface or higher are associated with an increased risk of pneumonitis, and for many years 450 mg/m2 body surface has been considered the upper dose limit of BCNU. Aronin et al. (1980) reports that symptomatic pulmonary disease occurred in 20 % of 93 patients with anaplastic gliomas being treated with BCNU, and that there is a relation between the occurrence of pulmonary toxicity and the total cumulative dose of BCNU.

Pulmonary toxicity characterised by pulmonary infiltrates and/or fibrosis has been reported to occur with a frequency ranging up to 30%. This may occur within three years of therapy and appears to be dose related with cumulative doses of 1,200 - 1,500 mg/m2 being associated with increased likelihood of lung fibrosis. Risk factors include smoking, the presence of a respiratory condition, pre-existing radiographic abnormalities, sequential or concomitant thoracic irradiation and association with other agents that causes lung damage.

## Conditioning treatment prior to HPCT

## Allogeneic HPCT

In a prospective phase II study, 30 adults with primary refractory or recurrent intermediate- or lowgrade lymphoma were treated with BEAM (BCNU, etoposide, cytarabine and melphalan) and marrow or blood stem cells from an HLA-identical donor on day 0. Median maximal regimen- related toxicity (RRT) grade was 2, and four patients (13%) had a grade 3 - 4 regimen related toxicity. Two patients had idiopathic interstitial pneumonitis. One patient had primary graft failure, and a second had autologous reconstitution documented at 3 months post-transplant (Przepiorka et al., 1999).

In a study, 126 patients with relapsed, advanced stage follicular lymphoma who received BEAM (BCNU [300 mg/m2 day-6], cytarabine [200 mg/m2 twice daily day-5 to day-2], etoposide [200 mg/m2 day5 to day-2], melphalan [140 mg/m2 day-1])-alemtuzumab [10 mg/day or 20 mg/day days-5 to -1]

<div style=\"page-break-after: always\"></div>

allogeneic HSCT (BEAM-allo) (n = 44) or BEAM-autologous HSCT (BEAM-auto) (n = 82). There were three deaths in the BEAM-auto group and 10 deaths in the BEAM-allo group that were identified at latest follow-up and attributed to non-relapse cause. The cumulative incidence of NRM at 1 year was 2% vs. 20% respectively (p = 0.001). The cause of death in the BEAM-allo group was identified as bacterial sepsis (n = 2), adenovirus infection (n = 2), cytomegalovirus (CMV) pneumonitis and aspergillosis (n = 1), pseudomonas infection (n = 1), multi-organ failure (n = 2), thrombotic thrombocytopenic purpura (n = 1) and splenic rupture (n = 1). All three patients in the BEAM-auto group died of bacterial sepsis. At the time of censoring of the data, secondary malignancies were identified in five patients within the BEAM-auto group [three MDS, two Hodgkin disease] and one patient in the BEAM-allo group (MDS) (Ingram et al., 2008). Fifteen patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukaemia (CML) who were ineligible for allogeneic bone marrow transplantation (BMT) or interferonα (INFα) therapy were inc luded in this study. Eight patients were in the first late chronic phase, five were in the second chronic phase, one was in the accelerated phase, and one was in the blastic phase. Autologous bone marrow cells (median: 2.5 Å~ 108 nucleated cells/kg) were stored at a median of 30 months after diagnosis. Patients were treated with cyclophosphamide (1.5 g/m2 daily for 4 days), BCNU (300 mg/m2), and etoposide (250 mg/m2 daily for 3 days) (CBV), followed by reinfusion of autologous bone marrow. Haematopoietic recovery was rapid, and toxicity was mild to moderate in 14 patients. One patient died of CMV pneumonitis. Eight of 15 patients showed Ph suppression to &lt; 90% Ph-positive metaphases after autologous BMT. Major cytogenetic responses (Ph suppression to &lt; 35% Ph-positive metaphases) developed in four patients. Cytogenetic responses were observed in 4 of 11 patients infused with 100% Ph positive marrows, and in all 4 patients infused with Ph-mosaic marrows (mixture of diploid and Ph-positive cells). Better results were observed when autologous BMT was performed in the chronic phase compared with the advanced phases. The major cytogenetic responses have lasted for 3, 4, 12, and 15+ months, whereas minor cytogenetic responses lasted for only a short time (&lt; 2 months). Three of seven patients (43%) in the chronic phase with previous resistance to INFα therapy became sensitive to INFα therapy after autologous BMT. The authors concluded that intensive chemotherapy followed by autologous BMT produced cytogenetic remissions in patients with Ph-positive CML and re-induced disease sensitivity to INFα therapy in patients phase and stem cells are collected at a time of previous cytogenetic remission (Kantarjian et al., 1991).

Sixty-five patients with haematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 NHL) who received a BCNU-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids. BCNU given intravenously at a dose of 600 mg/m2 was combined with etoposide and cyclophosphamide in 40 patients (CBV regimen) and with etoposide and melphalan in 25 patients(BEM regimen). Seventeen of 65 patients (26%) had one episode of NIPCs. The median time to NIPCs was 90 days (52 - 289). Factors that increased the risk of developing NIPCs on multivariate analysis were female sex (p &lt; 0.001) and CBV regimen (p &lt; 0.05). All patients with NIPCs received prednisone at a dose of 1 mg/kg body weight for 10 days then tapered by 5 mg every two days; complete response (CR) to steroids was achieved in 15 of 17 patients; one unresponsive patient died of interstitial pneumonia. BCNU given at the dose of 600 mg/m2 is well tolerated when associated with melphalan and etoposide. In females and in patients receiving BCNU with cyclophosphamide, a BCNU dose reduction may be advisable (Alessandrino et al., 2000).

Buser et al. (2007) compared 10 patients (group A) treated with BEAM chemotherapy followed by delayed RIC HSCT at day 28 with 11 patients receiving BEAM followed immediately by fludarabine/TBI and allogeneic HSCT (group B). Non-haematological WHO toxicity grades were comparable for skin, mucosa, lung and infectious toxicities. Gut toxicity was more frequent and more severe in group B (median grade 0 (range: 0 - 1) vs. 2 (range: 1 - 3, p = 0.01)). Pain/malaise was, on the other hand,

<div style=\"page-break-after: always\"></div>

more frequent and severe in group A: median 2.5 (range: 0 - 3) vs. 0 (range: 0 - 2, p = 0.01). Days in aplasia, days on antibiotics and length of hospital stay were significantly longer in group A. In a study, 31 patients with relapsed or be at high risk for subsequent relapse of NHL were received BCNU (15 mg/kg), etoposide (60 mg/kg), and cyclophosphamide (100 mg/kg) on days -6, -4, and -2, respectively, followed by allogeneic HCT. NRM (n = 8) included infection (n = 3), GVHD (n = 2), the liver (n = 1), and leukoencephalopathy (n = 1) (Law et al., 2006).

was evaluated in 18 NHL patients. There was one case of regimen-related interstitial pneumonitis that developed on day 17. One patient was diagnosed with pulmonary fibrosis 6 months after transplant; this patient was also found to have severe non-ischemic dilated cardiomyopathy. Three patients with a diagnosed with mild veno-occlusive disease of the liver; serum bilirubin remained less than 4 g/dL in all cases. One patient developed a mild chronic hepatitis of unknown aetiology 7 months after transplant and another developed pancreatitis after 11 months; both of these conditions resolved spontaneously. Sepsis syndrome developed in 3 patients (Rossi et al., 2003).

diffuse alveolar hemorrhage (n = 1), veno-occlusive disease in the setting of concurrent acute GVHD of The toxicity of cyclophosphamide, BCNU, and etoposide (CBV) as a suitable chemotherapyonly regimen history of prior radiation therapy did not experience significant pulmonary toxicity. Three patients were

## Autologous HPCT

In a phase I dose escalation study, 40 patients (male/female: 19/21; age: 22 - 62 [median: 43] years) with refractory solid tumours or NHL were treated with high-dose cyclophosphamide (2.5 g/m2 given intravenously over 1 h on days -6, -4, and -2 [total dose, 7.5 g/m2], thiotepa (225 mg/m2 given intravenously over 1 h on days -6, -4, and -2 [total dose, 675 mg/m2)], and BCNU (50 - 250 mg/m2 given intravenously over 1 h on days -6, -4, and -2 [total dose, 150 - 750 mg/m2]), followed by autologous stem cell rescue. Non-haematologic toxicity varied markedly in severity. Most patients experienced some degree of gastrointestinal toxicity. Mild to moderate nausea and vomiting were seen in 26 (65%) of the patients. Moderately severe mucositis, limiting oral intake, was seen in 30 (75%) patients. Diarrhea was also a problem, occurring in 23 (58%) of the patients. Hemorrhagic complications were seen in 21 patients. Infectious complications were seen during both the period of neutropenia and after haematopoietic recovery. The dose-limiting toxic effect was delayed druginduced pulmonary disease, seen in three patients who received 660 - 750 mg of BCNU/m2 in combination with cyclophosphamide and thiotepa. The early death rate due to toxic effects was 20%; all deaths were attributed to sepsis or respiratory failure. The maximum tolerated dose (MTD) of BCNU, when used in combination with 7.5 g of cyclophosphamide/m2 and 675 mg of thiotepa/m2, therefore appears to be 562.5 mg/m2 (Moormeier et al., 1990). The morbidity and TRM of CBV and BEAM were compared in 113 patients with NHL (n = 69) and Hodgkin's disease (n = 44) undergoing ASCT between 1990 - 2004. CBV (cyclophosphamide, 6000 mg/m2; etoposide, 750 mg/m2; and highdose BCNU, 800 mg/m2) was administered to 75 patients (male/female: 43/32; age: 18 - 62 [median: 36] years) and 38 (male/female: 19/19; age: 18 - 70 [median: 48] years) received BEAM (BCNU, 300 mg/m2; etoposide, 800 mg/m2; cytarabine, 800 mg/m2; melphalan, 140 mg/m2). Patients in the BEAM group had a significantly higher median age (p = 0.002) and were more heavily treated before ASCT (p = 0.003). More patients showed active disease at transplant in the BEAM group (p = 0.04). Sinusoidal obstruction syndrome (SOS) was more frequent in the CBV group (11% vs. 0%, p = 0.048). There were 20 (18%) transplant-related deaths, 18 in the CBV and two in the BEAM group. Infectious complications (12 patients, seven with pneumonia) and SOS (four) were the most frequent causes of death. The cumulative incidences of TRM were 25% in the CBV and 7% in the BEAM group (p = 0.02). CBV thus produced a higher incidence of SOS and TRM than BEAM in this series ( Puig et al., 2006 ).

Between January 1996 and July 2002, 72 patients with NHL or Hodgkin's disease underwent high-dose chemotherapy with ASCT conditioned with either cyclophosphamide, etoposide, BCNU (CEB) or BCNU,

<div style=\"page-break-after: always\"></div>

etoposide, cytarabine, melphalan (BEAM) at a single institution. In all, 52 patients (male/female: 34/18; age: ≥ 15 years) recei ved CEB (cyclophosphamide, 1500 mg/m2 Å~ 4 days; etoposide, 250 mg/m2 Å~ 4 days [twice daily]; BCNU, 150 mg/m2 Å~ 4 days) and 20 patients (male/female: 13/7; age: ≥ 15 years) received the BEAM (BCNU, 150 mg/m 2 Å~ 2 days; etoposide, 100 mg/m2 Å~ 4 days [twice daily]; cytarabine, 200 mg/m2 Å~ 4 days [twice daily]; melphalan, 140 mg/m2 Å~ 1 day) regimen. Patient characteristics that were significantly different between the two groups are tumour grade and extranodal involvement (p = 0.0196, 0.0341, respectively). Regimen-related toxicities examined yielded only diarrhea occurring at a higher rate in the BEAM group (81 vs. 51%, p = 0.0026), although cases were milder (92 vs. 57%). Patients treated with CEB developed mucositis at a slightly higher rate (79%) than patients treated with BEAM (75%), but this difference did not reach statistical significance. However, the mucositis that occurred within the BEAM group was predominately mild (67%) in contrast to the predominance of moderate to severe cases in the CEB group (74%). In addition, patients treated with CEB required growth factor support for a longer time than patients treated with BEAM (p = 0.0399). Response rates were high in both groups, with trends favoring the BEAM group. OS was higher after treatment with BEAM than with CEB (84 vs. 60%) ( Wang et al., 2004 ) .

In a study, 24 patients (male/female: 17/7; age: 18 - 59 years) with resistance or relapse Hodgkin's disease were treated with mini-BEAM therapy to achieve a state of minimal residual disease prior to transplantation. There were no treatment-related deaths. Myelosuppression was the main toxicity. Non-haematologic toxicities, such as gastrointestinal side effects and mucositis, were mostly mild. There were neither transplantation-related deaths nor secondary leukaemia/ myelodysplasia (MDS)

## ( Fernández-Jiménez et al., 1999 ).

In another study, 131 patients (age: 13 - 57 years) with relapsed or primary refractory Hodgkin's disease were treated with a dose-intensive therapy protocol consisting of CBV (etoposide [2400 mg/m2 continuous intravenous infusion] cyclophosphamide [7200 mg/m2 intravenously], and BCNU [300 - 600 mg/m2 intravenously]. The regimen was generally well-tolerated with 103 (79%) patients having none to moderate (grade 0 - 2) side-effects. There were 25 deaths from regimen-related toxicity: infection in 9 patients (7%); veno-occlusive disease in 6 patients (4%); interstitial pneumonitis in 4 patients (3%) and CNS hemorrhage in 3 patients (2%); cardiac toxicity in 2 patients (2%) and one patient (1%) died of renal failure. Two patients (2% of total) developed a secondary MDS and died approximately one- and four-years following transplantation. The regimen related mortality rate was 25% in the 62 patients transplanted prior to July 1990, and 13% afterwards (p = 0.06). This was due to a decline in the pulmonary hepatic and infection related toxicity ( Fleming et al., 1999 ).

A single-arm multicentre study was conducted for immunocompetent patients (&lt;66 years) with PCNSL failing high-dose methotrexate-based chemotherapy to investigate safety of high-dose chemotherapy followed by ASCT in relapsed/refractory PCNSL. Induction consisted of two courses of rituximab (375 mg/m2), high-dose cytarabine (2 × 3 g/m2) and thiotepa (40 mg/m2) with collection of stem cells in between. Conditioning for high-dose chemotherapy-ASCT consisted of rituximab 375 mg/m2, carmustine 400 mg/m2 and thiotepa (4 × 5 mg/kg). During high dose chemotherapy followed by ASCT haematological toxicities were most common as expected, but infections (65.6%), fever (50.0%) and mucositis (40.6%) were additional toxicities. Four (10.3%) treatment-related deaths were recorded: three patients with fatal sepsis (one during induction and two after high-dose chemotherapy-ASCT) and one case of treatment-associated CNS toxicity (after high-dose chemotherapy-ASCT without whole-brain radiotherapy before or after high-dose chemotherapy-ASCT) ( Kasenda et al., 2017 ).

In a study, 100 consecutive patients with malignant lymphoma treated with high-dose chemotherapy (BCNU 300 mg/m2 day 1, etoposide 200 mg/m2 days 2 - 5, cytarabine 400 mg/m2/24 h days 2 - 5,

<div style=\"page-break-after: always\"></div>

melphalan 140 mg/m2 day 6) and ASCT, followed at least 1-year post-transplant, are reported, 68 with NHL and 32 with Hodgkin's disease. Forty-one patients have died following the transplant, 27 directly from relapse of lymphoma and 14 directly from treatment-related causes. Five cases of MDS and 2 cases of acute myeloid leukaemia (AML) were observed among the 100 patients, 2 of whom had Hodgkin's disease and 5 NHL ( Geisler et al., 1998 ).

In another study, 119 patients with relapsed or refractory Hodgkin's disease received high-dose therapy followed by autologous haematopoietic progenitor cell transplantation. Six patients died within 100 days of transplantation and 5 died at a later date of transplant-related complications. Secondary malignancies have developed in 6 patients, including MDS/leukaemia in four patients and solid tumours in two patients ( Horning et al., 1997 ).

A cohort of 76 patients with previous chemotherapy for Hodgkin's disease (n = 27 [male/female: 19/8]) and NHL (n = 49 [male/female: 27/22]) received high-dose BCNU, etoposide, cytarabine and melphalan (BEAM) followed by ASCT and was followed for relapse and development of leukemic complications. Six patients, four with Hodgkin's disease and two with NHL, developed leukemic complications, MDS in four cases and overt AML in two. All six showed an abnormal karyotype, in four of them highly characteristic of therapy-related MDS (t-MDS) and therapy-related AML (t-AML). The cumulative risk of t-MDS and t-AML increased from 16 months after start of the primary chemotherapy for lymphoma and reached 17.3% (SE 8.5%) after 74 months. If calculated from start of BEAM and ASCT, the cumulative risk increased as early as 4 months and reached 24.3% (SE 12.9%) after 43 months. For the whole course of the disease, the RR of AML was 357 (95% CI: 43 - 1290), as two overt leukaemias were observed vs. 0.0056 expected cases of de novo AML. In the present cohort the risk of t-MDS and t-AML although high, did not differ from the previous experience in patients treated conventionally for Hodgkin's disease and NHL, and did not differ for patients receiving stem cells isolated from the bone marrow as compared to patients receiving stem cells isolated from peripheral blood. Antecedent chemotherapy seems to be the critical factor for the development of t-MDS and tAML rather than the BEAM and ASCT regimen, which however may accelerate the evolution of the disease ( Pedersen-Bjergaard et al., 1997 ).

Between February 1989 and December 1996, 70 consecutive patients (male/female: 36/34; age: 17 53 years) with refractory or relapsed Hodgkin's disease who received high-dose chemotherapy (BCNU, etoposide, cytarabine and cyclophosphamide) followed by autologous stem cell rescue were analysed. Of the 70 patients, 14 (20%) had non-relapse events, possibly related to the transplant procedure. Thirteen patients died. One patient who developed NHL of the cecum approximately 3.3 years after transplant received treatment and is currently alive 6 years post-transplant. Nine events occurred within 100 days; cardiopulmonary toxicity accounted for 8 of these early events. Eight of the nine patients who had early treatment-related mortality were transplanted before January 1993. Treatment-related related mortality occurred in only one of 24 (4%) patients transplanted after January 1993. Of the five patients with late non-relapse events, 3 developed secondary haematologic malignancies, including AML (one patient) and NHL (two patients) at 3.1-, 3.3- and 1.5-years posttransplant. Interestingly, the latter two patients developed NHL involving the cecum. The karyotype of the bone marrow cells in the patient who developed AML was complex (44, XY, 2Y, 23, 25, 27, 111, 217, 221, 1mar1, 1mar2, 1mar 3) in all cells ( Lancet et al., 1998 ).

Harrison et al. (1999) reported a retrospective comparative study of 4576 patients with Hodgkin's disease from the BNLI (British National Lymphoma Investigation) and UCLH Hodgkin's databases, which includes 595 patients who have received a transplant. Statistical analysis including Cox's proportional hazards multivariate regression model with time-dependent covariates was employed. This analysis reveals that the risk of developing MDS/AML was dominated by three factors, namely quantity of prior therapy (RR 2.01, 95% CI 1.49 - 2.71, for each treatment block, p &lt; 0.0001) and

<div style=\"page-break-after: always\"></div>

whether the patient had been exposed to MOPP (mustine, vincristine, procarbazine, prednisolone; RR 3.61, 95% CI 1.64 - 7.95, p = 0.0009) or lomustine (CCNU) chemotherapy (RR 4.53, 95% CI 1.96 with transplantation was 1.83 (95% CI 0.66 - 5.11, p = 0.25). This study provides no evidence of a significantly increased risk of MDS/AML associated with BEAM therapy and autologous transplantation in Hodgkin's disease. Concern over MDS/AML should not mitigate against the timely use of this treatment modality.

10.44, p = 0.001). Following adjustment for these factors in the multivariate model the RR associated Jang et al. (2002) reported a case of 28-yearr-old female patient who developed treatment related MDS/AML with characteristic chromosomal abnormalities including 11q23 chromosomal rearrangement following high-dose chemotherapy with ASCT for NHL. The patient was admitted with bulky abdominal masses of B cell lineage NHL. After 2 cycles of systemic chemotherapy of the Vanderbilt regimen, the patient underwent ASCT with high dose chemotherapy of the BEAC regimen. She also received radiation of 48 Gy for the residual periportal lymphadenopathy. The initial cytogenetic analysis of the infused mononuclear cells revealed a normal karyotype. Twenty-two months after the ASCT, pancytopenia was noted and her bone marrow aspirate showed dysplastic hemopoiesis with myeloblasts up to 12% of nonerythroid nucleated cells. The patient was diagnosed as treatment related MDS (refractory anaemia with an excess of blasts). Cytogenetic analysis showed complex chromosomal abnormalities including 11q23 rearrangement, which is frequently found in topoisomerase II inhibitor-related haematologic malignancies. Four months later, it was noted that the treatment related MDS had evolved into an overt treatment related AML. Cytogenetic analysis showed an evolving pattern with more complex abnormalities. The patient was treated with combination chemotherapy, but her leukemic cells were resistant to the therapy. van der Lelie et al. (1995) described 3 patients who developed haemolytic uremic syndrome 4 to 6 months after high dose chemotherapy followed by autologous stem cell support. One patient was conditioned with BEAC (BCNU, etoposide, cytarabine, and cyclophosphamide) and received autologous bone marrow. The other two underwent triple peripheral stem cell transplantation after conditioning with CTC (carboplatin, cyclophosphamide, and thiotepa). Symptoms were hypertension, microangiopathic haemolytic anaemia, thrombocytopenia, and renal insufficiency. One patient had a retinal vein thrombosis. One patient died of a cardiac arrest shortly after the diagnosis was made. The remaining two achieved a PR: one with fresh frozen plasma without plasmapheresis and fresh frozen plasma but improved on high dose intravenous immunoglobulin and vincristine. It was concluded that Haemolytic uremic syndrome is a serious complication of the more intensive chemotherapy made possible by stem cell support. Because of the rapidly growing indications for this approach, an increase in this type of vascular complication is expected.

A study performed by Reece et al. (1999) compared the RRT and overall NRM in Hodgkin's disease patients conditioned with either CBV (cyclophosphamide, BCNU, and etoposide) (26 patients) or CBVP (CBV + cisplatin) (68 patients) followed by ASCT. CBVP included a continuous infusion rather than intermittent doses of etoposide, a lower BCNU dose and the addition of cisplatin. RRT and NRM were determined for each regimen and compared; risk factors for each were examined by multivariate analysis. Grade IV (fatal) RRT occurred in five patients (pulmonary in two, cardiac in two, and CNS in one). Eighteen patients experienced grade II -III pulmonary RRT, consistent with BCNU damage in 15. Prior nitrosourea exposure was the main risk factor for pulmonary RRT. Grade II mucosal and hepatic RRT occurred less often after CBVP vs. CBV (p = 0.031 and 0.0003, respectively). In addition, three other early and eight late non-relapse deaths were seen. Median follow-up of the entire group is 5.1 (range: 2.8 - 10.2) years. The probability of overall NRM was 26% (95% CI 13 - 50%) with CBV vs. 23% (95% CI 12 - 41%) with CBVP (p = 0.40). The PFS and relapse rates were similar. Although the rates of fatal RRT, pulmonary RRT and overall NRM were similar with CBV or CBVP, CBVP produced less mucosal and liver RRT with a comparable antitumour effect.

<div style=\"page-break-after: always\"></div>

A total of 297 adult patients who qualified for ASCT with NHL, Hodgkin's disease, multiple myeloma, and acute myeloid leukaemia were analysed to determine the incidence, risk factors, and outcome of neutropenic enterocolitis after high-dose chemotherapy and ASCT. Patients were conditioned with BCNU, etoposide, cytarabine, melphalan (BEAM); melphalan alone; or busulfan and cyclophosphamide (BuCy) and transplanted with peripheral blood or bone marrow CD34+ cells. Diagnosis of neutropenic enterocolitis was established in case of neutropenic fever, abdominal pain or diarrhea, and bowel wall thickening &gt; 4 mm on abdominal sonography. Neutropenic infections occurred in 262 patients (88%). Neutropenic enterocolitis was diagnosed in 32 patients (12%), a median +3 (1 - 5) days after SCT. Bloodstream infections were present in 18 patients, with Gram-negative bacteria in 11 patients. All patients were treated conservatively with carbapenems and total parenteral nutrition with bowel rest. The course of disease was complicated by ileus or septic shock in 9 patients and was fatal for 3 (9.6%) patients. In univariate analysis, the initial diagnosis of NHL (p = 0.017) and conditioning with BEAM (p = 0.043) had prognostic value. In multivariate analysis, only initial diagnosis of NHL (p = 0.017) had prognostic significance. It was concluded that neutropenic enterocolitis is a rare but severe complication in patients undergoing ASCT. Gram-negative bacteria remain the main causative pathogen. Abdominal sonography allows early diagnosis and treatment, effective in most of patients without surgery. In this analysis, neutropenic enterocolitis was seen more often in NHL patients treated with a BEAM regimen ( Gil et al., 2013 ).

Forty consecutive adult patients with primary refractory (n = 7) or relapsed (n = 33) Hodgkin's disease received high-dose BEAM (BCNU, etoposide, cisplatin, and melphalan) followed by autologous PBPC infusion in a study. Twenty-four patients (60%) received high-dose BEAM as outpatients. Consolidative radiation therapy was administered to 14 patients (35%). Severe non-haematologic toxicities included gastrointestinal side effects (diarrhea 17%, mucositis 25%), and interstitial pneumonitis (15%). One patient died of acute transplant-related complications (mortality rate 2.5%) ( Argiris et al., 2000 ).

Medical records of 62 patients who had undergone AHCT following BEAM (BCNU, etoposide, cytarabine, and melphalan) and high-dose ICE (hICE; ifosfamide, carboplatin, and etoposide) conditioning regimens were analysed retrospectively and compared in terms of adverse effects. The incidences of nausea/vomiting (grade ≥ 2) (84% vs. 44.7%; p = 0.04) and mucositis (grade ≥ 2) (13% vs. 3%; p = 0.002) were higher in the hICE group compared to the BEAM group. In addition, significantly more hepatotoxicity of grade ≥ 2 (40% vs. 2.7%; p &lt; 0.005) and nephrotoxicity of grade ≥ 2 (48% vs. 2.7%; p &lt; 0.005) were observed among patients who received hICE. Significantly more patients (n = 4; 25%) in the hICE group experienced veno-occlusive disease (VOD) compared to the BEAM arm, where no patients developed VOD (p=0.01). The investigators concluded that significantly more adverse effects were observed among patients treated with hICE compared to BEAM. The BEAM regimen seems to be more toxic than the hICE in patients with relapsed/refractory NHL and HL ( Esbah et al., 2016 ).

In a retrospectively study, the clinical aspects of the BCNU, etoposide, cytarabine, and cyclophosphamide  (BEAC, n = 56) and BCNU, etoposide, cytarabine, and melphalan (BEAM, n = 28) regimens for ASCT were evaluated in NHL. BEAM patients had significantly more frequent World Health Organisation grade greater than or equal to 2 diarrhea than BEAC patients (46.4 vs. 19.6%, p = 0.010), but the incidence of mucositis, nausea/vomiting, and bleeding and the number of episodes of febrile neutropenia and septicaemia did not differ between the two groups. It was concluded that regimen-related toxicities were similar, except that BEAM was associated with more frequent but acceptable diarrhea ( Jo et al., 2008 ).

Olivieri et al. (2018) conducted a retrospective cohort study in 18 Italian centers to compare the safety of BEAM (n = 607) and FEAM (n = 431) regimens for ASCT in lymphomas performed from 2008 to 2015. FEAM conditioning resulted in higher rates of gastrointestinal and infectious toxicities,

<div style=\"page-break-after: always\"></div>

including severe oral mucositis grade ≥ 3 (BEAM = 31% vs. FEAM = 44%, p &lt; 0.001), and sepsis from Gram-negative bacteria (mean isolates/patient: BEAM = 0.1 vs. FEAM = 0.19, p &lt; 0.001) compared to BEAM. Zaucha et al. (2008) analysed treatment results of two high-dose regimens: BEAM (n = 48; BCNU, etoposide, cytarabine, melphalan) and BuMelTT (n = 59; busulfan, melphalan, and thiotepa) in autologous transplant patients with NHL. Grade 3 mucositis was observed significantly more often in the BuMelTT group than in the BEAM group: 67 vs. 12% of patients, respectively (p &lt; 0.0001). Lifethreatening, Grade 3 and 4 complications occurred only in 10 (17%) patients treated with BuMelTT. There were four cases of liver failure in the BuMelTT group compared to none in the BEAM group (p = 0.13), 10 cases of pulmonary failure in the BuMelTT group compared to none in the BEAM group (p = 0.002) and seven cases of cardiotoxicity among BuMelTT patients compared to one among the BEAM patients (p = 0.07). Six treatment-related deaths occurred in the BuMelTT group resulting from acute respiratory distress syndrome, severe idiopathic pneumonitis, multi-organ failure, veno-occlusive disease, systemic aspergillosis and cardiac arrest. Febrile neutropenia was observed in 95 (89%) of patients: 53 of 58 (91%) in the BuMelTT, and 42 of 49 (86%) in the BEAM group. Infection was documented in 40 (75%) patients receiving BuMelTT, due to viral (n = 14) (8 CMV), fungal (n = 5) (2 aspergillosis) and bacterial (n = 33) vs. 26 (62%) patients receiving BEAM due to 6 viral (2 CMV), 5 fungal (1 aspergillosis) and 22 bacterial cases.

In a phase I/II trial, intravenous BCNU (300 mg/m2 on day -4) with activity against myeloma (n = 49 [male/female: 32/17]; age: 34 - 69 years), was combined with escalating doses of intravenous melphalan (160, 180, 200 mg/m2) for myeloma patients undergoing SCT. There was one treatmentrelated death in phase II due to sepsis associated with the transfusion of bacterially contaminated platelets that resulted in multi-organ failure. Therefore, 100-day treatment related mortality, was 2% (1/49). Overall, one patient had grade 4 pulmonary toxicity with grade 3 hypoxia and four had asymptomatic grade 2 pulmonary toxicity at 3 months post- SCT without hypoxia. Of 16 patients with baseline diffusing capacity from 50 - 70% predicted, one developed grade 4 pulmonary toxicity, while of 30 patients with diffusing capacity &gt; 71% at baseline, four developed grade 2 toxicity. Although there was a minimal decrement in diffusing capacity at 2 months post-SCT in the majority of patients, by 12 months post-SCT there was recovery and overall improvement ( Comenzo et al., 2006 ). A total of 43 relapsed and refractory HL patients underwent autologous haematopoietic stem cell transplantation (AHSCT) between January 1992 and December 2004, were received an intensified regimen of etoposide 2,400 mg/m2, cyclophosphamide 7,200 mg/m2 and BCNU 600 mg/m2 (VCB). Grade III-IV RRT was 9% (n = 4). The 1-year cumulative incidence of interstitial pneumonitis was 36%, however only two patients died of interstitial pneumonitis complications. Disease progression was the most common cause of death (n=10, 23%) ( Benekli et al., 2008 ). Fifty-one consecutive patients with Hodgkin's disease have been treated with high-dose chemotherapy

(cyclophosphamide, etoposide, and BCNU) and transplantation of autologous bone marrow (n = 44), autologous bone marrow plus PBSC (n = 2), PBSC (n = 1), syngeneic (n = 1), or allogeneic bone marrow (n = 3). The main toxicity encountered with the CVB regimen was interstitial pneumonia (IP), seen in four of 15 patients (27%) receiving ≥ 600 mg/m 2 of BCNU. Three of these patients have died ( Schmitz et al., 1993 ).

Burns et al. (1995) analysed patient, disease, and treatment related factors associated with long term DFS in 62 patients with refractory or recurrent Hodgkin's disease treated with high-dose cyclophosphamide (6000 mg/m2), BCNU (300 mg/m2), and etoposide (900 mg/m2) (CBV) followed by ASCT. There were no deaths resulting from toxicity of the preparative regimen, and all 62 patients survived the peri-transplant period. The median time to absolute neutrophil count recovery to ≥ 0.5 × 109 L was 26 days. The major non-haematologic toxicity was bacteraemia in 12 patients. Three patients developed an idiopathic non-interstitial pneumonitis which resolved uneventfully on

<div style=\"page-break-after: always\"></div>

antibiotics. One patient developed respiratory syncytial virus and 1 patient CMV pneumonia, and an additional patient had both CMV and aspergillus pulmonary infections. Two patients who developed clinical evidence of veno-occlusive disease during the transplant course were managed conservatively with resolution of symptoms. A study was to prospectively evaluate the retinal and optic nerve changes in patients undergoing high-dose chemotherapy followed by autologous haematopoietic progenitor cell support (AHPCS). One hundred and forty patients undergoing high-dose chemotherapy and AHPCS underwent extensive pre- and post-transplant ophthalmologic evaluations for development of retinal microvascular complications. One hundred and ten patients received high-dose cyclophosphamide (1875 mg/m2/day Å~ 3), cisplatin (165 mg/m2 Å~ 1) and BCNU (600 mg/m2 Å~ 1); thirty received identical doses of cyclophosphamide and cisplatin but received paclitaxel (135 mg/m2 to 825 mg/m2) instead of BCNU. Thirty-four patients (24%) had retinal findings of either cotton wool spots (CWS) (n = 20) or retinal hemorrhages (n = 18) during follow-up, which ranged from 1 to 12 months. Ten (7%) of these patients, all of whom received BCNU, showed ocular toxicity characterised by CWS 1 to 4 months post-transplant (n = 10); optic disc edema (n = 3); and variable vision loss associated with the onset of BCNU-induced pulmonary toxicity. Retinal and optic disc microvascular complications may occur after high-dose chemotherapy followed by AHPCS. The association of ischemic retinal lesions and/or optic disc edema with BCNU-induced pulmonary toxicity and the lack of ocular toxicity in patients that did not receive BCNU may suggest that BCNU is the etiologic agent ( Johnson et al., 1999 ).

A 46-year old male patient diagnosed with PCNSL was admitted to a hospital for high-dose chemotherapy followed by ASCT. Conditioning regimen consisted of BCNU 400 mg/m2 intravenously over 3 h on day -6 and thiotepa 5 mg/kg on days -5 and -4. Ondansetron 8 mg and methylprednisolone 125 mg were administered as premedication 40 min prior to the BCNU infusion on day -6. One hundred and thirty minutes after the infusion began, the patient developed violent chest pains radiating into the jaw accompanied by tachycardia and hypertension (185/95 mmHg). The BCNU infusion was stopped, and an electrocardiogram (ECG) was performed, which showed sinus tachycardia and ST depression in leads II, aVE, V5 - V6. The chest pain finally resolved after administration of sublingual nitrates and intravenous morphine. ECG returned to baseline after 90 min. In conclusion, high-dose c BCNU cardiotoxicity is rarely encountered in a clinical setting but considering the common use of this drug in ASCT, this side effect deserves to be known and recognised ( Waibel et al., 2012 ).

Carmustine with total blood irradiation From January 1993 to October 2002), 101 relapsed or refractory NHL patients were treated with high-dose chemotherapy (BCNU 600 mg/m2, etoposide 2400 mg/m2, and cisplatin 200 mg/m2) and autologous transplantation. Within 3 weeks before transplantation, 70 patients received IFR 20 Gy to sites of currently active (&gt; 2 cm) or prior bulky (&gt; 5 cm) disease. Four patients (4%) died within 30 days of stem cell infusion (1 pulmonary embolism, 2 septicaaemias with multi-organ failure, and 1 progressive lymphoma). Two patients (2%) developed interstitial pneumonitis most likely secondary to high-dose BCNU. Neither of these patients had received radiation therapy to the mediastinum. Three cases (3%) of secondary acute myelogenous leukaaemia occurred ( Wadhwa et al., 2005 ).

## Carmustine without total blood irradiation

In a study, 85 consecutive patients with relapsed or refractory Hodgkin's disease underwent high-dose chemotherapy (BCNU, etoposide and cyclophosphamide) or chemo/radiotherapy (etoposide and cyclophosphamide) followed by autologous bone marrow (ABMT) and/or peripheral blood stem cell (PBSC) transplantation. Eleven patients (13%) died of transplant-related complications including venoocclusive disease of the liver in five, acute and late interstitial pneumonitis in three, graft failure in one, cerebral hemorrhage in one, and therapy-induced MDS/acute leukaemia in one patient. Three patients developed therapy-induced MDS at 9, 10, and 29 months post-ABMT. The estimated

<div style=\"page-break-after: always\"></div>

probability of developing monotherapy-induced MDS/acute leukaemia was 3% (95% CI, 0.7 - 11%) and 6% (95% CI, 2 - 17%) at 2 and 3 years, respectively ( Nademanee et al., 1995 ).

Wheeler et al. (2001) observed a higher frequency of secondary malignancies in patients with Hodgkin's disease than in patients with NHL undergoing high dose therapy with the same non - TBI conditioning regimen. Three hundred patients with Hodgkin's disease and NHL were treated with cyclophosphamide, BCNU and etoposide and autologous stem cell support from 1986 through 1994. Median follow up of survivors is 3.9 years. Five-year survival is 51% for Hodgkin's disease and 48% for NHL. Eleven patients developed second malignancies (9/150 treated for Hodgkin's disease vs. 2/150 treated for NHL) a median of 2.4 years from transplantation and 5.2 years from initial diagnosis. Six patients had MDS or AML and 5 had lymphomas or solid tumours. Actuarial risk of MDS/AML at five years for patients transplanted for non- HL is 3% (95% CI 0.6 - 9.6%). Hodgkin's disease patients had significantly different pre-treatment characteristics than patients with NHL. A Cox model showed that greater number of prior relapses and prior radiation therapy were significant risk factors for the development of MDS/AML. These data suggested that CBV is associated with a lower risk of secondary MDS/AML than TBI containing regimens and that much of the risk is associated with the pretransplantation therapy. The use of autotransplantation early in the course of therapy for relapsed lymphoma might prevent some cases of MDS/AML.

## Serious adverse event/deaths/other significant events

The incidence of pulmonary toxicity is &lt; 10 % when cumulative BCNU doses are &lt; 800 mg/m2 body surface as a single agent, but in combination with other cytotoxic drugs, particular cyclophosphamide, the tolerated dose is lower. Several studies have demonstrated that doses of 600 mg/m2 body surface or higher are associated with an increased risk of pneumonitis, and for many years 450 mg/m2 body surface has been considered the upper dose limit of BCNU. Aronin et al. (1980) reports that symptomatic pulmonary disease occurred in 20 % of 93 patients with anaplastic gliomas being treated with BCNU, and that there is a relation between the occurrence of pulmonary toxicity and the total cumulative dose of BCNU. An equation that allows prediction of pulmonary toxicity during the course of therapy with BCNU is presented. Pulmonary toxicity characterised by pulmonary infiltrates and/or fibrosis has been reported to occur with a frequency ranging up to 30%. This may occur within three years of therapy and appears to be dose related with cumulative doses of 1,200 - 1,500 mg/m2 being associated with increased likelihood of lung fibrosis. Risk factors include smoking, the presence of a respiratory condition, pre-existing radiographic abnormalities, sequential or concomitant thoracic irradiation and association with other agents that causes lung damage.

Pulmonary toxicities which is a major safety issue for carmustine, were reported in both the adult and paediatric populations, including fatal outcomes. Risk factors for pulmonary toxicity may be previous lung disease, a history of smoking, or chest radiotherapy. According to Alessandrino etr al (2000) the increased toxicity was noticed in females.

## Overdose

The main symptom of intoxication (overdose) is myelosuppression. In addition, the following serious side effects may occur: liver necrosis, interstitial pneumonia and encephalomyelitis. BCNU contains 0.57 vol% ethanol which means 7.68 g per dose.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

No data on clinical laboratory data from the literature were available and discussed in this safety overview.

There was no systematic reporting of clinical laboratory parameters available from this overview. Some biochemistry parameters were mentioned with respect to liver toxicity. There was also no reporting on vital signs or physical findings.

## Safety in special populations

Limited experience is available for older patients. Martin et al. (2015) presented a retrospective analysis of 73 consecutive patients (male/female: 54/19) aged over 65 years treated for aggressive or relapsed lymphoma by high-dose chemotherapy with BEAM (BCNU 300 mg/m2 on day -7, etoposide 100 mg/m2 every 12 h on days - 6 to -3, cytarabine 100 mg/m2 every 12 h on days -6 to -3 and melphalan 140 mg/m2 on day - 2)) at full dosage followed by ASCT. Patient data were obtained from medical charts from two institutions. Median age was 67 years (65 - 74). Significant comorbidities were present in 24.7% of patients. The median number of days for grade 4 neutropenia was 9 (5 18). The early treatment- related mortality rate (&lt; 100 days) was 2.7%. The estimated 2-year PFS and OS rates were 67.2% and 78.5%, respectively. In conclusion, the full-dose high-dose chemotherapy- ASCT regimen is feasible, safe and efficient in selected patients over 65 years old.

## Paediatric patients

Paediatric patients were represented in a few published studies, although not clinically relevant to this application, since carmustine is not intended for use in this population.

In a retrospective analysis, 24 paediatric patients (age: 7 - 21 years; median: 17 years) with primary refractory or relapsed Hodgkin's disease were received high-dose therapy regimens consisted of cyclophosphamide (100 mg/kg) and etoposide (60 mg/kg) combined with either BCNU (n = 17; 10 15 mg/kg), CCNU (n = 11; 6 mg/kg), or fractionated TBI (n = 6). Five patients succumbed to treatment-related toxicities, of whom 4 died of pulmonary failure. Fifteen patients (44%) developed post-AHCT idiopathic diffuse lung injury syndrome: acute alveolitis (n = 2); diffuse alveolar hemorrhage (n = 2); acute respiratory distress syndrome (n = 2); delayed interstitial pneumonitis (n = 8); and bronchiolitis obliterans (n = 1). The following factors did not predict for the development of a diffuse lung injury syndrome in univariate analysis: prior treatment with bleomycin, pre-high-dose therapy pulmonary function tests, and prior thoracic irradiation ( Frankovich et al., 2001 ).

In a prospective study, the safety and efficacy of cyclophosphamide, BCNU, and etoposide (CBV) conditioning and APBSCT was evaluated in children (n = 69) with relapsed or refractory HL (n = 39 [49% male]; median age: 14.5 years) and NHL (n = 30 [70% male]; median age: 12.8 years). All 6 patients receiving 450 mg/m2 of BCNU developed grade III or IV pulmonary toxicity with onset between 30 to 60 days post-transplant. Four of the 6 required supplemental oxygen (duration 5 days to 9 months) and 5 received steroids. All but 2 came off supplemental oxygen therapy after a few days. One patient developed persistent abnormal pulmonary function testing's but came off oxygen after 9 months. The other patient relapsed 6 months after transplant while on steroids and oxygen.

Carmustine Obvius is contra-indicated in paediatric patients.

## Elderly

Safety data in elderly patients were reported in at least one study ( Martin et al, 2015 ) where increased frequency of AEs and therefore increased risk to certain ADRs cannot be excluded.

<div style=\"page-break-after: always\"></div>

## Fertility

There is currently minimal data on fertility outcomes in premenopausal women undergoing ASCT with BCNU, etoposide, cytarabine and melphalan (BEAM) conditioning. A retrospective analysis of fertility outcomes in premenopausal females aged between 18 and 40 years who underwent BEAM/ASCT for lymphoma between 1995 and 2011 was performed at four transplant centres. Of 41 premenopausal women who underwent BEAM conditioning, 25 met the inclusion criteria with the main exclusion criterion being inadequate documentation. Eighteen had Hodgkin lymphoma, and seven had nonHodgkin lymphoma. Median number of chemotherapy regimens pre-transplant was 2 (1 - 3). Seventeen women (68%) with a median age at transplant of 25 years (range: 17 - 33) recovered their menses. The comparative group without recovery was older with a median age of 34 years (range: 20 - 40) (p = 0.007). Ten patients, with a median age at transplant of 22 years (range: 17 - 30), had 15 naturally conceived pregnancies.

## Pregnancy

Since high-dose conditioning with AHCT is contraindicated in pregnant woman, therefore publications about such cases were not to be expected. Brice et al. (1994) reported two cases of normal pregnancy after high dose chemotherapy and ASCT in two of the 72 women belonging to a group of 188 patients transplanted in clinical unit for advanced malignant lymphoma. These pregnancies occurred 19 and 33 months after high dose therapy in two women aged 27 and 28, neither of whom had received previous TBI or pelvic radiotherapy.

## Safety related to drug-drug interactions and other interactions

Carmustine in combination with;

- -phenytoin and dexamethasone (alone or together) results in reduced activity of antiepileptic medicinal products. Phenytoin used as anticonvulsant drug in patients receiving chemotherapy is reported to interact with BCNU to give unexpected low phenytoin levels and thereby seizures. Bollini et al. (1982), reports of a case where a patient receives phenytoin 350 mg/day and phenobarbital 100 mg/day together with a combination of antineoplastic drugs including BCNU, vinblastine and methotrexate. Plasma concentrations of phenytoin dropped from 9.4 to 5.6 μg/mL and partial seizures occurred. In another case Grossman et al. (1989) describes that in patients given BCNU and cisplatin ten out of 17 patients receiving phenytoin required an increase in their daily dose to maintain therapeutic levels, whereas Gattis &amp; May (1996) in a review article reported one case of interaction between phenytoin and dexamethasone in which phenytoin concentrations were decreased, which lead to inadequate seizure control and further medical complications and decreased quality of life. Finally, Ghosh et al. (1992) reports of patients receiving BCNU 900 - 1,050 mg/m2 body surface together with irradiation or in combination with other chemotherapeutics, that phenobarbital and carbamazepine levels remained relatively stable, but all patients required increased doses of phenytoin anticonvulsant therapy after beginning chemotherapy with BCNU. The increase in phenytoin dose ranged from 50 - 300 % above baseline.
- -cimetidine, a histamine H2-receptor antagonist is used in the treatment of peptic ulcer disease. Despite its clinical effectiveness and relative lack of toxicity, a number of isolated reports suggest that cimetidine may be responsible for a severe, but usually reversible leukopenia and thrombocytopenia. Alone cimetidine has been associated with bone-marrow toxicity (James &amp; Prout, 1978; Chang &amp; Morrison, 1979; Carloss et al., 1980 ) but together with BCNU this effect is magnified. Selker et al. (1978) reported that six out of eight patients receiving triple therapy (80 mg/m2 BCNU for three days, 300 mg cimetidine every six hours and steroids in variable dose levels) demonstrated nadirs well below that normally attributed to the chemotherapy

<div style=\"page-break-after: always\"></div>

alone (white cell count &lt; 500 and platelet count &lt; 8,000), and the authors concluded that cimetidine magnifies bonemarrow depression. Volkin et al. (1982) showed that the use of cimetidine together with BCNU (and cranial irradiation) enhanced the myelosuppressive effect of the cytotoxic therapy e.g. neutrophil cell count averaged 2,160 ± 240/μL without cimetidine and 650 ± 220/μL with t he contemporary use of cimetidine. Further cimetidine interacts with BCNU indirectly due to binding to cytochrome P450 isoenzyme-system in the liver with subsequent inhibition of microsomal oxidative metabolism and degradation of BCNU.

- -digoxin is a cardiac glycoside used in the management of supraventricular arrhythmias, particularly atrial fibrillation and in heart failure. A study in patients undergoing antineoplastic therapy found that the absorption of digoxin from tablets was reduced by an average of 46.6 % whereas that of digoxin from liquid-filled capsules was not significantly changed ( Bjornsson et al., 1986 ). Another study ( Kuhlmann, 1982 ) with patients undergoing antineoplastic therapy found that the steady-state concentration of digoxin after giving acetyl-digoxin was reduced, but that digitoxin concentrations were maintained. It was suggested that the interaction was due to reduced absorption of digitalis glycosides through the damaged gastrointestinal mucosa and that liquidfilled capsules or digitoxin might be preferred in these patients. The study by Kuhlmann (1982 ) was cited by Marcus (1985) and adds that the inhibition of digoxin absorption is reversible after one week and that the damaged to the gastrointestinal mucosa therefore is temporary. Finally, Graves et al. (1989) investigated the factors underlying the hypertension seen as a complication in autologous bone marrow transplantation when therapy includes multiple alkylating agents. Out of 18 patients 15 developed hypertension usually eight to ten days after the beginning of chemotherapy. The authors suggest a relationship between digoxin-like immune-reactive factor and blood pressure in hypertensive patients treated with multiple alkylating agents ( Graves et al., 1989 ).
- -melphalan, a nitrogen mustard alkylating drug, results in increased risk of pulmonary toxicity. This was shown in a study by Zulian et al., (1989) where 38 patients with treated Hodgkin´s disease were given high dose combination chemotherapy using melphalan, BCNU and etoposide (a topoisomeriase inhibitor) in different combinations for autologous bone marrow transplantation. The most severe toxicity of the drug combination was respiratory failure. There were seven toxic deaths from this cause, five occurring before four months and two late deaths. The clinical cause was acute pneumon itis leading to adult respiratory distress syndrome and autopsy showed interstitial pneumonitis compatible with drug-induced damage and no residual Hodgkin´s disease. The authors conclude that combination of doses of 600 mg/m2 body surface BCNU and 140 mg/m2 body surface melphalan represents an additive toxic effect and a high rate of toxic deaths due to lung damage ( Zulian et al., 1989 ).

## Discontinuation due to adverse events

No data were presented from the literature.

## Post marketing experience

The Applicant has included and discussed post-marketing safety data from EudraVigilance and from literature (see above).

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

Overall, 84 publications were submitted in support to the proposed indication. Submitted data set comprises 37 articles related to carmustine use in haematological malignancies (except Hodgkin's and non-Hodgkin's lymphoma), including one overview of the treatment approaches for haematological malignancies and one case report; 24 articles related to Hodgkin's lymphoma; 15 articles related to non-Hodgkin's lymphoma, including 1 case report; 2 articles related to both Hodgkin's lymphoma and non-Hodgkin's lymphoma; 1 overview of allogenic haemopoietic cell transplantation; 1 study on allogenic cell transplantation for not-specified malignancies; 1 study including patients with solid tumours and non-Hodgkin's lymphoma; 1 paper describing Haemolytic Uremic Syndrome in  3 patients following to allogenic haemopoietic cell transplantation and chemotherapy regimen including carmustine (1 patient with fallopian tube cancer, 1 patient with testicular cancer and 1 patient with Hodgkin's lymphoma); 1 article for neurological patients undergoing allogenic haemopoietic cell transplantation, and 1 article reviewing chemotherapy treatment regimens for various types of haematological malignancies.

The safety data from literature are derived from a population with mostly malignant haematological diseases. However, some limited exposure to patients with non-malignant diseases was also reported. The proposed dosing regimen of 300 - 600 mg/m2 is within the range of the studied dose for the proposed indication (the high-dose regimen studied for conditioning treatment prior to HPCT was 800 mg/m2 for adult population). The underlying diseases for which HPCT has been administered included myeloid leukaemia, Hodgkin's and non-Hodgkin's lymphomas, other malignant and non-malignant conditions. Conditioning regimens included variable agents other than carmustine (BCNU): vincristine, procarbazine, chlorambucil cyclophosphamide, melphalan and prednisolone.  The combination with other cytotoxic drugs hampers assessment of AE's causality for carmustine. Furthermore, safety outcomes for carmustine strongly correlates with the Disease Risk Index.

Patient exposure seems sufficient to assess the safety profile of carmustine for the newly proposed indication. However, a major shortcoming for the safety data presented is lack of a systematic reporting of AEs in the publications. Furthermore, some studies reported and discussed the serious adverse events only. Cumulative overview of safety population and data obtained from studies where severity of AEs was reported - were submitted. As expected, the most frequently reported severe AE was pulmonary toxicity. Severity increases by increasing the dose and most frequently was reported with the dose 45-700 mg/m2. Lower incidence in the 800-1000 mg/m2 group was more likely related to a very small sample.

The applied dose in the new indication is two to three times higher (300-600mg/m2) compared to the dosage in the approved indications (150-200mg/m2).

The effect of the dose increase has been discussed including information about studies investigating safety issues between different carmustine dosages and an evaluation of the line-listing which is based on studies included in the updated Clinical Overview. Different doses have been compared in the linelisting and it was concluded that higher dose of BCNU increases the risk of adverse events, such as the risk for pulmonary toxicity. A warning statement regarding pulmonary toxicity has been included in the SmPC: 'High-dose therapy with carmustine (especially with 600 mg/m2) prior to haematopoietic stem cell transplantation has been shown to increase the risk for incidence and severity of pulmonary toxicities. Therefore, in patients with other risks for pulmonary toxicities, use of carmustine needs to be weighed against the risks.'

Pulmonary toxicities, a major safety issue for carmustine, were reported in both the adult and paediatric populations, including fatal outcomes. Risk factors for pulmonary toxicity may be previous lung disease, a history of smoking, or chest radiotherapy. Alessandrino et al. (2000) and Chen et al.

<div style=\"page-break-after: always\"></div>

(2015) noticed an elevated risk to develop pulmonary toxicities in females. This is addressed in the newly updated SmPC which includes a warning that high-dose carmustine increases incidence and severity of pulmonary toxicities. It was suggested that use of oral contraceptives might be associated with the elevated risk of pulmonary toxicities in females, however there was a lack of evidence supporting this hypothesis.

The results from provided literature review can be used to characterize the safety profile in the new indication. The type of ADRs reported are generally in line with what is known from the safety profile of carmustine in the approved indications. In summary, use of carmustine before HPCT can cause all severity grades gastrointestinal disorders, haemorrhagic complications, ocular toxicity, interstitial pneumonitis, pulmonary complications, liver toxicity, veno-occlusive disease, and MDS.

Furthermore, warning statements regarding cardiac, renal, nervous system disorders and infectious diseases have been included in the SmPC which seems acceptable.

Electrolytic abnormalities grade 3-4 have been observed in 0.6 % of patients in the 300 mg group and in 4.6% of the 600 mg group. The occurrence of electrolytic abnormalities (hypokalemia, hypomagnesemia and hypophosphatemia) was listed under 4.8. in the SmPC.

In addition, a warning for cardiac, renal, nervous system disorders and infectious diseases is included in the updated SmPC. The Applicant provided analysis of the pooled safety data, including line-listing of safety data from studies indicating severity of AEs, as well as post-marketing safety data, including EudraVigilance line-listing. Tachycardia was added to the SmPC section 4.8.

There was no systematic reporting of clinical laboratory parameters available from this overview. Some biochemistry parameters were mentioned with respect to liver toxicity.

Neutropenic enterocolitis is now included in the SmPC (see section 4.8) as it can occur as therapyrelated adverse event upon treatment with chemotherapeutic agents.

Safety data in elderly patients were reported in at least one study (Martin et al, 2015). Elderly patients may have more comorbidities potentially affecting the frequency of AEs and therefore increased risk to certain ADRs cannot be excluded for elderly patients. Furthermore, elderly patients may have reduced renal clearance requiring close monitoring as already stated in the SmPC. A further warning into the SmPC that patients with higher disease status and comorbidities have a higher risk for adverse events (see section 4.2. and 4.4).

## Assessment of paediatric data on clinical safety

Paediatric patients were represented in a few published studies, although not clinically relevant to this application, since carmustine is not intended for use in this population and in fact it is contra-indicated in children (see SmPC section 4.3).

## 2.5.2. Conclusions on clinical safety

The type of ADRs reported in the published trials assessed in this application are generally in line with what is known from the safety profile of carmustine in the approved indications.  The PI was updated with the addition of neutropenic enterocolitis and tachycardia. Pulmonary toxicity is a known complication from conditioning regimen including carmustine with a major impact on morbidity/mortality. Some publications revealed an elevated risk to develop pulmonary toxicities in females. This is also addressed in the updated SmPC.

<div style=\"page-break-after: always\"></div>

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 3.2 is acceptable.

The CHMP endorsed the Risk Management Plan version 3.2 with the following content:

## Safety concerns

Table SVIII.1: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                 |
|------------------------------|------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Pulmonary toxicity (including in paediatric population) Bone marrow toxicity Hepatotoxicity Nephrotoxicity |
| Important potential risks    | Embryotoxicity and teratogenicity                                                                          |
| Missing information          | None                                                                                                       |

## Pharmacovigilance plan

There are neither ongoing nor planned categories 1-3 safety studies.

## Risk minimisation measures

| Safety concern                                          | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pulmonary toxicity (including in paediatric population) | Routine risk minimisation measures: SmPC section 4.8. PL section 4. Section 4.4 of the SmPC includes a warning stating that pulmonary toxicity occurs with a frequency ranging up to 30% in patients receiving carmustine. High-dose therapy with carmustine (especially with 600 mg/m 2 ) prior to haematopoietic stem cell transplantation has been shown to increase the risk for incidence and severity of pulmonary toxicities. Therefore, in patients with other risks for pulmonary toxicities, use of carmustine needs to be |

<div style=\"page-break-after: always\"></div>

| Safety concern       | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | weighed against the risks. As a precautionary measure, baseline pulmonary function studies and chest X-ray should be conducted along with frequent pulmonary function tests during treatment. Section 2 of the PL states that before treatment and regularly during treatment the patient's lung function must be tested. This section of the PL also states that since an X-ray of the chest region and lung function test will be conducted before treatment is started. In addition, high-dose treatment with Carmustine Obvius (up to 600 mg/m 2 ) is only performed in combination with subsequent stem cell transplantation. Such a higher dose can increase frequency or severity of lung, kidney and heart toxicities as well as infections. Legal status: Restricted medical prescription medicine. Additional risk minimisation measures:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Bone marrow toxicity | None. Routine risk minimisation measures: SmPC section 4.8. PL section 4. According to section 4.3 of the SmPC, product is contraindicated in case of severe bone marrow depression. In addition, section 4.4 of the SmPC includes a warning stating that bone marrow toxicity is a common and severe toxic adverse reaction in patients receiving carmustine. As a precautionary measure, complete blood count should be monitored frequently for at least six weeks after a dose. In case of a decreased number of circulating platelets, leucocytes or erythrocytes either from previous chemotherapy or other cause the dose should be adjusted. Repeat doses of Carmustine Obvius should not be given more frequently than every six weeks. The bone marrow toxicity of carmustine is cumulative and therefore the dosage adjustment must be considered on the basis of nadir blood counts from prior doses. Section 2 of the PL states that product must not be used in patients suffering from suppression of blood cell formation in the bone marrow. This section of the PL also states that the doctor will monitor blood counts of the patient weekly for at least 6 weeks after a dose and that product would not be given more frequently than every 6 weeks. The dosage will be confirmed with the blood count. Legal status: Restricted medical prescription medicine. Additional risk minimisation measures: None. |
| Hepatotoxicity       | Routine risk minimisation measures:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Safety concern                    | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                   | SmPC section 4.8. PL section 4. Section 4.4 of the SmPC includes a warning stating that hepatic function should be checked prior to treatment and regularly monitored with carmustine therapy. Section 2 of the PL states that before treatment and regularly during treatment the patient's liver function must be tested. Legal status: Restricted medical prescription medicine. Additional risk minimisation measures: None.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Nephrotoxicity                    | Routine risk minimisation measures: SmPC section 4.8. PL section 4. According to section 4.3 of the SmPC, product is contraindicated in case of severe (end-stage) renal impairment. In addition, section 4.4 of the SmPC includes a warning stating that upon high-dose therapy with carmustine, the risk and severity for renal toxicity rises. Renal function should be checked prior to treatment and regularly monitored with carmustine therapy. Section 2 of the PL states that product must not be used in patients suffering from higher-grade kidney dysfunction. This section of the PL also states that before treatment and regularly during treatment the patient's renal function must be tested. In addition, high-dose treatment with Carmustine Obvius (up to 600 mg/m 2 ) is only performed in combination with subsequent stem cell transplantation. Such a higher dose can increase frequency or severity of kidney toxicity. Legal status: Restricted medical prescription medicine. Additional risk minimisation measures: |
| Embryotoxicity and teratogenicity | Routine risk minimisation measures: SmPC section 4.8. PL section 4. Section 4.6 of the SmPC includes a warning stating that carmustine is embryotoxic in rats and rabbits and teratogenic in rats when given in doses equivalent to the human dose. Therefore, carmustine should not be administered to patients who are pregnant. As a precautionary measure, women should use effective contraception to avoid becoming pregnant while on treatment and for at least 6 months after treatment. Male patients should be advised to use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | adequate contraceptive measures while on treatment with carmustine and for at least 6 months after treatment. If Carmustine Obvius is used during pregnancy, or if the patient becomes pregnant while taking (receiving) Carmustine Obvius, the patient should be apprised of the potential hazard to the foetus. Section 2 of the PL states that Carmustine Obvius should not be used during pregnancy because it may harm the unborn baby. Therefore, this medicine should not normally be administered to pregnant women. If used during pregnancy, the patient must be aware of the potential risk to the unborn baby. Women of childbearing potential are advised to use effective contraception to avoid becoming pregnant whilst being treated with this medicine and for at least 6 months after treatment. Male patients should use adequate contraceptive measures while on treatment with Carmustine Obvius and for at least 6 months after treatment to prevent their partners becoming pregnant. Legal status: Restricted medical prescription medicine. Additional risk minimisation measures: None. |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 6.3 of the SmPC have been updated. Particularly, a new warning with regard to neutropenic enterocolitis has been added to the product information. The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other relevant guideline(s) [e.g. Excipients guideline, storage conditions, Braille, etc…], which were reviewed by QRD and accepted by the CHMP.

## 2.7.1. User consultation

No justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH. However, the changes to the package leaflet are minimal and do not require user consultation with target patient groups.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

This application concerns the use of carmustine Obvius as part of a conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin's disease / Non-hodgkin's lymphoma).

## 3.1.2. Available therapies and unmet medical need

Several treatment options are authorised in the EU for patients undergoing HSCT. These included radiation treatment or intensive treatment with cancer medicines such as busulfan to clear the bone marrow of existing cells in preparation for HSCT. The choice of conditioning regimen varies and is typically based on institutional experience. The most frequently used intensive chemotherapy cited in the literature is a combination of carmustine, etoposide, cytarabine and melphalan (BEAM) (Damaj et al, 2017). BEAM regimen is considered the regimen of choice for patients with HL and NHL submitted to ASCT, due to its acceptable safety profile and a quite high antitumor efficacy.

## 3.1.3. Main clinical studies

The Applicant identified 9 main studies for BCNU in conditioning regimens prior to autologous HCT. All the main studies represent retrospective analyses comparing different conditioning regimes, especially comparing BEAM to other regimes where BCNU is substituted. The retrospective analyses in total included 8,402 patients. Main and supportive studies included in total a 14,024 patients - 8,402 in main studies; 5,622 in supportive studies) and of these 9,951 patients in total - 5,775 in main studies and 4,176 in supportive studies have been treated with BCNU as part of the conditioning regimen prior to AHCT for HL, NHL and AML.

## 3.2. Favourable effects

The efficacy endpoints used to evaluate efficacy of conditioning treatment prior allogenic HPCT were disease control (relapse rate); disease free-survival (DFS)/ event-free survival (EFS)), the transplantation-related mortality (TRM)/ non-relapse mortality (NRM) and overall survival (OS).In adults with malignant diseases use of carmustine based conditioning regiments provided OS similar or comparable to that of a thiotepa containing regimen. The submitted evidence support the use of carmustine in the new indication.

## 3.3. Uncertainties and limitations about favourable effects

There is limited number of randomized well-controlled up-to-date studies of carmustine use in conditioning regimen prior HPTC. Considerable amount of efficacy data are retrospective and uncontrolled studies. The size of the effect on OS is difficult to evaluate due to lack of randomized controlled clinical trials. Majority of studies are either retrospective or prospective, uncontrolled reallife studies. Although these studies reflect clinical practice, there are many factors related to patient and disease characteristics as well as physician choice which can influence the treatment decision.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

Treatment-related  mortality  (TRM)  remains  a  matter  of  concern  and  acute  toxicities,  although  well known, are not always easily managed.

Pulmonary toxicity is a known complication from conditioning regimen including carmustine with a major impact on morbidity/mortality. Especially high dose regimens with carmustine pose further risks regarding pulmonary toxicity. An increased risk for pulmonary toxicities upon treatment with conditioning regimes and HPCT for females has been reported. So far, this increased risk is described for the treatment itself including conditioning regimes without carmustine (e.g. TBI or busulfancyclophosphamide) or with carmustine (BEAM: carmustine, etopside, cytarabine and melphalan or CBV: cyclophosphamide, carmustine and etoposide).

Upon high-dose therapy with carmustine, the risk and severity for infections, cardiac, hepatic, gastrointestinal, and renal toxicity, diseases of the nervous system and electrolyte abnormalities (hypokalemia, hypomagnesemia and hypophosphatemia) rises. Patients with comorbidities and worse disease status have a higher risk for adverse events. This needs to be considered on individual case basis especially for elderly patients.

As part of this assessment 'tachycardia' was included in section 4.8.

Carmustine is carcinogenic in rats and mice at doses less than the recommended human dose based on body surface area. Secondary primary malignancies such as MDS have been reported in patients.

Neutropenic enterocolitis can occur as therapy-related adverse event upon treatment with chemotherapeutic agents. This finding has been added under section 4.8 of the SmPC.

This medicinal product contains 0.57 vol% ethanol (alcohol), it can be harmful in patients suffering from alcoholism and for high-risk groups such as patients with liver disease or epilepsy (see SmPC section 4.4).

## 3.5. Uncertainties and limitations about unfavourable effects

Pulmonary toxicity is a known complication from conditioning regimen including carmustine with a major impact  on  morbidity/mortality.  Some  publications  revealed  an  elevated  risk  to  develop  pulmonary toxicities in females, reasons for this elevated risk have not been established.

## 3.6. Benefit-risk assessment and discussion

## 3.6.1. Importance of favourable and unfavourable effects

The main studies identified as relevant to the indication represent retrospective analyses comparing different conditioning regimes, especially comparing BEAM to other regimes where BCNU is substituted. The retrospective analyses in total included 8,402 patients and could be considered as supportive. These analyses demonstrated that carmustine as part of the BEAM regimen is an established, widely used and effective conditioning regimen prior to AHCT in HL and NHL.

Pulmonary toxicity is a known complication from a conditioning regimen including carmustine with a major impact on morbidity and is also seen in the submitted publications; an elevated risk to develop pulmonary toxicities was observed in females and is addressed in the updated SmPC. Upon high-dose therapy with carmustine, the risk and severity for infections, cardiac, hepatic, gastrointestinal, and renal toxicity, diseases of the nervous system and electrolyte abnormalities (hypokalemia,

<div style=\"page-break-after: always\"></div>

hypomagnesemia and hypophosphatemia) rises. Patients with comorbidities and worse disease status have a higher risk for adverse events (see section 4.2 of the SmPC).

## 3.6.2. Balance of benefits and risks

The well-established use of carmustine as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation in NHL and HL has been adequately documented. It can be concluded that the benefits outweigh the risks.

## 3.6.3. Additional considerations on the benefit-risk balance

The submitted published scientific literature primarily pertains to the use of carmustine in the autologous stem cell transplantation procedure in patients with Non-Hodgkin or Hodgkin lymphoma. The evidence provided by Applicant regarding use of carmustine with TBI and in the scope of allogenic hematopoietic cell transplantation is limited.

The initially proposed indication included all malignant and non-malignant haematological diseases in adult patients, however this broad indication was not justified on the basis of submitted literature.

No data were provided on the use of carmustine as a part of conditioning regimens in patients with severe aplastic anaemia, where allogeneic HSCT is the only available potential curative treatment, thalassaemia, sickle-cell disease, primary immunodeficiency. In fact, there is no data on use of carmustine as a part of conditioning regimens in patients with any non-malignant haemothological disease.

Bibliographic evidence was considered sufficient only for Hodgkin's disease, Non-Hodgkin's lymphoma and the indication was restricted accordingly to the use of carmustine as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin´s disease / Non-Hodgkin's lymphoma).

## 3.7. Conclusions

The overall B/R of Carmustine Obvius is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected     |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|----------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II, IIIA and IIIB |

Extension of indication to include: 'carmustine with or without total body irradiation (TBI), as

<div style=\"page-break-after: always\"></div>

conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases' for Carmustine Obvius; as a consequence, sections 4.1, 4.2, 4.4 and 4.8 of the SmPC are updated. The Package Leaflet is updated in accordance. Furthermore, the PI is brought in line with the latest QRD template version 10.1. Version 3.2 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics, Annex II, Labelling, Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Carmustine Obvius is not similar to Tepandina and Mozobil within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Carmustine Obvius-H-C-4326-II-0002.